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ABSTRACT 
CHAD M. MCCALL: Substrate Targeting and Control of DNA Replication by the 
CUL4/DDB1 Ubiquitin Ligase 
 
 (under the direction of Dr. Yue Xiong) 
 
 Ubiqutin-mediated proteolysis is an essential pathway in the cell, by which 
specific proteins are targeted for degradation at specific times.  The small protein 
ubiquitin is conjugated onto targets for proteolysis by a series of three enzymatic 
reactions, catalyzed by an E1 ubiquitin activating enzyme, an E2 ubiquitin conjugating 
enzyme, and one of hundreds of E3 ubiquitin ligases.  E3 ubiquitin ligases provide 
specificity for the reaction by interacting with specific substrates and an E2.  The cullin 
family of ligases is particularly important because their modular domain structure allows 
for many ligases to be formed from a minimum of components.  In this study, I describe 
research into the substrate-targeting mechanism of Cullin 4A.  First, I identified by mass 
spectrometry a substrate receptor family containing a specific motif within WD-40 
repeats that interacts with a common Cullin 4A adaptor, DDB1.  In collaboration with 
others in my laboratory, we determined that more than 90 potential receptors contain this 
“DWD” motif.  I then characterized one of these receptors, VprBP, which is required for 
normal cellular proliferation.  VprBP silencing leads to a defect in DNA replication, 
whereby replication stress leads to an upregulation of cryptic origins of replication but an 
overall decrease in nucleotide incorporation.  It also interacts with the HIV-1 accessory 
protein Vpr, and bridges the Vpr ubiquitination substrate UNG2 to the CUL4A ligase.   
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INTRODUCTION
2 
Covalent modification with ubiquitin alters protein fate and function 
 
The cell targets almost all of its proteins for post-translational covalent 
modification, in order to rapidly change various properties, from catalytic activity to 
binding partners to cellular fate.  These modifications take various forms, from small 
molecular weight additions like phosphorylation, acetylation, and methylation, to 
conjugation of small proteins such as ubiquitin, Nedd8, and SUMO-1.  Ubiquitin is of 
particular interest, because its conjugation is associated with the targeted degradation of 
proteins at specific points in the lifetime of the cell when they are no longer needed. 
 
Ubiquitin (Ub), a small protein of 76 amino acids, is strongly conserved 
throughout all eukaryotes.  Via its carboxyl-terminal glycine, it may be conjugated 
through an isopeptide bond to the epsilon amino groups of lysine residues on specific 
proteins in the cell (Jentsch 1992).  This conjugation occurs through a cascade of 
reactions requiring three enzymes: an E1 ubiquitin activating enzyme, an E2 ubiquitin 
conjugating enzyme, and an E3 ubiquitin ligase (Figure 1.1) (Pickart and Eddins 2004).  
The E1 functions by first catalyzing the ATP-dependent formation of a ubiquitin-
adenylate intermediate.  The catalytic cysteine residue of the E1 then attacks the 
adenylate intermediate, forming a high-energy thioester bond between the E1 and 
ubiquitin.  The activated ubiquitin is then passed in an ATP-independent manner to the 
catalytic cysteine of the E2.   
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Figure 1.1 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 -- The Ubiquitination Cascade 
Ubiquitin modification requires a series of three enzymes: the E1 ubiquitin 
activating enzyme (yellow), which in an ATP-dependent manner covalently binds to 
ubiquitin (grey) in a high-energy thioester bond.  The E1 then passes ubiquitin to one of 
more than twenty E2 ubiquitin conjugating enzymes (orange).  An E3 ubiquitin ligase 
(brown) interacts with a substrate (red) and the E2, allowing the E2 to transfer ubiquitin 
onto the substrate.  For polyubiquitin chain formation, multiple ubiquitin moieties are 
conjugated onto a single substrate.  
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E3 ubiquitin ligases target substrates for ubiquitin conjugation 
 
The E2-Ub intermediate then interacts with an E3 ubiquitin ligase in order to 
covalently conjugate ubiquitin to the target protein lysine.  There are two broad families 
of E3 ligases: those containing either RING (Really Interesting New Gene) or HECT 
(Homologous to the E6AP Carboxyl Terminus) domains (Huibregtse et al. 1995; Jackson 
et al. 2000).  A smaller family, the U-box ligases, are structurally and catalytically very 
similar to RING ligases, with the major difference being electrostatic instead of zinc-ion 
interactions producing structural stability to the catalytic domain (Hochstrasser 2006).   
Both RING and HECT domains interact with E2 enzymes; however, HECT ligases form 
a covalent E3-Ub thioester intermediate before ligating ubiquitin to substrates, while 
RING (and U-box; hereafter, any discussion of RING ligases includes U-box) ligases 
pass ubiquitin directly from the E2 to the substrate without a covalent intermediate.  
RING ligases can be subdivided into two families as well: those that contain intrinsic 
RING domains as well as substrate-binding domains in a single protein, and those that 
utilize RING and substrate-interacting domains on separate polypeptides.   
 
The RING domain is critical for E3 ubiquitin ligase catalytic activity, but how this 
occurs is not as clear as in the case of HECT ligases, which form covalent E3-Ub 
intermediates.  The characteristic structural feature of a RING domain is a “cross-brace” 
scaffold formed by the coordination of two zinc ions by a series of cysteine or histidine 
residues (Pickart 2001).  The spacing of the zinc ions, and not the primary sequence, is 
conserved among RING family members, and as the zinc ions are inert, the domain likely 
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serves as a rigid scaffold, not in catalysis.  Studies on the RING subunit of the cullin 
ubiquitin ligases, ROC1/2, have provided the most insight into this conundrum.  The 
RING finger directly binds to the E2 ubiquitin conjugating enzyme; the residues within 
the RING finger required for maintaining its “cross-bridge” zinc-coordinated structure 
are required for its catalytic activity; and, the RING domain is sufficient to catalyze 
polyubiquitin chain formation (Kamura et al. 1999; Ohta et al. 1999; Seol et al. 1999; 
Skowyra et al. 1999; Tan et al. 1999).  Moreover, studies from our laboratory have shown 
that the ROC1 RING domain by itself, without its cullin binding partner, is sufficient to 
catalyze polyubiquitin chain formation by the E2 UbcH5c (Furukawa et al. 2002).  In 
some RING ligases, such as Cbl, the RING domain is required for binding to the E2, but 
in others, such as ROC1, mutating the RING domain does not abolish E2 binding but 
only inhibits ubiquitin chain formation (Jackson et al. 2000).  Another layer of 
complexity is added by the specificity of E2/E3 interactions: ROC1 requires its cullin 
binding partner to catalyze polyubiquitination by the E2 Cdc34, but activates UbcH5C 
regardless of whether the cullin subunit is present or not (Seol et al. 1999; Furukawa et al. 
2002).  The most likely explanation for these data is that the RING domain’s primary role 
is in E2 catalytic activation, by a heretofore-unclear mechanism, while it has a secondary 
role in E2/E3 interaction.  
 
Ubiquitin ligases may, depending upon characteristics of E2 enzymes, substrates, 
and the ligases themselves, either conjugate a single ubiquitin or poly-ubiquitin chains 
onto substrates.  Mono-ubiquitination serves to alter the cellular fate of various proteins, 
such as targeting membrane proteins for internalization, sorting nascent proteins to the 
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trans-Golgi network, viral budding, and altering transcriptional activity, histone 
modification, and DNA repair (d'Azzo et al. 2005).  Poly-ubiquitination serves various 
roles in the cell depending upon the nature of the ubiquitin chain.  Ubiquitin molecules 
linked in chains through lysine-63 play a poorly-characterized role in modulating cellular 
signaling pathways, in particular the NF-κB pathway and the regulation of error-prone vs. 
error-free translesion DNA synthesis by PCNA (Pickart 2004).  However, lysine-48-
linked polyubiquitin chains function to target modified proteins for proteolytic 
degradation by the 26S proteasome.  It is this prominent function of polyubiquitination, 
to target specific proteins, at specific times, for degradation, that has been the focus of 
research in our laboratory for the past several years. 
 
The formation of polyubiquitin chains proceeds by a poorly defined mechanism. 
 
The exact mechanism by which ubiquitin chains are formed is not well defined.  
The classical model, whereby single ubiquitin molecules are conjugated to each other, 
one by one, by rounds of charged ubiquitin, has never been experimentally established 
(Hochstrasser 2006).  However, another possibility has been recently demonstrated for 
one particular E2/E3 pair: mouse Ube2g2 (E2) and human gp78 (endoplasmic reticulum 
RING E3) (Li et al. 2007).  The authors experimentally demonstrate that a polyubiquitin 
chain forms on the E2, in a manner that requires interaction between two E2 molecules as 
well as E2-E3 interaction; and, the chain is thus transferred as a unit onto a substrate.  It 
is not clear, though, whether this model can be generalized to all E2’s or ubiquitination of 
all substrates.  Other studies have generated data that fits the sequential addition 
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(classical) model better than preformed chain addition, such as differential ubiquitination 
of different anaphase-promoting complex (APC) E3 substrates and mechanistic studies of 
ubiquitin chain formation by the E3 SCFCdc4 and its E2 Cdc34 (Petroski and Deshaies 
2005b; Rape et al. 2006).  However, as Hochstrasser points out in his recent review, none 
of these data rules out preformed chain assembly entirely; therefore, the real mechanism 
of polyubiquitination may be either yet to be defined, or depend on the individual E2, E3, 
and/or substrate (Hochstrasser 2006). 
 
The cullin E3 ligases function in multisubunit complexes to target a wide variety of 
substrates for ubiquitination 
 
Our laboratory has focused upon the cullin family of multisubunit RING ligases, 
which play critical roles in a large number of cellular processes.  There are six canonical 
cullins in mammalian cells: CUL1, CUL2, CUL3, CUL4A, CUL4B, and CUL5, as well 
as three more distantly-related proteins, CUL7, Parc, and APC11.   Orthologous to the six 
canonical cullins, C. elegans and Drosophila have five cullins (a single CUL4 ortholog 
rather that both CUL4A and CUL4B), while S. pombe contains four (single CUL4 
(Pcu4p) and single CUL2/5 (Pcu2p) orthologs) and S. cerevisiae has but three (CUL1 
(Cdc53), Cul3, and the more distantly-related Cul8/RTT101) (Petroski and Deshaies 
2005a).  Each canonical cullin contains three characteristic features: an amino-terminal 
domain required for recruiting specific substrates, a carboxyl-terminal domain required 
for the interaction with one of the Roc/Rbx/Hrt family of small RING finger proteins 
(which recruit and allosterically activate E2 enzymes to ubiquitinate cullin substrates), 
and a lysine adjacent to the Roc binding domain, which is covalently modified by the 
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ubiquitin-like protein Nedd8/Rub1 to activate cullin function in a manner to be described 
below.  The crystal structures of both CUL1 and CUL4A ligase complexes have been 
solved, and show a clear spatial separation of the N-terminal substrate-recruitment 
domain from the C-terminal ROC1-binding/catalytic domain by a rigid central scaffold 
(Zheng et al. 2002b; Angers et al. 2006).  This rigid structure hypothetically serves to 
hold the activated E2 at the proper distance and orientation from the substrate, as 
mutations disrupting the rigidity of the central domain of CUL1 abolish ligase activity 
(Zheng et al. 2002b); however, there are no structures available of a full cullin-substrate 
complex, so the actual structural basis for interaction between the substrate and the E2 
remains to be elucidated. 
 
Each cullin recruits substrates through distinct N-terminal domains interacting with 
different families of substrate receptors 
 
 The canonical cullins, while quite homologous in their Roc-binding and Nedd8-
modification domains, have divergent amino-terminal sequences, which are required for 
interaction with their substrates.  However, these substrates do not bind to the cullins 
directly, but interact through a series of linker molecules specific to each cullin (Figure 
1.2).  CUL1, the first family member to be well characterized, interacts at its amino 
terminus with the small protein SKP1 (Feldman et al. 1997; Skowyra et al. 1997; Zheng 
et al. 2002b).  SKP1, in turn, interacts with one of greater than 60 mammalian proteins 
containing an F-box domain.  These secondary linkers then interact with specific 
substrates, often through recognition of a phosphorylation event, such as the F-box 
proteins β-TrCP with phosphorylated substrates IκBα and β-catenin, and SKP2 with 
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phosphorylated p27Kip1 (Carrano et al. 1999; Latres et al. 1999; Tan et al. 1999; Tsvetkov 
et al. 1999).  In this manner, the SKP1-CUL1-F-box (SCF) modular complexes can 
potentially ubiquitinate and target for proteasomal degradation tens, if not hundreds, of 
substrates.  The vast majority of F-box proteins have yet to be well characterized, leaving 
fertile ground for future characterization of CUL1 substrates. 
 
 CUL2 and CUL5 recruit substrates in a very similar manner to CUL1.  The 
heterodimeric linker complex of Elongins B and C (Elongin C being structurally 
homologous to SKP1) interacts with both the amino-terminus of CUL2/5 and secondary 
linkers containing either VHL- or SOCS-box domains (for CUL2 or CUL5 respectively) 
(Kamura et al. 1998; Stebbins et al. 1999; Zhang et al. 1999; Kamura et al. 2001; Kamura 
et al. 2004).   These secondary linkers interact with specific substrates, such as 
hydroxylated HIF-1 transcription factor interacting with the linker VHL (Figure 1.2B).  
CUL3, on the other hand, interacts with substrates through a single hybrid linker 
containing both a cullin-interacting BTB domain and another domain interacting with 
substrates, such as the BTB-Kelch protein Keap1 interacting with the substrate Nrf2 
(Figure 1.2C) (Geyer et al. 2003; Pintard et al. 2003; Xu et al. 2003; Furukawa and Xiong 
2005).  In the human genome, there are at least 40 VHL- or SOCS-box proteins, and over 
200 BTB domain proteins, which allow CUL2/5 and CUL3 to also potentially recruit 
hundreds of substrates.  
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 – The Cullin Family of E3 Ubiquitin Ligases 
The canonical cullins form multisubunit E3 ubiquitin ligase complexes.  (A) 
CUL1 interacts with SKP1 and one of greater than 60 F-box proteins to recruit substrates.  
(B) CUL2 and CUL5 interact with Elongins B and C and either VHL- or SOCS-box 
proteins to recruit substrates.  (C) CUL3 interacts with a series of over 200 BTB-domain 
proteins to recruit substrates.  (D) CUL4A and CUL4B interact with DDB1 and one of 
over 90 DWD-domain proteins to recruit substrates. 
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The cullins are regulated through cyclical modification by the ubiquitin-like protein 
Nedd8 and inhibition by the regulatory protein CAND1 
 
 Substrate recruitment and ubiquitination by the cullin ligases is tightly regulated 
in the cell by cyclical modification of the cullins with the small ubiquitin-like protein 
Nedd8 and its subsequent removal by the “deneddylase” COP9/signalosome.  Several 
years ago, our laboratory and others discovered that CUL1 and all other canonical cullins 
are strongly associated with a 120-kDa protein, CAND1 (Cullin Associated Nedd8-
Dissociated) (Liu et al. 2002; Zheng et al. 2002a; Oshikawa et al. 2003).  CAND1 
associates with cullins that are unmodified by Nedd8, and its cullin binding is mutually 
exclusive with binding of the cullins to their substrate receptors, such as CUL1 with 
SKP1 and CUL4A with DDB1 (Liu et al. 2002; Zheng et al. 2002a; Oshikawa et al. 
2003; Hu et al. 2004).  By an unknown mechanism, SKP1 associated with an F-box 
protein, but not SKP1 alone, is able to initiate the dissociation of CAND1from CUL1 and 
promote Nedd8 modification (Bornstein et al. 2006).  Nedd8 removal, catalyzed by the 
metalloprotease COP9/signalosome, is also essential for normal cullin function (Lyapina 
et al. 2001).  Failure to remove Nedd8 results in ubiquitination and degradation of not 
only proper substrates, but also their cognate receptors, which leads paradoxically to 
accumulation of various cullin substrates (Cope and Deshaies 2006; Lo and Hannink 
2006).  It is speculated that removal of Nedd8 preserves receptor stability by enhancing 
the affinity of cullins for CAND1, which then competes with the receptors for cullin 
binding.  This “cullin cycle” of CAND1 binding, substrate recruitment, and Nedd8 
modification and removal ensures both the stability of substrate receptors and, by limiting 
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the time each substrate receptor resides on the ligase, the availability of the ligase for 
ubiquitination of the correct substrates in response to cellular signals. 
 
Cullins 4A and 4B recruit substrates through interacting with the damaged DNA 
binding protein DDB1 
 
 The primary focus of my research has been to characterize the substrate-recruiting 
functions of CUL4A/B.  CUL4A is of particular interest because the gene is amplified in 
over 20% of primary breast tumors, and the protein is overexpressed in another 30% of 
breast tumors (Chen et al. 1998a).  It may, therefore, have some oncogenic activity that 
contributes to breast cancer, or more broadly, tumor development.  My laboratory first 
established that CUL4A interacts with ROC1, as do all other known cullins (Ohta et al. 
1999).  We also have firmly established that CUL4A interacts in a stoichiometric manner 
with the damaged DNA binding protein 1 (DDB1), and that DDB1 is required for UV-
dependent degradation of the known CUL4A/B substrate CDT1 (Hu et al. 2004).  
(CUL4A and CUL4B both bind to DDB1 and thus may be at least partially redundant in 
function.)  CDT1, a factor required for the licensing of DNA replication, was the first 
CUL4A substrate to be well-studied; C. elegans with RNAi against CUL-4 showed a re-
replication phenotype in certain cell types, which was found to be the result of 
accumulation of CDT1 (Zhong et al. 2003).  
 
 Contemporaneous with our and others’ work on CDT1, other labs showed that the 
DDB2 immunocomplex contains DDB1 and CUL4A, and a similar Cockayne Syndrome 
protein A (CSA) complex also contains DDB1 and CUL4A (Groisman et al. 2003).   The 
authors demonstrated that CUL4A/DDB1 function is required for normal global genomic 
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repair (a function of DDB2) and transcription-coupled nucleotide excision repair (a 
function of CSA).   They also found that the DDB2/DDB1/CUL4A complex responds 
differently to UV irradiation than does the CSA/DDB1/CUL4A complex; within 30 
minutes of UV treatment, the DDB2 complex associates with chromatin and dissociates 
from the Nedd8-deconjugating enzyme COP9/signalosome, which results in increased 
CUL4A-Nedd8 (its putatively active state).  After two hours, the signalosome 
reassociates, and CUL4A is de-neddylated, likely ceasing its ligase activity.  CSA 
behaves with different kinetics—always chromatin-bound, its signalosome-bound 
fraction increases after UV, suggesting a different pattern of substrate degradation.  
DDB2 itself is also ubiquitinated by CUL4A, and its protein levels oscillate during the 
cell cycle while its mRNA levels stay relatively constant.  This suggests that DDB2 is 
itself regulated by proteolysis, perhaps after targeting its substrates for ubiquitination 
(Nag et al. 2001).   
 
 After these initial discoveries of CUL4A mutisubunit complexes and substrates, 
the picture of how CUL4A/B target their substrates for degradation has gradually come 
into focus through a series of findings over the past few years.  The transcription factor c-
Jun is a CUL4A substrate, through interaction with a series of linkers: DDB1, DET1 and 
COP1 (Wertz et al. 2004).  In an unclear manner, the homeobox protein HOXA9 is also 
targeted by CUL4A for polyubiquitination and degradation (Zhang et al. 2003).  The 
CSA/DDB1/CUL4A complex targets the Cockayne Syndrome protein B (CSB) for 
ubiquitination as well (Groisman et al. 2006).    And, the DDB2/DDB1/CUL4A complex 
has been shown to ubiquitinate (but not target for proteolysis) the nucleotide excision 
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repair factor XPC (Sugasawa et al. 2005), histones H3 and H4 (Wang et al. 2006), and 
histone H2A at UV-damaged DNA sites (Kapetanaki et al. 2006).  Finally, the WD-40 
domain protein L2DTL/CDT2 and PCNA are required for targeting of the substrate 
CDT1 for CUL4A-dependent ubiquitination (Higa et al. 2006a; Hu and Xiong 2006; 
Senga et al. 2006). 
 
DDB1 associates with a subset of WD40-domain substrate receptors 
 
 These several findings clearly implicate DDB1 as the primary linker for 
CUL4A/B-based E3 ligases.  However, how DDB1 recruits substrates is substantially 
more complex than the one- or two-linker systems used by other cullins.  Several proteins 
known to interact with DDB1 contain WD-40 beta-propeller domains: DDB2, CSA, 
CDT2, and two novel proteins that I identified by mass spectrometry (see Chapters 2 and 
3), VprBP and WDR23.  This led Joe He in my laboratory to hypothesize that there is a 
specific domain within these WD-40 proteins that interacts with DDB1.  His 
bioinformatic approach yielded a putative domain, which led to the identification of 17 
novel DDB1-interacting WD (DWD) proteins (He et al. 2006).  This research, to which I 
contributed significantly, is described in Chapter 2.  At the same time, three other 
laboratories by mass-spectrometric and structural approaches identified the same domain 
and other novel DWD proteins (Angers et al. 2006; Higa et al. 2006b; Jin et al. 2006).  
The greater than 90 DWD proteins in the human genome suggest that there are numerous 
CUL4A substrates yet to be identified.  And, it is also clear that not only DWD proteins 
recruit substrates to CUL4A/DDB1.  The linker DET1 has no identifiable WD domain, 
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yet links c-Jun to CUL4A; and, the paramyxovirus SV5 V protein, which does not fold 
into a beta-propeller, hijacks the CUL4A/DDB1 ligase to degrade STAT1/2 (Ulane and 
Horvath 2002; Li et al. 2006).   
 
CUL4A/DDB1 has broad and essential cellular functions 
 
 
 In addition to the description of the biochemical mechanism, and identification of 
a wide variety of WD-40 domain and other cellular substrate receptors, several groups 
have studied CUL4A/DDB1 function at the organismal level.  CUL4A knockout mice, as 
would be expected for a ubiquitin ligase functioning on a broad variety of cellular 
substrates, die between days E4.5 and E7.5, and fewer heterozygotes are born than 
expected by Mendelian ratios, suggesting some haploinsufficiency (Li et al. 2002).  
CUL4-silenced C. elegans and dCul4 mutant Drosophila also die in larval stages, and 
demonstrate a growth arrest phenotype ((Zhong et al. 2003) and unpublished data from 
Sima Zacharek in my laboratory).  The close paralog CUL4B, however, is clearly not 
essential and cannot completely compensate for CUL4A function.  CUL4A loss alone is 
embryonic lethal, and loss of CUL4B function in humans only leads to an X-linked 
mental retardation syndrome (Tarpey et al. 2007; Zou et al. 2007).  Molecular data from 
the study of CDT1 degradation suggested strongly that, at least in that case, the two 
CUL4 ligases were redundant because silencing of both was necessary to stabilize CDT1 
after UV treatment; however, the organismal data proves that the redundancy is not total 
(Hu et al. 2004).  CUL4B also contains over 100 amino acids in its amino terminus 
upstream of the DDB1-interaction site, which may contribute to its specialized functions.   
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Most importantly for understanding CUL4A/DDB1 cellular function, DDB1 has 
been conditionally knocked out, in both the brain and in the epidermis.  Loss of DDB1 in 
the brain led to widespread apoptosis of neural progenitor cells, severe brain 
developmental abnormalities, and neonatal lethality.  Mouse embryonic fibroblasts 
produced from these mice had very slow growth, eventually stopping dividing, and 
mitotic abnormalities, increased evidence of oxidative DNA damage, and accumulation 
of the CUL4A substrates CDT1 and p27 (Cang et al. 2006).  In the epidermis, the same 
group did a much more detailed characterization of DDB1 function.  Loss of DDB1 led, 
again, to neonatal lethality due to a total loss of epidermal proliferation, and apoptosis of 
epidermal progenitor cells.  DDB1-/- keratinocytes had high levels of apoptosis, G2/M 
accumulation, and activation of the ATM-dependent DNA damage pathway.  
Concomitant p53 loss rescued the apoptotic phenotype but not the accumulation of DNA 
damage, growth inhibition, aneuploidy, or neonatal lethality.  Regardless of p53 state, c-
Jun and p21Cip1 accumulated.  c-Jun is a known CUL4A/DDB1 substrate, but it will be 
highly interesting to examine whether p21 is also a substrate for the ligase.  These DDB1 
knockout studies have firmly established CUL4A/DDB1’s role in DNA metabolism, 
cellular proliferation, and organismal development. 
 
Viral proteins utilize cellular ubiquitin ligases to target specific cellular proteins for 
proteasomal degradation 
 
 
 Ubiquitin ligases are an excellent target for viral modification of cellular activity, 
because they can rapidly polyubiquitinate and signal for proteolysis specific cellular 
proteins.  The degradation of the immune modulators STAT1 and 2 by CUL4A/DDB1 
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bridged by the paramyxovirus SV5 V protein is one example of many.  The founding 
member of the HECT E3 ligase family, E6AP (E6 associated protein), is named for its 
association with human papillomavirus E6 protein. E6 links the tumor suppressor p53 to 
E6AP, causing its polyubiquitination and degradation, a critical event in the 
papillomavirus-mediated development of cervical cancer (Talis et al. 1998).  p53 is also 
targeted by the adenoviral proteins E4orf6 and E1B55K to a CUL5-dependent ubiquitin 
ligase (Querido et al. 2001).  The human immunodeficiency virus (HIV) also utilizes 
cellular ubiquitin ligase machinery.  The accessory protein Vif also interacts with CUL5, 
targeting the host antiviral factor APOBEC3G for degradation (Yu et al. 2003).  Recently, 
another HIV-1 accessory protein, Vpr, was also shown to target cellular proteins, the 
uracil DNA glycosylases UNG2 and SMUG, for proteolytic degradation in a 
CUL4A/DDB1-dependent manner (Schrofelbauer et al. 2005; Schrofelbauer et al. 2007).  
This interaction is physiologically significant, as Vpr’s interaction with UNG2 inhibits 
UNG2’s critical role in immunoglobulin class switch recombination, thereby impairing 
antibody production and possibly inhibiting an antibody-based immune response against 
HIV (Begum et al. 2006).  
  
The Vpr binding protein VprBP is a major binding partner of CUL4A/DDB1 
 
HIV-1 Vpr may have more broad effects on CUL4A/DDB1 function than has 
been reported.  The most abundant protein that I identified by mass spectrometry in the 
CUL4A immunocomplex was the Vpr interacting protein VprBP (see Chapters 2-4).  
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This protein was initially identified through co-immunoprecipitation and peptide 
sequencing of HIV-1 Vpr-interacting proteins (Zhao et al. 1994; Zhang et al. 2001), and 
its physiological functions are the focus of my dissertation research, particularly in 
Chapter 3, while initial explorations into its function with Vpr are described in Chapter 4.   
 
Vpr, a 96-amino-acid, 14-kDa protein, is dispensable for in vitro viral growth and 
replication, yet is essential for HIV function in vivo.   It has been implicated in a number 
of different viral and cellular processes, from enhancing accuracy of reverse transcription 
to nuclear import of viral DNA, and from anti- and pro-apoptotic activities to 
transactivation of HIV LTR and host genes (Le Rouzic and Benichou 2005).  Yet, its 
most well studied cellular phenotype, when expressed alone or in the context of whole 
viral infection, is arrest of the cell cycle in G2, followed subsequently by apoptosis (He et 
al. 1995; Re et al. 1995; Bartz et al. 1996; Stewart et al. 1997; Roshal et al. 2003; 
Andersen et al. 2005; Lai et al. 2005).  There have been many studies into the mechanism 
of this G2 arrest, yet it is still not entirely clear how it occurs.  Inhibition of either the 
ATR or Chk1 DNA damage checkpoint kinases inhibits this arrest (Roshal et al. 2003), 
which occurs regardless of the presence of the p53 or Rb stress response pathways,  as 
HeLa cells readily arrest.   The G2 arrest has characteristics of replication stress or DNA 
damage: Vpr binds directly to chromatin (Lai et al. 2005), it induces H2AX 
phosphorylation and RPA foci, requires Rad17 and Hus1 (Zimmerman et al. 2004), and 
activates Brca1 and its target GADD45α (which is also required for the arrest) (Andersen 
et al. 2005).  Despite all this data, there has yet to be clear mechanistic evidence showing 
how Vpr activates this DNA damage/replication stress pathway.  Very recent data 
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showed that Vpr disrupts the association of CUL4A/DDB1 with its substrate receptor 
DDB2, thereby disrupting nucleotide excision repair (Schrofelbauer et al. 2007).  
Knowing that DDB1 loss also leads to G2 cell cycle arrest, the authors speculate that the 
loss of DNA repair capacity by disrupting DDB1-DDB2 interaction may be the direct 
cause of Vpr-mediated G2 arrest.  However, this remains purely correlative, as G2 arrest 
is not a very specific cellular phenotype. 
 
Summary 
 
 In subsequent chapters, I explore several aspects of the function of the 
CUL4A/DDB1 E3 ubiquitin ligase.  In Chapter 2, modified and expanded from a 
publication in 2006 in Genes and Development, Joe He and I, together with contributions 
from others in our lab, discovered by mass spectrometry, followed by bioinformatics and 
molecular biological approaches, a common motif shared by many CUL4A/DDB1-
interacting WD40 (DWD) repeat proteins.  In Chapter 3, soon to be reformatted into a 
manuscript for submission, I selected one novel DWD protein, VprBP, and characterized 
its interactions with CUL4A/DDB1, and have begun to explore its essential role in DNA 
replication.  Following up on the reported interaction between VprBP and the HIV-1 
protein Vpr, in Chapter 4, I have included preliminary studies into the detailed 
characterization of this interaction.  Finally, Chapter 5 contains broad conclusions and a 
discussion of future prospects for research in VprBP, CUL4A/DDB1, and the cullin 
family in general. 
 
 CHAPTER 2 
 
DDB1 FUNCTIONS AS A LINKER TO RECRUIT WD40 PROTEINS TO CUL4-
ROC1 UBIQUITIN LIGASES  
 
(including modified portions from He YJ, McCall CM, Hu J, Zeng Y, and Xiong Y.  
Genes Dev 20(21): 2949-2954, 2006)
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Summary 
Cullins assemble the largest family of ubiquitin ligases by binding with ROC1 
and various substrate receptors.  CUL4 function is linked with many cellular processes, 
but its substrate-recruiting mechanism remains elusive.  We identified a protein motif, the 
DWD box (DDB1-binding WD40 protein), and demonstrated the binding of 15 DWD 
proteins with DDB1-CUL4A.  We provide evidence supporting the critical function of 
the DWD box and DDB1’s role as the linker mediating DWD protein association with 
CUL4A.   A database search predicts that about one-third of WD40 proteins, 90 in 
humans, contain the DWD box, suggesting a potentially large number of DWD-DDB1-
CUL4-ROC1 E3 ligases.
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Background 
The ubiquitin-proteasome pathway regulates the concentration and conformation 
of many cellular proteins in response to changes in physiological conditions.  This 
pathway consists of a cascade of three activities performed by E1 (ubiquitin activating), 
E2 (ubiquitin conjugating) and E3 (ubiquitin ligase) enzymes (Hochstrasser 1996; King 
et al. 1996; Hershko and Ciechanover 1998).  A critical step in this process is how 
individual protein substrates are recruited to specific E3 ligases.  The RING family 
represents the major family of E3 ligases.  Members either contain an intrinsic RING 
finger domain (as in MDM2 and BRCA1), or bind in trans with a small RING finger 
protein, such as  ROC1 (also known as Rbx1 and Hrt1) by the cullins, to recruit and 
activate an E2 (Jackson et al. 2000; Petroski and Deshaies 2005a).   
 
A remarkable aspect of cullin E3 ligases is that each cullin can assemble into 
many distinct cullin-RING dependent ligases (CRLs) by interacting with a conserved 
motif present in multiple proteins (Petroski and Deshaies 2005a).  To recruit specific 
substrates, CUL1 utilizes an N-terminal domain to bind with a linker protein, SKP1 
(Feldman et al. 1997; Skowyra et al. 1997; Zheng et al. 2002b), which does not interact 
with other cullins (Michel and Xiong 1998).  SKP1 uses a separate domain to bind with a 
conserved protein motif, the F-box, which via its additional protein-protein interaction 
modules recruits various substrates, often phosphorylated, to the CUL1-ROC1 catalytic 
core.  To bring specific substrates to CUL2- and CUL5-dependent ligases, a 
heterodimeric linker complex containing elongins B and C binds simultaneously to an 
analogous N-terminal domain in CUL2 and CUL5 and to two similar protein motifs, the 
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VHL-box and SOCS box.  VHL and SOCS proteins, via their additional protein-protein 
interaction modules, target various substrates differentially to the CUL2-ROC1 or CUL5-
ROC2 catalytic cores (Kamura et al. 1998; Stebbins et al. 1999; Zhang et al. 1999; 
Kamura et al. 2001; Kamura et al. 2004).  Omitting a linker, CUL3 utilizes its N-terminal 
domain to bind to proteins with a conserved 100-residue protein motif known as a BTB 
domain, which via additional protein-protein interaction domains then target various 
substrates to the CUL3-ROC1 catalytic core (Furukawa et al. 2003; Geyer et al. 2003; 
Pintard et al. 2003; Xu et al. 2003).   The presence of multiple substrate receptors—
mammals express more than 60 F-box, 40 SOCS and 200 BTB proteins—suggests that 
cullins may form the largest family of E3 ligase complexes and control the ubiquitination 
of a wide variety of substrates.  The substrate recruiting mechanism of CUL4, which has 
two closely related paralogues, CUL4A and CUL4B, in mammals and presents as a 
single gene in S. pombe, C. elegans and Drosophila, has remained elusive.  Various 
reports have suggested that CUL4 may assemble multiple ligases to target many different 
substrates.  One protein that has frequently been found in association with these various 
different CUL4 complexes is DDB1, first identified as a damaged DNA binding protein 
(Chu and Chang 1988).   The emerging picture is that DDB1 functions as a critical factor 
for CUL4-ROC ligases and possibly acts as a linker to bridge a substrate receptor(s) to 
CUL4.  This chapter is directed toward understanding the substrate recruiting mechanism 
and the architecture of DDB1-CUL4 ligases.  
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Experimental Procedures 
 
Antibodies, immunopurification and mass spectrometric analysis 
 
Antibodies to HA (12CA5, Boehringer-Mannheim), Myc (9E10, NeoMarker), T7 
(Novagen), and FLAG (M2, Sigma) were purchased commercially.  Rabbit polyclonal 
antibodies to CUL4A, DDB1 and CDT1 have been described (Hu et al. 2004).  A rabbit 
polyclonal antibody against CUL4B was produced by injection of a synthetic peptide 
antigen to residues 34-62 of CUL4B (AAQEVRSATDGNTSTTPPTSAKKRKLNSS).  A 
rabbit polyclonal antibody against DDB2 was the kind gift of Dr. Altaf Wani (Ohio State 
University).  To purify the endogenous CUL4A complex, BT474 cells from 47 150-mm 
plates were lysed with a 0.5% NP-40 lysis buffer (50 mM Tris-HCl at pH 7.5, 150 mM 
NaCl, 0.5% NaCl, 50 mM NaF) with addition of additional inhibitors immediately before 
lysis (1 mM DTT, 1 mM Na3VO4, 1 mM PMSF, 1 mM benzamidine, 100 µg/mL trypsin 
inhibitor, 25 µg/mL leupeptin, 25 µg/mL aprotinin) and lysates were pooled (300 mg 
total).  Clarified lysates were immunoprecipitated with affinity-purified anti-CUL4A 
antibody (2 µg per mg protein in lysate, +/- 10 µg/mg antigen peptide).  
Immunocomplexes were resolved by SDS-PAGE, stained with Coomassie blue, and the 
protein bands were digested with trypsin and subjected to mass spectrometric analysis at 
the UNC Proteomics Core Facility.   
 
Plasmids, cell culture and cell transfection   
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Plasmids expressing human CUL4A, DDB1, and CDT1 were as previously 
described (Ohta et al. 1999; Liu et al. 2002; Furukawa et al. 2003; Hu et al. 2004).  
Plasmids expressing DDB2, CSA, and all other WD40 proteins were produced by 
amplifying cDNA from either human HeLa or thymus (kind gift of Dr. Lishan Su) cDNA 
libraries and subcloning into pcDNA3-based mammalian expression vectors.  Mutations 
were introduced by site-directed mutagenesis using the Quick-Change Kit (Stratagene) 
and verified by DNA sequencing.  All human cells were cultured in DMEM containing 
10% FBS in a 370C incubator with 5% CO2, except 293T cells, which were cultured in 
DMEM containing 10% newborn calf serum.  Cell transfections were carried out using a 
calcium-phosphate buffer.   
 
Gel filtration chromatography 
 
To examine the elution profile of CUL4A and associated proteins, HeLa cells 
were lysed with the 0.5% NP-40 lysis buffer, and clarified lysate was resolved through a 
Superdex-200 gel filtration column (GE/Amersham).  0.5 mL fractions were collected, 
and 50 µL of each was resolved via SDS-PAGE and immunoblotted with antibodies as 
indicated.  High molecular weight standards (GE/Amersham) were resolved through the 
same column, and the peak fraction for each was determined. 
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35S-IP  
 
About 80% confluent 100-mm tissue culture dishes of cells were washed with 1X 
PBS and then incubated in DMEM without methionine or cysteine (ICN, Inc.) + 10% 
dialyzed FBS, for 30 minutes.  0.5 mCi of 35S-methionine (NEN) was added to each dish 
and incubated for 4 hours to label newly synthesized proteins.  The cells were then 
washed twice with 5 mL of cold 1X PBS and lysed with 1 mL of 0.5% NP-40 lysis buffer 
per plate.  Clarified lysates were divided in half, and each half was immunoprecipitated 
with 10 µg of anti-CUL4A antibody, +/- 50 µg of antigen peptide.  The 
immunocomplexes were immobilized on Protein-A agarose beads, and resolved via SDS-
PAGE.  The gel was then dried and exposed to film. 
 
RNA interference (RNAi)   
 
A duplex oligonucleotide encoding human DDB1-specific shRNA  (5’-
CCGGCAGCATTGACTTACCAGGCATCTTCCTGTCAATGCCTGGTAAGTCAATG
CTGTTTTTG-3’) was ligated into the PMKO.1 vector (Addgene plasmid 8452).  
Retrovirus production was carried out according to a standard protocol and then used to 
infect U2OS and HeLa cells. The infected cell lines were then selected by puromycin (2 
µg/mL) for 4 days before analyzing protein expression and complex formation. 
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Results 
 
CUL4A associates with a potentially large number of cellular proteins 
 
 To begin searching for the substrate targeting mechanism of CUL4, I first 
examined CUL4A complexes in vivo by size-exclusion chromatography to gain an initial 
view of their size distribution.  This study revealed that CUL4A exists in a number of 
different complexes, varying in size from approximately 250 kDa to over 700 kDa (Fig. 
2.1A).  Notably, two proteins that are critical partners of CUL4A, DDB1 and ROC1, also 
exist in many different complexes.  In comparison, the distribution of most CUL1 
complexes is limited to a much narrower size range smaller than 440 kDa, very similar to 
that of CAND1, a negative regulator of CRLs that binds to un-neddylated form of cullins 
and blocks the binding of SKP1 linker with CUL1 (Liu et al. 2002; Zheng et al. 2002a; 
Goldenberg et al. 2004).  The distribution of CSN5, the catalytic subunit of the 
COP9/signalosome, exhibits an almost mutually exclusive pattern from that of CUL1 and 
CAND1, but yet overlaps significantly with CUL4A.  These observations are consistent 
with the finding that CUL4A molecules abundantly associate with the COP9/signalosome 
[(Groisman et al. 2003) and Fig. 2.1C], but only a small portion is associated with 
CAND1, suggesting that CUL4A assembles into many different and active complexes in 
vivo.   
 
 To identify proteins that interact with CUL4A in these different complexes, I 
analyzed CUL4A complexes by 35S-IP in various tissues (data not shown) and cell lines, 
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including two breast cancer lines (SKBR3 and BT474) known to overexpress CUL4A 
(Chen et al. 1998b), as well as two other cell lines that do not overexpress CUL4A.  
These analyses revealed a large number of potential CUL4A-interacting proteins as 
determined by antigen peptide competition (Fig. 2.1B).  I then scaled up 
immunopurification of the CUL4A complex from BT474 cells and analyzed it by mass 
spectrometry.   I have thus far identified 13 CUL4A-associated proteins (Fig. 2.1C).  
These include 11 proteins whose association with CUL4A had been previously identified 
(ROC1, DDB1, CAND1 and the eight COP9/signalosome subunits), and two novel 
proteins, WDR23 and VprBP.  Coomassie blue staining indicates that CUL4A associates 
nearly stochiometrically with DDB1, but with the COP9/signalsome at a much lower 
level.  Together, these results support the notion that CUL4A may associate with multiple 
different cellular proteins to assemble various E3 complexes and that DDB1 is a critical, 
if not essential, component of CUL4A ligases.   
  
Identification of a DWD box conserved in DDB1-binding WD40 proteins 
 
One intriguing finding from my preliminary studies of CUL4A-interacting 
proteins is the identification of two WD40 repeat proteins, WDR23 and VprBP.   While 
neither protein has been functionally characterized or linked with CUL4-DDB1, the 
significance of this identification is appealing when considering that four previously-
identified CUL4A interacting proteins, DDB2, CSA, COP1 and CDT2, also contain 
WD40 repeats (Groisman et al. 2003; Wertz et al. 2004; Holmberg et al. 2005; Liu et al. 
2005).  The WD40 repeat is loosely defined at the primary sequence level by a Gly-His 
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dipeptide 10-20 residues N-terminal from a Trp-Asp (WD) dipeptide, and is typically 
about 40 residues in length.  WD40 proteins form a propeller-like structure, typically 
with 7 blades, each composed of four anti-parallel b-sheets.  There are more than 700 
human WD40 repeat protein entries in the current PFAM database 
(http://www.sanger.ac.uk/Software/Pfam/index.shtml), corresponding to 320 unique 
genes after eliminating duplicates and truncated forms.  As not all WD40 repeat proteins 
associate with DDB1 or CUL4 even when overexpressed (see below), it is likely that 
only a subset of WD40 repeat proteins interact with the DDB1-CUL4A ligase.  
 
To identify the signature motif shared by DDB1-binding WD40 proteins, Mr. He 
carried out extensive primary sequence alignment and computer modeling.  The WD40 
repeats were first compared using NCBI-Blast searches and the CLUSTAL algorithm, 
then adjusted manually and continuously refined as more DDB1-binding proteins were 
experimentally identified (see below).  This analysis identified a 16-residue stretch that 
we refer to as the DWD box (DDB1-binding and WD40 repeat, Fig. 2.1D) and is defined 
by three features.  (i) The first 14 residues in the DWD box correspond to the second half 
of a WD40 repeat that is more conserved than other WD40 repeats.  These 14 residues 
include three highly conserved residues, Asp7, Trp13, Asp14, five hydrophobic residues 
(Ile, Leu or Val) at position 1, 2, 10, 12 and 15, and three small residues (Ala, Gly, Ser or 
Thr) at position 3, 4, and 5.  (ii) Arg16 following the WD dipeptide is a signature residue 
of the DWD box.  Notably, the Arg residue in the DWD box of DDB2 is mutated in 
several human patients with xeroderma pigmentosum group E (XP-E), and reduces its 
binding with DDB1 [(Rapic-Otrin et al. 2003), see Fig. 2.3 below].  The crystal structure 
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Figure 2.1 
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Fig. 2.1.  Human CUL4 associates with potentially multiple WD40 repeat proteins 
(A) Clarified lysate from HeLa cells was fractionated over a Superdex 200 gel filtration 
chromatography column, resolved by SDS-PAGE, and Western blotted with indicated 
antibodies. 
 
(B) 35S-labeled, clarified lysates from four cell lines were immunoprecipitated with an 
anti-CUL4A antibody and resolved by SDS-PAGE, followed by autoradiography.  
Identity of CUL4A and DDB1 were subsequently confirmed by mass spectrometric 
analysis.   
 
(C) Immunopurification and mass spectrometric analysis of CUL4A complexes.  CUL4A 
immunocomplexes were precipitated from human BT474 cells and resolved by SDS-
PAGE followed by staining with Coomassie Brilliant Blue.  Bands identified by mass 
spectrometry are indicated. 
 
(D) Identification of a putative DDB1-binding motif in WD40 proteins, the DWD box. 
The DWD box is predicted to be present in more than 100 human WD40 repeat proteins.  
Only three reported in the literature (DDB2, CSA and COP1) and 15 demonstrated in this 
study are included.  CDC20 does not contain a DWD box and does not detectably interact 
with DDB1-CUL4A. 
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of the heterotrimeric G protein b1 subunit, a DWD protein (see below), has been solved 
and shows that several conserved residues, including the Arg16, within the DWD box are 
located on the protein surface (Sondek et al. 1996), suggesting that these residues might 
participate in binding with other proteins.  (iii) A DWD protein usually contains one and 
sometimes two DWD boxes, but rarely three.     
 
Multiple DWD proteins associate with DDB1-CUL4A 
 
To experimentally test the DWD hypothesis, Mr. He and I randomly chose and 
expressed a number of putative DWD proteins and examined their binding with 
CUL4A/DDB1 by coupled IP-Western assays.  Considering DDB1 as a possible linker, 
Mr. He triply transfected plasmids expressing CUL4A, DDB1 and individual WD40 
proteins.  Association between WD40 proteins and DDB1-CUL4A was determined by 
either Western blotting of the WD40 protein in the CUL4A immunocomplex, or 
conversely blotting either CUL4A or DDB1 protein in the WD40 protein 
immunocomplex (Fig. 2.2A and 2B).  DDB2 and CSA, the two best-characterized DWD 
proteins, interact with DDB1 strongly and were included as positive controls.  We have 
identified thus far 15 novel human WD40 proteins that positively bind with DDB1-
CUL4A.  Twelve are associated with CUL4A/DDB1 in a readily detectable manner when 
compared with DDB2 and CSA, including VprBP and WDR23 (Fig. 2.1C), FBXW5, 
RBBP7, and Gb2 (Fig. 2.2A), WSB1, WSB2, PWP1 and GRWD1 (Fig. 2.2B), and 
FBXW8, APG16L and KATNB1 (Fig. 2.3B).  Three WD40 proteins, NUP43, mbTrCP 
and RBBP4, weakly interact with DDB1 and CUL4A (Fig. 2.2B).   COP1 contains 
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conserved WD40 repeats, but not the signature Arg16, and only associates with DDB1-
CUL4A weakly in comparison with other WD40 proteins (Fig. 2.2B).  It is currently not 
clear whether COP1 directly interacts with DDB1 or is bridged by another protein as 
suggested by the finding that a mutation outside the WD40 repeats in COP1 disrupted its 
binding with DET1 as well as with DDB1 (Wertz et al. 2004).  CDC20, a WD40 protein 
that is missing several conserved residues including the signature Arg16 (Fig. 2.1D), did 
not detectably interact with DDB1-CUL4A in a reciprocal IP-Western assay (Fig. 2.2A), 
suggesting that only a subset of, but not all, WD40 proteins interact with DDB1-CUL4A.  
Thus, together with three previously reported DDB1-binding WD40 proteins, DDB2, 
CSA and COP1, a total of 18 DWD proteins have been demonstrated to bind with DDB1-
CUL4 experimentally.  
 
The DWD box is important for DWD proteins binding to DDB1-CUL4A 
 
To provide evidence supporting the DWD hypothesis, Ms. Zeng first determined 
the in vivo association of endogenous CUL4A with a newly identified DWD protein, 
RBBP7, to which an antibody is available.  RBBP7 was readily detected in the CUL4A 
immunocomplex and was competed off by molar excess of antigen peptide (Fig. 2.3A).   
 
Finding that at least two F-box-containing WD40 repeat proteins, FBXW5 (Fig. 
2.2A) and FBXW8 (Fig. 2.3A), interact with DDB1-CUL4A is somewhat unexpected 
given that F-box proteins interact with CUL1.  Mr. He determined whether the F-box is  
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Figure 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2.  Multiple WD40 repeat proteins bind with CUL4A/DDB1 
(A, B) WD40 proteins were cloned into pcDNA3-myc3 expression vectors and co-
transfected into 293T cells with plasmids expressing HA-CUL4A and T7-DDB1.  Cell 
lysates were immunoprecipitated and Western blotted as indicated. 
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required for the binding of WD40 proteins with DDB1-CUL4A.  Binding assays showed 
that the F-box protein SKP2, which does not contain WD40 repeats, did not interact with 
CUL4A, and that deletion of the F-box from FBXW5 did not seem to affect its binding 
with CUL4A (Fig. 2.3A).  Two additional WD40 proteins that do not contain an F-box, 
APG16L and KATNB1, were readily detected in the CUL4A immunocomplex in the 
same binding assay.  We therefore conclude that WD40 repeats, but not the F-box, are 
required for interacting with DDB1-CUL4A. 
 
To directly test the DWD hypothesis, Mr. He performed site-directed mutagenesis 
of the DWD box of DDB2 (Fig. 2.3C).  Nine residues in the DWD box were changed to 
alanine and individual mutant proteins were co-expressed with CUL4A.  The expression 
of both CUL4A and DDB2 mutants were verified by direct Western blotting and DDB2-
CUL4A association was determined by IP-Western analysis.  DDB2-CUL4A association 
was nearly completely disrupted by the mutation of the signature Arg at position 16 
(corresponding to Arg273 in DDB2), substantially reduced by the mutations of five 
conserved residues, Leu at position 2 (corresponding to Leu258 in DDB2), Asp at 
position 7 (Asp264), Ile at position 10 (Ile269), Trp at position 13 (Trp270) and Leu at 
position 15 (Leu272), and reduced to a lesser extent by the mutation of Ser at position 3 
(Ser262).  Mutation of Val at position 11 (Val267), which is not highly conserved among 
the DWD proteins, and another residue, Gln274, outside the DWD box did not 
appreciably affect DDB2-CUL4A binding.    
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 To further test the DWD hypothesis, Mr. He introduced alanine substitutions 
targeting the signature arginine residue in the DWD box of three additional DWD 
proteins, CSA, PWP1 and APG16L. The Arg–to-Ala substitution nearly completely 
disrupted the binding of DDB1-CUL4A with CSA, and substantially reduced the binding 
of DDB1-CUL4A with PWP1 and APG16L (Fig. 2.3D). Together, these bioinformatic 
analysis and binding and mutagenesis experiments demonstrate that the DWD box not 
only correlates with, but is also directly involved in mediating the binding of a subset of 
WD40 proteins with DDB1-CUL4.  Whether the DWD motif is sufficient for binding 
with DDB1 has not been tested due to the unique structure of WD40 proteins.  Each 
WD40 propeller contains seven blades and every blade is made of four β-sheets, three 
from one WD40 repeat and one from the next repeat.  The DWD box corresponds to the 
second and third β-sheets of one blade.  These features suggest that while the DWD box 
is required for binding to DDB1, other residues are likely involved as well and also make 
it unfeasible to map the binding sequence by deletion analysis without causing 
conformational collapse of the entire blade.      
 
DDB1 links the DWD protein DDB2 to CUL4A  
 
The results from our binding assays are most consistent with a model where 
DDB1 functions as a linker to bridge the DWD proteins to CUL4A.  To directly test this 
model, we examined the interaction of DDB2 with CUL4A in more detail.  Two 
hydrophobic helical surfaces in the N-terminal tip of CUL1, H2 and H5, bind with 
hydrophobic and polar residues from SKP1 to form a large interface.  The N-terminal  
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Fig. 2.3.  Testing the DWD hypothesis 
(A)  CUL4A associates with endogenous RBBP7.  293T cells were lysed with 0.1% NP-
40 lysis buffer and immunoprecipitated with an anti-CUL4A antibody, with or without 
molar excess of antigen peptide.  The immunocomplexes were resolved by SDS-PAGE, 
and Western blotted with indicated antibodies.   
 
(B)  F-box-and-WD40 proteins FBXW5 and FBXW8 were characterized for binding with 
DDB1-CUL4A.  SKP2 (F-box protein without WD40 repeats) and DDB2 were included 
as a negative and a positive control, respectively.  A mutant of FBXW5 deleting the F-
box was tested for binding with DDB1-CUL4A along with two additional DWD proteins, 
APG16L and KATNB1, that do not contain an F-box. 
 
(C)  Individual residues of the DWD box of DDB2 protein were changed to alanine and 
tested for binding with CUL4A by IP-Western analysis.  
 
(D)  The conserved arginine of the DWD box is critical for binding with DDB1-CUL4A.  
The arginines of three DWD proteins were changed to alanine and tested for binding with 
CUL4A by IP-Western analysis. 
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regions of other cullins form similar H2 and H5 helices, which contain residues that are 
invariably conserved in orthologues, but are different in paralogues (Zheng et al. 2002b).  
We have previously shown that the substitution of residues in the H2 (86LYQAV90 -> 
86AAAAA90) or H5 (139WQDH142 -> 39AADA142) helices of CUL4A substantially 
reduced DDB1-CUL4A binding ((Hu et al. 2004) and Fig. 2.3B).  Binding assays 
demonstrated that mutation of either the H2 or H5 helix of CUL4A almost completely 
abolished CUL4A-DDB2 interaction (Fig. 2.4A).  Mr. He noted that the steady-state level 
of DDB2 was higher when co-expressed with either the H2 or H5 mutant of CUL4A, a 
finding that is consistent with the possibility that DDB2 is degraded by the DDB1-
CUL4A-ROC1 ligase, either as a direct substrate or as a substrate receptor that is 
degraded after delivering the substrate.  Infection of a retrovirus expressing shRNA 
targeting DDB1 reduced the steady state level of DDB1 by more than 85% in U2OS cells 
and about half in HeLa cells, and did not change the steady state level of either CUL4A 
or RBBP7, but substantially reduced the in vivo association of CUL4A-RBBP7 in both 
U2OS and HeLa cells (Fig. 2.4B).   Together, these results support a model that DDB1 
acts as a linker bridging the binding of DWD proteins and CUL4. 
 
 We previously demonstrated that like SKP1-CUL1, the DDB1-CUL4A 
association is also negatively regulated by CAND1 (Hu et al. 2004).  The model that 
DDB1 acts as a linker to bring other DWD proteins to CUL4 predicts that CAND1 and 
DWD proteins would interact with CUL4 in a mutually exclusive manner.  To test this 
prediction, Mr. He determined the interactions among these proteins.  As expected, 
CAND1, DDB1 and the DWD protein DDB2 were readily detected in the CUL4A 
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Figure 2.4 
 
 
 
 
 
 
Fig. 2.4.  DDB1 bridges WD40 repeat proteins to CUL4 
(A) Intact H2 and H5 helices of CUL4A are required for binding with DDB1 and DDB2.  
293T cells were co-transfected with plasmids expressing indicated proteins.  The steady 
state level and protein-protein interactions were determined by direct immunoblotting and 
IP-Western, respectively. 
 
(B) Silencing DDB1 reduced CUL4A-RBBP7 association.  DDB1 was knocked down by 
the infection of a retrovirus expressing shRNA targeting DDB1.  The steady state level 
and CUL4A-RBBP7 association were determined by direct Western and IP-Western 
analysis. 
 
(C) CAND1 and DDB2 form mutually exclusive complexes with CUL4A.  293T cells 
were co-transfected with plasmids expressing HA-DDB2, T7-DDB1, and myc3-CUL4A.  
Cell lysates were immunoprecipitated and blotted with indicated antibodies. 
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immunocomplex (Fig. 2.4C).  In the same assay, both DDB1 and CUL4A, but not 
CAND1, were detected in the DDB2 immunocomplex (Fig. 2.4C), further supporting the 
model that DDB1 acts as a linker bridging the binding of DWD proteins and CUL4. 
 
Multiple DWD proteins interact with each other, potentially in an oligomeric cullin 
complex. 
 
 
There is mounting evidence that RING finger ubiquitin ligases may function in 
dimeric complexes.  Mdm2/MdmX, BRCA1/BARD1, and Bmi1/Ring1B are three recent 
examples (Sharp et al. 1999; Tanimura et al. 1999; Brzovic et al. 2001; Buchwald et al. 
2006).   Recently, CUL3 was also shown to function as a dimer, and dimerization 
required modification with Nedd8 (Wimuttisuk and Singer 2007).  Together with our 
evidence that CUL4A and DDB1 exist in very high molecular weight complexes (Figure 
2.1A), I hypothesized that CUL4A might also exist in dimeric complexes.  To test this, I 
co-transfected CUL4A constructs with different epitope tags (Figure 2.5A).  I found that 
CUL4A both homodimerizes and heterodimerizes with CUL1, and the dimerization is 
stabilized by additional overexpression of DDB1.  To confirm this, I co-
immunoprecipitated endogenous CUL1 using an anti-CUL4A antibody (Figure 2.5B).  
The component of such a dimeric complex are not known, but one possibility is that 
multiple complete CUL4A/DDB1/DWD complexes might exist in one unit.  To test this, 
I co-transfected the DWD protein VprBP and several other DWD proteins.  All tested 
DWD proteins co-immunoprecipitated with VprBP (Figure 2.5C).  To confirm that this 
was not specific to VprBP, I also tested the binding of the DWD protein DDB2 to the 
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Figure 2.5.  CUL4A exists in homo- and hetero-dimeric complexes. 
(A) Ectopically-expressed CUL4A dimerizes.  293T cells were transfected with plasmids 
expressing myc3- or HA-tagged CUL4A and/or myc3-tagged CUL1 and/or T7-tagged 
DDB1.  24 hrs after transfection, cells were lysed in 0.5% NP-40 lysis buffer, 
immunoprecipitated with anti-HA or anti-myc antibodies, and Western blotted as 
indicated. 
 
(B) Endogenous CUL4A heterodimerizes with CUL1.  U2OS cells were lysed with 0.5% 
NP-40 lysis buffer, and lysates were immunoprecipitated with an anti-CUL4A antibody.  
The immunocomplexes were split in half and resolved alongside 10% input control lanes.  
One set of IP and input was blotted with anti-CUL4A, the other with anti-CUL1, along 
with other antibodies as indicated. 
 
(C) Multiple DWD proteins interact with each other, presumably in a cullin complex.  
293T cells were co-transfected with myc3-tagged VprBP and one of a series of other 
DWD proteins, as indicated.  Cells were lysed with 0.1% NP-40 lysis buffer,  
immunoprecipitated with an anti-VprBP antibody, and Western blotted with an anti-myc 
antibody.   
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same series of DWD proteins, and it also interacted with them all (data not shown).   In 
these preliminary experiments, no negative control WD-40 protein that does not interact 
with CUL4A/DDB1 was included; therefore, the possibility remains that these 
interactions are non-specific.  However, that both DDB2 and VprBP can form these 
dimeric complexes argues that the interaction is specific.  These data suggest that CUL4A 
functions as an oligomeric ligase as well, but the functional consequence of this has yet to 
be determined. 
 
Discussion 
 
A remarkable feature of the cullin family of E3 ligases is the assembly of multiple 
E3 ligases by each individual cullin.  Despite its linkage with multiple cellular pathways 
and many putative substrates, the substrate recruiting mechanism for CUL4 has remained 
elusive.  The evidence presented here supports the model that a subset of WD40 proteins, 
defined by the presence of a DWD box, bind to DDB1, and that DDB1 functions as a 
linker connecting the DWD proteins to CUL4.  A DWD protein could either be a 
substrate itself or function as a substrate receptor to recruit other protein(s) for 
ubiquitination by the CUL4-ROC catalytic core.  
 
Database searches predict that there may be as many as 90 DWD proteins in 
humans, 74 in mice, 75 in Drosophila, 36 in C. elegans, 122 in Arabidopsis, 33 in S. 
pombe, and 20 in S. cerevisiae (see Appendix 1).  These observations suggest that CUL4-
ROC1 could potentially form a large family of distinct ubiquitin ligases with individual 
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DWD proteins and target the ubiquitination of many substrate proteins.   Among the 
DWD proteins that have been experimentally tested positive for binding with DDB1-
CUL4A are two F-box proteins, FBXW5 and FBXW8, and two SOCS proteins, WSB1 
and WSB2 (Fig. 2.2).  FBXW5 and WSB1 have been shown to bind with CUL1 and 
CUL2/5, respectively (Kamura et al. 2001; Arai et al. 2003).  Whether these receptor 
proteins bind simultaneously with both CUL1 and CUL4 or CUL2/5 and CUL4, and 
whether cullin heterodimers more efficiently promote substrate polyubiquitination is an 
interesting possibility that is yet to be tested.   Data recently presented in the dissertation 
of Jian Hu, a graduate student from our laboratory, shows that the F-box of FBXW5 is 
dispensable for the degradation of a novel cullin 4A substrate, TSC2, but this does not 
prove that other receptor proteins containing multiple cullin binding domains do not 
utilize a cullin heterodimer, or in some other way multiple cullins, to target substrates for 
polyubiquitination.  My preliminary data (Figure 2.5) clearly indicates that CUL4A and 
CUL1 may form heterodimers, and CUL4A may form homodimers, but what role these 
dimers play in cullin function is unclear.    
 
Furthermore, our identification of the “DWD box” as an identifiable feature of 
DDB1-interacting WD-40 proteins does not imply that this is the only necessary surface 
for DDB1 interaction.  It is unlikely that one or two arginine residues are all that is 
necessary to interact specifically with DDB1.  We may find, through more careful 
analysis of DWD proteins, that only a subset of these proteins actually interact with 
DDB1, and/or that other sequences are also required for interaction in addition to the 
conserved box.  Preliminary data from Yaxue Zeng in our laboratory shows that 
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mutagenesis of the critical arginine residues in several DWD proteins does not disrupt 
their interaction with DDB1, which strongly suggests that other sequences are definitely 
required, or stabilize the DDB1-DWD interaction.  However, our mutagenesis data and 
that of others shows that for other DWD proteins, such as DDB2 and CSA, changing 
even one arginine residue to alanine almost completely disrupts DDB1 interaction.  At 
this point, all we can conclusively say is that the definition of the DWD motif is only the 
beginning of understanding how DDB1 interacts with its substrate receptors. 
 
The presence of twenty WD40 proteins in the S. cerevisiae genome with the 
potential to bind with DDB1 is surprising, since there is no obvious homologue of either 
DDB1 or CUL4 in budding yeast.  Two obvious candidate linkers for binding with these 
putative DWD proteins are CPSF160 (the cleavage and polyadenylation specificity factor 
A, 160 kDa subunit) and SAP130 (spliceosome-associated protein 130).  Both CPSF160 
and SAP130 are present in budding yeast, and exhibit a low level similarity with DDB1 
at the primary sequence level, but contain similar β-propellers, as predicted by 
computational modeling (Neuwald and Poleksic 2000) and reinforced by comparison 
with the DDB1 crystal structure (Li et al. 2006).  Even more speculatively, Joseph 
McCarville and Jen Michel from our laboratory discovered that S. cerevisiae lacking 
Cul8 have an anaphase delay and mitotic defects, which are somewhat similar to the 
chromosome segregation and mitotic defects seen in S. pombe and mouse cells lacking 
DDB1 (Bondar et al. 2003; Michel et al. 2003; Cang et al. 2007).  It would be very 
interesting to see if Cul8 interacts with CPSF160 and/or SAP130 in S. cerevisiae.   
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The data presented in this chapter establishes the first evidence for a family of 
substrate receptor proteins that interact with the CUL4/DDB1 ubiquitin ligase.  The exact 
composition of the “DWD box” motif remains to be firmly elucidated, however, and in 
the future, we may be able to more firmly establish which subset of WD-40 proteins, and 
which other possible proteins, may interact with DDB1 and form functional ubiquitin 
ligase complexes.  
 
Contributions of individuals to work in this chapter: 
 
Figure 2.1: A-C, Chad McCall.  D, Yizhou He 
Figure 2.2: cDNA cloning and plasmid preparation: Chad McCall and Yizhou He.  
 Western blotting: Yizhou He. 
Figure 2.3: Yizhou He 
Figure 2.4: A and C: Yizhou He, B: Yaxue Zeng 
Figure 2.5: Chad McCall 
 
 CHAPTER 3 
 
VprBP, A CUL4/DDB1-INTERACTING DWD PROTEIN, 
IS ESSENTIAL FOR NORMAL DNA REPLICATION 
 
 
49 
Summary 
 
 The CUL4/DDB1 E3 ubiquitin ligase interacts with a set of WD40 repeat proteins 
containing a specific motif, the DWD box.  The most abundant of these DWD box 
proteins in the CUL4A immunocomplex, VprBP, has yet to be fully characterized.  
VprBP interacts with CUL4A/DDB1 through its WD40 domain, and binds 
stoichiometrically with DDB1, suggesting that its major cellular function is acting 
through the CUL4A/DDB1 ligase.  Silencing of VprBP results in inhibition of cellular 
growth in a partially p53-dependent manner, and this inhibition is due to a defect in DNA 
replication.  VprBP-deficient cells incorporate significantly less BrDU than controls, do 
not respond to S-phase or M-phase chemical cell cycle inhibitors, and activate cryptic 
origins of replication, an indicator of replication stress.  In the absence of Rb function, 
VprBP loss results in G2 accumulation and cell death, while in the presence of wildtype 
p53 and Rb, its loss results in G1 accumulation and little evidence of cell death.  Ongoing 
studies in my laboratory are aimed at discovering the CUL4A/DDB1 substrates whose 
dysregulation results in the DNA replication stress found in VprBP-silenced cells. 
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Background 
 
Ubiquitin ligases play a critical role in cellular function, by recruiting various 
protein substrates for covalent modification by the small protein ubiquitin (Hochstrasser 
1996; King et al. 1996; Hershko and Ciechanover 1998).  Ubiquitin modification, either 
monomeric or in polyubiquitin chains, leads to various changes in cellular protein 
function, most prominently the targeting of polyubiquitin-conjugated proteins to the 26S 
proteasome for proteolytic degradation.  The cullin family of ubiquitin ligases have 
particularly broad function, due to their ability to recruit a wide variety of substrates 
through modular interaction with substrate receptors containing specific protein-protein 
interaction motifs (Petroski and Deshaies 2005a).   Cullins interact with their substrate 
receptors either directly, as in the case of CUL3 with one of over 200 BTB-domain-
containing receptors (Geyer et al. 2003; Pintard et al. 2003; Xu et al. 2003; Furukawa and 
Xiong 2005), or indirectly through a conserved linker protein, such as SKP1 bridging one 
of more than 70 F-box-containing receptors to CUL1 (Feldman et al. 1997; Skowyra et 
al. 1997; Zheng et al. 2002b) and the heterodimer of elongins B and C linking one of the 
more than 30 VHL-box or SOCS-box receptors with CUL2 or CUL5 (Kamura et al. 
1998; Stebbins et al. 1999; Zhang et al. 1999; Kamura et al. 2001; Kamura et al. 2004).  
Through interaction with these common motifs, the cullins may target hundreds of 
substrates for ubiquitination. 
 
We and other groups recently identified a family of substrate receptors that 
interact with the CUL4A and CUL4B ligases through a single linker protein, DDB1: a 
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subclass of WD-40 repeat proteins containing a specific motif, which we term the DWD 
box (Angers et al. 2006; He et al. 2006; Higa et al. 2006b; Jin et al. 2006).  The most 
critical feature of this motif is the presence of surface arginine residues immediately 
adjacent to the WD (Trp-Glu) of consecutive WD-40 repeats (WDxR).   These DWD-box 
proteins include the CUL4A substrate receptors DDB2, which targets histones H2A, H3, 
and H4 for ubiquitination (Kapetanaki et al. 2006; Wang et al. 2006), the Cockayne 
syndrome protein CSA, which targets CSB for degradation (Groisman et al. 2006), and 
L2DTL/CDT2, which targets the DNA licensing factor CDT1 (Zhong et al. 2003; Hu et 
al. 2004; Arias and Walter 2005; Arias and Walter 2006; Higa et al. 2006b; Hu and 
Xiong 2006; Jin et al. 2006; Nishitani et al. 2006; Senga et al. 2006).  Notably, all these 
substrates are involved in DNA repair or replication, though this common feature could 
simply be due to the systems focused on by laboratories investigating CUL4A/DDB1 
ligases.  However, there are more than 90 DWD proteins in the human genome, and the 
most abundant of these in the CUL4A immunocomplex, VprBP/DCAF1, has yet to be 
fully characterized.   
 
VprBP was initially identified through co-immunoprecipitation and peptide 
sequencing of HIV-1 Vpr-interacting proteins (Zhao et al. 1994; Zhang et al. 2001), but 
its function has yet to be explored beyond the initial binding observations.  Vpr, a 96-
amino-acid, 14 kDa HIV-1 accessory protein, is dispensible for in vitro viral growth and 
replication, yet is essential for HIV function in vivo.   It has been implicated in a number 
of different viral and cellular processes, from enhancing accuracy of reverse transcription 
to nuclear import of viral DNA, and from anti- and pro-apoptotic activities to 
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transactivation of HIV LTR and host genes (Le Rouzic and Benichou 2005).  Yet, its 
most well studied cellular phenotype, when expressed alone or in the context of whole 
viral infection, is arrest of the cell cycle in G2, followed subsequently by apoptosis (He et 
al. 1995; Re et al. 1995; Bartz et al. 1996; Stewart et al. 1997; Roshal et al. 2003; 
Andersen et al. 2005; Lai et al. 2005).   
 
In this chapter, I have initiated the characterization of the roles of VprBP in the 
cell apart from its function in HIV biology.  I first verified by binding experiments that 
VprBP behaves much as other DWD-box proteins in its interactions with CUL4A and 
DDB1.  Then, turning to RNA interference studies, I first noticed growth inhibition and 
cell death, which led me to examine whether VprBP played a role in the cell cycle, which 
was reasonable given the function of all other known DWD substrates, as well as the 
physiological effect of HIV-1 Vpr expression.  I demonstrated that loss of VprBP causes 
a partially p53-dependent G1 and growth arrest in primary human cells, and causes 
failure of DNA replication associated with presence of double-strand breaks and likely 
firing of cryptic origins of replication in HeLa cells lacking p53- or Rb-pathway 
checkpoints.   
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Experimental Procedures 
 
Antibodies, immunopurification, and mass spectrometric analysis 
 
Antibodies to HA (12CA5, Boehringer-Mannheim), Myc (9E10, NeoMarkers), 
T7 (Novagen), FLAG (M2, Sigma), p53 (DO-1, NeoMarkers), p21 (NeoMarkers), Bax 
(N-20, Santa Cruz), and CSN5 (JAB1, GeneTex) were purchased commercially. Rabbit 
polyclonal antibodies to CUL4A, DDB1, and CDT1 have been described (Hu et al. 
2004). A rabbit polyclonal antibody against VprBP was produced by injection of a 
synthetic peptide antigen to residues 1493-1507 of VprBP (DNSDLEDDIILSLNE).  To 
purify the endogenous CUL4A complex, BT474 cells from 47 150-mm plates were lysed 
with a 0.5% NP-40 lysis buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.5% NaCl, 
50 mM NaF), and lysates were pooled (300 mg total).  Clarified lysates were 
immunoprecipitated with affinity-purified anti-CUL4A antibody (2 µg/mg lysate, ±10 
µg/mg antigen peptide). Immunocomplexes were resolved by SDS-PAGE and stained 
with Coomassie blue, and the protein bands were digested with trypsin and subjected to 
mass spectrometric analysis at the University of North Carolina Proteomics Core Facility.  
To purify the endogenous VprBP complex, an analogous protocol was used, but with 
U2OS cells. 
 
Plasmids, cell culture, and cell transfection 
 
Plasmids expressing human CUL4A and DDB1 were as previously described 
(Ohta et al. 1999; Liu et al. 2002; Furukawa et al. 2003; Hu et al. 2004).  pFSZ2-VprBP-
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FLAG was the kind gift of Dr. L.J. Zhao (St. Louis University), and was used to subclone 
VprBP into a pcDNA3-based mammalian expression vector.  Mutations were introduced 
by site-directed mutagenesis using the QuickChange Kit (Stratagene) and verified by 
DNA sequencing.  Cell lines were cultured as follows: HeLa cells in DMEM containing 
10% FBS in a 37°C incubator with 5% CO2, U2OS cells in McCoy’s 5A medium 
containing 15% FBS, WI-38 cells in MEM with sodium pyruvate, non-essential amino 
acids, and 10% FBS, and 293T cells in DMEM containing 10% newborn calf serum.  
Cell transfections were carried out using a calcium-phosphate buffer. 
 
Gel filtration chromatography 
 
To examine the elution profile of CUL4A and associated proteins, HeLa cells 
were lysed with the 0.5% NP-40 lysis buffer, and clarified lysate was resolved through a 
Superdex-200 gel filtration column (GE/Amersham). Fractions (0.5 mL) were collected, 
and 50 µL of each was resolved via SDS-PAGE and immunoblotted with antibodies as 
indicated. High-molecular-weight standards (GE/Amersham) were resolved through the 
same column, and the peak fraction for each was determined. 
 
RNA interference (RNAi) 
 
r-Dicer-generated siRNA to VprBP was generated by first amplifying nt 4008-
4625 of VprBP cDNA using PCR primers with 5’ overhangs with T7 promoter 
sequences.  This PCR product was then used as a template for in vitro transcription of 
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both strands of a dsRNA using the T7 RiboProbe kit (Promega), then annealing the 
dsRNA by heating the transcribed mixture to 95ºC and slowly cooling to room 
temperature.  This double-stranded RNA was then immediately added, without 
purification, to a reaction mixture containing 8 U of recombinant Dicer (Stratagene) and 
Dicer reaction buffer to a total of 500 mL.  After digesting for 18 hrs at 37ºC, the Dicer 
products were purified by a series of three spin columns (G-25 (Amersham, Piscataway, 
NJ), EZ-pure (Millipore, Bedford, MA), Microcon-100 (Millipore)) (Myers et al. 2003).  
The final product was resolved on a 15% native polyacrylamide gel along with a known 
quantity of a synthetic siRNA to estimate final concentration.  Control GFP r-Dicer 
siRNA were prepared as described in Myers et al, 2003.   
 
Two duplex oligonucleotides encoding human VprBP-specific shRNA (sh1:  5'-
CCGG GAA TAC TCT TCA AGA ATG ATG CCTCCTGTCA CAT CAT TCT TGA 
AGA GTA TTC TTTTTG-3' and sh2: 5’-CCGG GAA ATA CCT CGT CCT TCT ATG 
CTTCCTGTCA CAT AGA AGG ACG AGG TAT TTC TTTTTG), one duplex encoding 
human DDB1-specific shRNA  (5’-CCGG CAG CAT TGA CTT ACC AGG CAT 
CCTCCTGTCA ATG CCT GGT AAG TCA ATG CTG TTTTTG-3’) and one duplex 
oligonucleotide encoding firefly luciferase-specific shRNA (5’-CCGG GAGCT GTTTC 
TGAGG AGCC CCTCCTGTCA GGCT CCTCA GAAAC AGCTC CCGG TTTTTG-3’) 
were ligated into the PMKO.1 vector (Addgene plasmid 8452). Retrovirus production 
was carried out according to a standard protocol and then used to infect WI-38, U2OS, 
and HeLa cells. Twenty-four hours after infection, cell lines were selected by puromycin 
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(2 µg/mL) for 2 d before cell cycle analysis, replating for cell proliferation assays, or 
analyzing protein expression and complex formation. 
 
 
Flow cytometry 
 
To analyse DNA content by propidium iodide staining, WI-38, U2OS, or HeLa 
cells were fixed in 75% ethanol overnight at 4ºC, then washed once in 1X PBS + 1% fetal 
bovine serum, and permeabilized for 30-45 mins at 37ºC in 1X PBS + 0.1 mg/mL RNAse 
A + 0.1% Triton X-100.  The fixed and permeable cells were stained with 50 µg/mL 
propidium iodide for at least 90 mins at room temperature, shielded from light.   
 
To analyze ongoing replication of DNA by bromodeoxyuridine (BrDU) labeling, 
HeLa cells were fixed in 80% ethanol overnight at 4ºC, then washed once in 1X PBS.  
Nuclei were isolated by incubating cells in 0.1M HCl/0.08% pepsin for 20 min at 37ºC, 
then DNA was denatured by incubating cells in 2M HCl for a further 20 mins at 37ºC.  
After neutralizing the HCl with 2 volumes of 0.1M sodium borate, pH 8.5, the cells were 
washed once with IFA buffer (10 mM HEPES (pH 7.3), 150 mM NaCl, 4% FBS) + 0.5% 
Tween-20.  The cells were labeled with FITC-conjugated anti-BrDU (BD Biosciences) at 
1:10 in IFA + Tween for 45 min at room temperature, then washed once with IFA + 
Tween.  Finally, cells were stained for DNA content by incubating for 30 mins at room 
temperature with IFA + 0.1 mg/mL RNase A + 50 mg/mL propidium iodide.  Stained 
cells were analyzed at the UNC School of Medicine Flow Cytometry Facility on either a 
57 
FACScan (Becton Dickinson) or CyAN (Dako Cytomation) flow cytometer, and data 
analyzed using Summit 4.3 software (Dako Cytomation).  
 
Molecular combing  
To analyze the properties of replication forks, HeLa cells were double labeled by 
incubation, first in medium with 100 µM IdU for 10 min, and second in 50 µM CldU for 
20 min. DNA spreads were stained for IdU and CldU and analyzed for individual 
replication tracks as described previously (Unsal-Kacmaz et al. 2007).   
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Results 
 
VprBP is a CUL4A/DDB1-interacting DWD protein. 
 
We previously used large scale immunoprecipitation and mass spectrometry to 
identify a series of CUL4A/DDB1-interacting proteins, and used this to define a common 
motif found in potential CUL4A/DDB1 substrate receptors, the DWD box (He et al. 
2006).  The most abundant of these DWD proteins in our CUL4A immunocomplex was 
VprBP (Figure 3.1A, left panel).  To further characterize the interaction partners of 
VprBP, I generated a rabbit polyclonal antibody and used it to perform a large-scale 
immunoprecipitation (Figure 3.1A, right panel), and submitted bands that were 
specifically competed off by antigen peptide for mass spectrometric identification.  I 
found that VprBP associated with almost stochiometric amounts of DDB1 and smaller 
amounts of CUL4A and the subunits of the COP9/signalosome deneddylase.  In order to 
verify the specificity of these interactions, I performed immunoprecipitation-Western blot 
experiments (Figure 3.1B).  VprBP co-immunoprecipitated preferentially with Nedd8-
modified CUL4A, which was more noticeable upon enrichment of CUL4A-Nedd8 by 
proteasome inhibition. 
 
The Coomassie blue-stained immunocomplex suggested to me that VprBP might 
exist in a large multisubunit complex.  To examine that, I separated HeLa lysate by gel 
filtration chromatography (Figure 3.1C).  VprBP exists in complexes of more than 450 
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Figure 3.1 
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Figure 3.1.  VprBP is a CUL4A/DDB1-interacting DWD protein. 
(A)  VprBP is one of the most abundant binding partners of CUL4A/DDB1.  The CUL4A 
immunocomplex was precipitated from human BT474 cells and resolved by SDS-PAGE, 
followed by staining with Coomassie Brilliant Blue.  Bands identified by mass 
spectrometry are indicated. 
 
(B)  Endogenous VprBP and CUL4A co-immunoprecipitate.  U2OS cells were treated 
with MG132 (25 µM x 5 hrs), then lysed with 0.5% NP-40 lysis buffer and 
immunoprecipitated with antibodies against VprBP or CUL4A.  Immunocomplexes were 
resolved by SDS-PAGE and Western blotted with the indicated antibodies. 
 
(C)  VprBP exists in very large molecular weight complexes.  HeLa S3 0.5% NP-40 
lysate was resolved into 32 fractions on a Superdex-200 gel filtration column, along with 
molecular weight standards as indicated.  The void volume corresponded to a molecular 
weight over 700 kDa, and the input control was 100 µg of HeLa S3 lysate.  Equal 
volumes of each fraction were resolved by SDS-PAGE and Western blotted as indicated. 
 
(D)  The VprBP immunocomplex contains stoichiometric amounts of DDB1, and 
substoichiometric amounts of other CUL4A ligase components.  U2OS cells (48 150-mm 
dishes) were lysed with 0.5% NP-40 lysis buffer, immunoprecipitated with anti-VprBP 
(antibody generated in our laboratory) with or without excess of antigen peptide.  The 
immunocomplexes were resolved by SDS-PAGE, stained with Coomassie Brilliant Blue, 
and specific bands were submitted for mass spectrometric identification.  Identified bands 
are indicated. 
 
(E)  VprBP associates with CUL4A but not other cullins.  293T cells were transfected 
with pcDNA3-myc3-cullin plasmids, and lysates were immunoprecipitated and Western 
blotted as indicated.   
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kDa to greater than 700 kDa in size, and I was unable to detect any VprBP in size 
fractions corresponding to a monomeric form.  This, combined with the very abundant 
DDB1 in the VprBP immunocomplex, implies that VprBP primarily functions through its 
interactions with the CUL4A ubiquitin ligase.  
 
In order to rule out that VprBP functions with other cullin ubiquitin ligase family 
members, I also immunoprecipitated ectopically-expressed cullins, and Western blotted 
for endogenous VprBP (Figure 3.1D).  I was only able to detect VprBP in the CUL4A 
immunocomplex, which verifies that it, like other “DWD proteins,” serves as a modulator 
of CUL4A ligase function.   
 
The WD40 domain of VprBP is required and sufficient to interact with DDB1-
CUL4A 
 
We have also previously shown that CUL4A interacts with DDB1 and its DWD 
substrate receptors through its N-terminus (Hu et al. 2004; He et al. 2006), and I sought 
to verify that VprBP functions similarly.  I co-expressed VprBP with a panel of CUL4A 
mutants (Figure 3.2A), and found that deletion of the N-terminal 52 or 100 amino acids, 
which constitute the DDB1- and DWD-interaction domain, completely abrogated the 
VprBP-CUL4A interaction (Figure 3.2B).  Moreover, VprBP contains conserved 
domains in its N-terminus in addition to its C-terminal WD-40 domain.  I examined 
whether these domains might influence its binding with CUL4A/DDB1.  Expression of 
the C-terminus of VprBP alone, containing the WD repeats and a highly acidic “tail,” was 
sufficient to 
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Figure 3.2.  The WD domain of VprBP is sufficient to interact with CUL4A/DDB1. 
 
(A)  CUL4A and VprBP mutants used in B and C.  
 
(B)  VprBP interacts with the substrate-recruiting N-terminus of CUL4A.  293T cells 
were transfected with pFSZ2-VprBP-FLAG and pcDNA3-myc3-CUL4A plasmids as 
indicated.  0.5% NP-40 lysates were immunoprecipitated with anti-FLAG (M2), resolved 
by SDS-PAGE, and Western blotted as shown.  The CUL4A mutants used are 
diagrammed in (A) above. 
 
(C)  The WD domain of VprBP is sufficient to interact with CUL4A/DDB1.  293T cells 
were transfected with pcDNA3-myc3-VprBP, wildtype or mutants as indicated.  0.5% 
NP-40 lysates were immunoprecipitated with anti-Myc (9E10) or anti-CUL4A, resolved 
by SDS-PAGE, and Western blotted as shown.  VprBP mutants used are diagrammed in 
(A) above. 
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bind endogenous CUL4A and DDB1, indeed even more abundantly than full-length 
VprBP (Figure 3.2C).  This, combined with the inability of the conserved N-terminal 
domain (N751) to interact with CUL4A or DDB1, strongly suggests that VprBP interacts 
with CUL4A/DDB1 through its WD-40 domain. 
 
VprBP expression is essential for normal proliferation and DNA replication. 
 
After identifying VprBP as a potential substrate receptor, or otherwise modulator, 
of the CUL4A/DDB1 ubiquitin ligase, I then sought to explore its cellular function 
through the use of RNA interference.  First, I used recombinant Dicer to generate siRNA 
to VprBP (Figure 3.3A).  Silencing was very efficient, and led to an immediately obvious 
growth phenotype.  To quantify that phenotype, I plated equal numbers of VprBP siRNA-
treated cells 72 hours after transfection, alongside DDB1 siRNA (which our unpublished 
data had already indicated had a growth arrest) and several controls.  We found that 
VprBP-treated cells had essentially ceased proliferating. 
 
Due to concerns about toxicity of transfected oligonucleotides and the transient 
nature of siRNA, I then sought to confirm this result by the use of small hairpin RNAs 
produced by retroviral infection.  I produced three hairpin RNA sequences targeting 
different regions of VprBP, and two were very successful at silencing and at reproducing 
the siRNA growth arrest phenotype (Figure 3.4).  Because of the potential of checkpoint 
pathways masking the phenotype of VprBP siRNA (leading to growth arrest), I infected 
HeLa cells with one of the two shRNA constructs, which produced nearly 
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Figure 3.3.  VprBP is required for normal cellular proliferation and DNA 
replication. 
 
(A)  r-Dicer-generated VprBP siRNA is efficient in silencing.  U2OS cells were 
transfected with r-Dicer-generated VprBP siRNA or GFP siRNA, or synthetic DDB1 
siRNA, and 72 hrs after transfection, cells were lysed using 0.5% NP-40 lysis buffer.  
Lysates were resolved by SDS-PAGE and Western blotted as indicated.   
 
(B)  VprBP and DDB1 siRNA inhibit cellular proliferation.  72 hrs after transfection in 
(A), equal numbers of siRNA-transfected U2OS cells were plated, and counted after 72 
more hours of growth.  The amount of proliferation over the number plated were plotted, 
with standard error of >4 separate counts indicated. 
 
(C)  shRNA retroviruses to VprBP efficiently silence expression.  HeLa cells were 
infected with pMKO.1 retroviruses encoding shRNA to VprBP or luciferase (as a 
negative control).  24 hrs after infection, cells were selected for 48 hrs with 2 µg/mL 
puromycin.  Dead cells were washed away with PBS, and selected cells were trypsinized, 
lysed in 0.5% NP-40 lysis buffer, resolved by SDS-PAGE, and Western blotted as 
indicated, using CUL4A as a loading control. 
 
(D)  VprBP-silenced HeLa cells are arrested in S-phase and unable to further respond to 
chemical inhibitors.  Trypsinized cells from (C) above were replated into new dishes.  24 
hrs later (96 hrs post-infection), cells were treated with 1 mM hydroxyurea, 2 mM 
thymidine, or 0.1 µg/mL nocodazole as indicated.  24 hrs after treatment, cells were 
trypsinized, and fixed overnight in 75% ethanol.  After propidium iodide staining, the cell 
cycle was analyzed by flow cytometry. 
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Figure 3.4 
 
 
Figure 3.4.  Two VprBP shRNA constructs silence protein expression efficiently. 
(A)  Both VprBP shRNA efficiently silence expression. WI-38/E6 cells were infected 
with retroviruses expressing empty pMKO.1 vector or vectors expressing two different 
shRNA sequences to VprBP.  24 hrs after infection, the cells were selected with 2 mg/mL 
puromycin for 48 hrs, then viable cells were lysed in 0.5% NP-40 lysis buffer.  Lysates 
were resolved by SDS-PAGE and Western blotted as indicated. 
 
(B)  Both VprBP shRNA contribute to an inhibition of cellular proliferation.  72 hrs 
after infection with shRNA against VprBP or empty viral vector (48 hrs after selection), 
equal numbers of viable WI-38 or WI-38/E6 cells were replated.  72 hrs after plating, cell 
numbers were counted and normalized against empty vector control cells.  Standard error 
of >4 counts indicated. 
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complete silencing (Figure 3.3C).  To my surprise, the HeLa cells also ceased 
proliferating, as dramatically as in p53-competent U2OS and WI-38 cells (data not 
shown).  I examined the cellular DNA content of fixed, stably shRNA-infected HeLa 
cells 72 hrs after infection, and found a pronounced S-phase accumulation compared with 
control luciferase shRNA-infected cells (Figure 3.3D).  This arrest was not altered by 
treatment with the S-phase inhibitors hydroxyurea or thymidine (Figure 3.3D) or 
aphidicolin (not shown), and only mildly shifted to G2/M by the metaphase inhibitor 
nocodazole, indicating an almost complete cessation of DNA synthesis.   
 
Defects in DNA synthesis often result in double-strand breaks, leading to 
phosphorylation of H2AX on Ser-139 and the ATM-dependent phosphorylation of Chk2 
on Thr-68.  I measured the levels of each phosphorylated species in whole-cell extracts 
from VprBP-silenced HeLa cells.  Chk2 phosphorylation increased significantly, while 
H2AX phosphorylation increased less dramatically (Figure 3.5A).  I was unable to detect 
any increase in Chk1 phosphorylation (data not shown).  These data suggest that stalled 
replication due to VprBP silencing might lead to collapsed replication forks, which 
produce double-strand breaks and the phosphorylation of the markers shown. 
 
VprBP silencing decreased the incorporation of nucleotides throughout S phase. 
 
 
 
To further characterize the S-phase phenotype of cells lacking VprBP, I pulse 
labeled HeLa cells with bromodeoxyuridine (BrDU) and examined the pattern of its 
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Figure 3.5. VprBP silencing reduces overall DNA replication but increases the firing 
of new replication forks. 
 
(A)  Silencing of VprBP leads to formation of double-strand breaks. .  HeLa cells were 
infected with pMKO.1 retroviruses encoding shRNA to VprBP or luciferase (as a 
negative control).  24 hrs after infection, cells were selected for 48 hrs with 2 µg/mL 
puromycin.  Dead cells were washed away with PBS, and selected cells were trypsinized.  
Cells were then lysed in a x% SDS lysis buffer, sonicated for 45 secs, and then Western 
blotted as indicated. 
 
(B)  Silencing of VprBP produces a decreased overall rate of DNA replication.  Cells 
from (A), 80 hrs after infection and 56 hrs after puromycin selection, were pulse-labeled 
with 10 µM BrDU for 30 min.  After labeling, the cells were washed with 1X PBS, 
trypsinized, and fixed in 80% ethanol/20% 1X PBS overnight.  After staining with a 
FITC-conjugated anti-BrDU antibody and propidium iodide, the cells were analyzed by 
flow cytometry as shown. 
 
(C)  Silencing of VprBP results in decreased BrDU incorporation.  Mean BrDU staining 
intensity was extracted from (B) by gating for BrDU-positive cells, and graphed +/- 
standard deviation. 
 
(D)  DNA combing allows for analysis of individual replication forks.  HeLa cells, 90 hrs 
after VprBP shRNA infection (with both shRNA sequences), were labeled for 10 mins 
with iododeoxyuridine (IdU), then washed, and labeled for 20 mins with 
chlorodeoxyuridine (ClDU).  The cells were then trypsinized and resuspended in 1X 
PBS.  After fixing cells, combing DNA out onto slides, and staining for IdU (red) and 
ClDU (green), individual replication tracks were counted and analyzed.  Representative 
data is shown here to demonstrate the types of tracks possible to distinguish. 
 
(E)  VprBP silencing leads to a relative increase in the proportion of newly fired origins 
of replication.  After combing as described in (D), the number of ClDU-only tracks 
(representing origins which fired during the labeling period), increased in VprBP-
silenced cells by over 250%.  For other combing data, see Table 3.1. 
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incorporation.  Consistent with our data showing a lack of response to S- and G2/M-
phase inhibitors, BrDU incorporation was markedly reduced in VprBP-silenced cells 
(Figure 3.5B).  The pattern of decreased BrDU incorporation is present in cells 
throughout S-phase based on DNA content measured by propidium iodide staining, and  
BrDU intensity is inversely correlated with increase in DNA content, as compared with a 
gradual increase in BrDU intensity throughout S-phase in control cells.  The mean BrDU 
intensity in VprBP-silenced cells averaged slightly more than half that of control cells 
(Figure 3.5C).  These data strongly suggest that VprBP is required for normal replication 
of DNA, and the pattern of BrDU incorporation—relatively normal in early S phase but 
much reduced later—suggests that the impairment is strongest in mid- to late-S phase, 
which is most consistent with a role in the maintenance or firing of forks throughout S, 
not initiation. 
 
VprBP silencing results in firing of cryptic origins of replication. 
 
To better examine the physical mechanism by which VprBP is functioning in 
DNA replication, Dr. Paul Chastain performed DNA combing experiments to examine 
the replication of DNA at individual replication forks (see Figure 3.5D for a diagram of 
the experimental design).  In VprBP-silenced HeLa cells, with either of the two VprBP 
shRNA constructs, the proportion of newly fired DNA replication forks increased two- to 
three-fold over control cells, and the relative number of actively replicating forks 
correspondingly decreased (Figure 3.5E).  Neither the relative number of terminated 
forks nor the track length (therefore the rate of replication of active forks) had statistically  
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Table 3.1 
 
Distribution of DNA tracks with CldU-only, IdU-only, or containing both labels. 
 
 
 
 
Hours (h) 
 
Red-only  
(IdU) 
 
Green-only  
(CldU) 
 
Red-Green  
(Idu-CldU) 
 
Total Tracks Scored 
 
Luc 
 
72 
 
87 (15%) 
 
72 (12%) 
 
435 (73%) 
 
594 
 
VprBP sh #1 
 
72 
 
41 (10%) 
 
85 (22%) 
 
269 (68%) 
 
395 
 
Luc 
 
90 
 
22 (6%) 
 
20 (5%) 
 
339 (89%) 
 
381 
 
VprBP sh #1 
 
90 
 
43 (8%) 
 
72 (14%) 
 
416 (78%) 
 
531 
 
VprBP sh #2 
 
90 
 
49 (12%) 
 
55 (14%) 
 
294 (74%) 
 
398 
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Figure 3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.  VprBP shRNA does not consistently affect the rate of elongation of 
replication forks. 
 
(A)  Diagram of the tracks measured in (B). 
 
(B)  VprBP shRNA inconsistently affects the rate of DNA elongation.  The length of 
individual green (ClDU-stained) sections of actively elongating (red-green) tracks of 
VprBP and control shRNA-transduced HeLa cells were measured, as indicated.  As a 
comparison, Paul Chastain included results from previously published experiments on 
Tipin (Unsal-Kacmaz et al. 2007). 
 
a 
A
. 
B
. 
-, 57 82% Tipin siRNA 
50, 54 91% 143% VprBP shRNA 
60, 54 100% 100% Luciferase shRNA  
Number  
Analyzed 
Greenii  
(90 h) 
Greeni  
(72 h)  
Average Relative Length  
i Relative to the green portion of the luciferase control red-green tracks produced at 72H. 
ii Relative to the green portion of the luciferase control red-green tracts produced at 90H. 
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significant changes (see Table 3.1 and Figure 3.6).  The most likely explanation for an 
increase in the relative number of newly fired forks combined with a decrease in overall 
DNA replication (measured by BrDU incorporation per cell) is that VprBP-silenced cells 
are firing cryptic origins of replication as a result of replication stress, similar to what has 
been seen for cells with depleted Mcm2-7 licensing helicases (Woodward et al. 2006).    
 
VprBP associates with chromatin in a cell-cycle-dependent manner. 
 
 Due to the effect that VprBP silencing has upon DNA replication, I reasoned that 
it might associate with chromatin in a cell-cycle specific manner.  To test this, I 
synchronized HeLa cells by arresting them at the G1-S boundary by a double-thymidine 
block, then releasing them and taking fractions throughout the cell cycle.  After Dr. Jean 
Cook isolated chromatin-bound proteins from each fraction, I found that VprBP is 
chromatin-bound, and its association with chromatin increases from early S through G2, 
and decreases again upon return to G1 phase (Figure 3.7A-B).  This is in contrast to 
MCM2, which, as expected, leaves chromatin during S phase progression as DNA is 
replicated.  CUL4A follows a very similar pattern to VprBP, and both proteins (and 
MCM2 as well) were not detectable on chromatin after arrest of cells in prometaphase by 
nocodazole block (Figure 3.7A).  These results suggest that VprBP and CUL4A are 
recruited to chromatin as DNA is being replicated, and are released from chromatin in 
mitosis.  However, they do not establish which of these proteins is required for the other 
to be chromatin-associated. 
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Figure 3.7 
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Figure 3.7. VprBP and CUL4A progressively associate with chromatin during S and 
G2 phases of the cell cycle. 
 
(A)  VprBP and CUL4A progressively associate with chromatin during S and G2 phases 
of the cell cycle, but are not associated with chromatin after mitotic block.  HeLa cells 
were synchronized at the G1-S boundary by double thymidine block, then released into 
fresh media.  Time points were collected as indicated, with a fraction of cells being fixed 
for flow cytometry analysis, and the rest pelleted at frozen at -80ºC.  The frozen pellets 
were then chromatin fractionated (see Materials and Methods), and whole cell extract and 
chromatin-associated proteins were resolved by SDS-PAGE and Western blotted as 
indicated. 
 
(B)  Propidium iodide staining reveals good synchronization in (A).  After fixing with 
75% ethanol for 30+ minutes, cells were permeabilized and stained with propidium 
iodide, then analyzed by flow cytometry.  An overlay of different time points is shown.  
After 16 hours, the cells became asynchronous, with an increasing percentage in G2 by 
24 hours. 
 
(C)  VprBP shRNA does not affect CUL4A, DDB1 or MCM2 loading onto chromatin.  
HeLa cells were transduced with VprBP shRNA, then selected with puromycin for 24 
hours starting 24 hours after transduction.  The cells were then passaged, and 36 hours 
later, were trypsinized and pelleted.  Pellets were fractionated as in (A), resolved by SDS-
PAGE, and Western blotted as indicated. 
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 To test this, Dr. Cook again chromatin fractionated HeLa cells, this time after 
VprBP shRNA, with the added conditions of MG132 and/or UV treatment to examine 
whether proteasome inhibition or UV-damaged DNA influences VprBP association with 
chromatin damage.  I established that VprBP shRNA does not affect CUL4A, DDB1 or 
MCM2 association with chromatin (Figure 3.7C).  Moreover, VprBP shRNA does not 
change CUL4A’s or DDB1’s increased association with chromatin 30 minutes after UV 
treatment, which is well established in the literature (Groisman et al. 2003).   That VprBP 
does not affect MCM2 loading strongly suggests that its effect on replication must come 
after formation of the pre-replication complex.  However, the lack of any change in 
CUL4A/DDB1 association with chromatin, either with or without UV damage, alongside 
CUL4A and VprBP’s very similar pattern of cell cycle association with chromatin, 
implies that VprBP may require interaction with CUL4A for its chromatin-based cellular 
functions, but may not be required for the UV-damaged DNA repair functions of 
CUL4A. 
 
Cell proliferation arrest after VprBP silencing is partially p53-dependent. 
 
 Because of the growth arrest and replication stress phenotype of VprBP-silenced 
cells (Figures 3.3D and 3.5), I examined what role the p53 pathway might play in 
response to loss of this protein.  I found that, in both U2OS (Figure 3.8A) and WI-38 
(Figure 3.8B) cells, loss of VprBP led to moderate but consistent accumulation of p53, 
and significant upregulation of the cell cycle inhibitor p21.   Consistent with the lack of 
sub-G1 cells seen in flow cytometric analysis (data not shown), I did not see any increase 
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in the expression of the pro-apoptotic protein Bax in either cell line, which points toward 
a p53-dependent cell cycle arrest, but not significant induction of apoptosis.  I then 
examined the cell proliferation characteristics of WI-38 cells versus WI-38 cells stably 
infected with a retrovirus expressing HPV E6 to eliminate p53 function.  The WI-38/E6 
cells proliferated at a higher baseline rate, and the inhibition of growth due to loss of 
VprBP was reduced (Figure 3.8C).  However, U2OS, WI-38, and WI-38/E6 cells all have 
G1 accumulation (Figure 3.9, 3.10, and data not shown) and growth inhibition in 
response to VprBP silencing, which clearly suggests, along with the HeLa data (Figure 
3.3D), that the growth arrest is not entirely p53-dependent.  Interestingly, WI-38 cells 
expressing HPV E7 to inhibit pocket protein function do not arrest in G1, but rather, have 
G2 accumulation, strong induction of p53, and massive cell death (by observation that 
within seven days after infection, essentially no cells remained adherent), which suggests 
that Rb function is critical for cell survival and G1 arrest after VprBP silencing in the 
presence of p53 (Figure 3.10). 
 
VprBP silencing correlates with decreased levels of the CUL4A/DDB1 substrate 
CDT1 
 
 
In addition to the replication stress and p53 activation phenotypes, we further examined 
what role VprBP might be playing in normal CUL4A/DDB1 cellular function.  Its 
extreme abundance in the CUL4A immunocomplex, orders of magnitude more than any 
other DWD protein (we have only identified two others, DDB2 and WDR23, in the 
CUL4A immunocomplex by mass spectrometry ((He et al. 2006) and data not shown), 
suggests the possibility that it might be playing a regulatory, not a substrate-recruiting, 
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role.  Consistent with that interpretation, we found that protein levels of the 
CUL4A/DDB1 substrate CDT1 are reduced in both VprBP siRNA- and shRNA-treated 
cell lines (Figure 3.11A and 3.11B).  However, this CDT1 reduction could be the product 
of transcriptional or other indirect regulation; therefore, these preliminary studies must be 
followed up by future assays to determine the effect of VprBP loss on CDT1 
ubiquitination, in vivo and/or in vitro, by CUL4A/DDB1. 
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Figure 3.8 
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Figure 3.8.  Arrest of cellular proliferation after VprBP silencing is partially p53-
dependent. 
 
(A)  VprBP shRNA activates p53 and p21.  HeLa (p53 negative) and U2OS (p53 
wildtype) cells were infected with pMKO.1 shRNA retroviruses to VprBP or luciferase  
24 hrs after infection, cells were selected with 2 µg/mL puromycin for 48 hrs (HeLa) or 
24 hrs (U2OS).  U2OS cells were grown for 24 hrs in normal growth medium after 
selection.  72 hrs after infection, cells were lysed with 0.1% NP-40 lysis buffer, resolved 
by SDS-PAGE, and Western blotted as shown. 
 
(B)  WI-38 cells expressing HPV E6 abrogate the VprBP shRNA-dependent activation of 
p53 and p21 expression.  WI-38 cells, or WI-38 cells stably expressing HPV E6 (WI-
38/E6) were infected with pMKO.1 shRNA retroviruses to VprBP or luciferase  24 hrs 
after infection, cells were selected with 2 µg/mL puromycin for 48 hrs.  After selection, 
cells were lysed with 0.1% NP-40 lysis buffer, resolved by SDS-PAGE, and Western 
blotted as shown. 
 
(C)  Inactivation of p53 partially rescues the VprBP growth arrest phenotype.  48 hrs after 
selection with puromycin, shRNA-infected WI-38 or WI-38/E6 cells were trypsinized, 
and equal numbers were replated.  72 hrs later, cells were again trypsinized and counted.  
The amount of growth over the number plated is indicated, with standard error of 16 
separate counts each.  
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Figure 3.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.  VprBP silencing leads to G1 accumulation and reduction of S phase in 
U2OS cells. 
 
 U2OS cells were transduced with retroviruses encoding shRNA hairpins as 
indicated.  24 hours after transduction, transduced cells were selected with puromycin for 
48 hours, then passaged 1:4 into fresh media.  24 hours later, the cells were labeled for 30 
mins with 10 µM BrDU, then fixed overnight and stained with FITC-conjugated anti-
BrDU and propidium iodide.  BrDU intensity and DNA content (propidium iodide 
intensity) were measured by flow cytometry.  BrDU positive and negative (2N and 4N 
DNA content) cell populations were quantified using Summit 4.3 software. 
 
 
shRNA luciferase DDB1 VprBP 1 VprBP 2 
G1% (BrDU neg) 23.9 13.8 46.6 37.0 
S% (BrDU pos) 56.2 52.5 22.9 36.6 
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Figure 3.10.  VprBP silencing in cells with active p53 but not Rb leads to G2/M 
accumulation and dramatic activation of p53. 
 
(A)  Silencing of VprBP in WI-38 cells expressing HPV E7 leads to high induction of 
p53. WI-38/E7 cells were infected with retroviruses expressing empty pMKO.1 vector or 
vectors expressing two different shRNA sequences to VprBP.  24 hrs after infection, the 
cells were selected with 2 mg/mL puromycin for 48 hrs, then viable cells were lysed in 
0.5% NP-40 lysis buffer.  Lysates were resolved by SDS-PAGE and Western blotted as 
indicated. 
 
(B)  Silencing of VprBP in WI-38/E7 cells leads to loss of cell proliferation. 72 hrs after 
infection with shRNA against VprBP or empty viral vector (48 hrs after selection), equal 
numbers of viable WI-38 or WI-38/E7 cells were replated.  72 hrs after plating, cell 
numbers were counted and normalized against empty vector control cells.  Standard error 
of >4 counts indicated. 
 
(C)  VprBP silencing in WI-38/E7 cells leads to G2/M accumulation.  When cells were 
collected for lysis in (A), an aliquot of each sample was fixed in 75% ethanol, stained 
with propidium iodide, and analyzed for DNA content by flow cytometry. 
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Figure 3.11 
 
 
Figure 3.11.  VprBP silencing correlates with decreased levels of CDT1. 
(A)  siRNA to VprBP decreases steady-state levels of CDT1 under the same conditions 
where siRNA to DDB1 accumulates CDT1. .  U2OS cells were transfected with r-Dicer-
generated VprBP siRNA or GFP siRNA, or synthetic DDB1 siRNA, and 72 hrs after 
transfection, cells were lysed using 0.5% NP-40 lysis buffer.  Lysates were resolved by 
SDS-PAGE and Western blotted as indicated.   
 
(B)  shRNA to VprBP decreases steady-state levels of CDT1 proportional to the level of 
silencing of VprBP.  WI-38/E6 cells were infected with retroviruses expressing empty 
pMKO.1 vector or vectors expressing two different shRNA sequences to VprBP.  24 hrs 
after infection, the cells were selected with 2 mg/mL puromycin for 48 hrs, then viable 
cells were lysed in 0.5% NP-40 lysis buffer.  Lysates were resolved by SDS-PAGE and 
Western blotted as indicated. 
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Discussion 
 
In this chapter, I examined the cellular function of the novel CUL4A/DDB1 
interacting protein VprBP.  I confirmed that VprBP interacts with CUL4A/DDB1 in a 
manner analogous to other DWD-box proteins that have been described, binding through 
DDB1 with the N-terminus of CUL4A, and requiring only its WD-40 domain (Figures 1 
and 2).  VprBP preferentially interacts with the active, Nedd8-modified form, of the 
CUL4A ligase, which suggests that it plays a role in either recruiting specific substrates, 
or regulating the recruitment of other substrates, to the ligase.  I have yet to identify these 
substrates, but the cellular phenotype and subcellular localization data I have 
accumulated can narrow down the possibilities. 
 
First, I can speculate on the function of VprBP in the CUL4A ligase based on the 
extensive characterization we have done of the cellular phenotype upon VprBP silencing 
by both transfected siRNA and stably infected shRNA oligonucleotides.  Recently, two 
manuscripts have been published describing the effects of DDB1 conditional knockout in 
three mouse tissues: the brain, lens, and the epidermis (Cang et al. 2006; Cang et al. 
2007).  In both manuscripts, loss of DDB1 resulted in inhibition of cellular proliferation, 
and in induction of apoptosis.  In the epidermis, concurrent loss of p53 resulted in rescue 
of the apoptotic phenotype, but did not rescue the loss of cellular proliferation and also 
led to the accumulation of aneuploid and polyploid cells (Cang et al. 2007).  Similarly, in 
the p53-/-;DDB1-/- mouse brain, there was a reduction in apoptosis and increase in cells 
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with abnormal nuclear morphology, although proliferation was not completely impeded 
(Cang et al. 2006). 
My VprBP data are similar, yet not completely overlapping, with these results.  
Loss of VprBP in p53 wildtype cells did result in p53 accumulation and inhibition of 
proliferation (Figure 3.8 and 3.9), but we see no evidence of induction of apoptosis unless 
Rb function is also lost (Figure 3.10).  We see induction of p21, but not in the context of 
p53-null cells (Figures 3.8A and 3.8B), unlike the p53-independent induction of p21 that 
was reported in p53-/-;DDB1-/- epidermal cells (Cang et al. 2007).  These results suggest 
that VprBP might be partially mediating the regulation of DNA replication that is a major 
function of DDB1, particularly since VprBP silencing in p53 and Rb-deficient HeLa cells 
results in inhibition of DNA replication and proliferation (Figures 3 and 4).  But, 
functional DDB1 must, in the absence of VprBP, be enough to prevent an apoptotic 
response when Rb activity is present.  In addition, our experiments in WI-38 cells and the 
same cells stably expressing E6 to remove p53 clearly indicate a partial rescue of the 
VprBP proliferation defect, though the WI-38/E6 cells proliferate quite slowly (Figure 
5C).  This response may be analogous to the partial rescue of DDB1 knockout 
phenotypes by p53 loss.  An obvious future experiment is to silence VprBP in DDB1-
deficient cells to further dissect the relationship between these two proteins. 
 
The replication stress phenotype produced by VprBP silencing may, in the future, 
lead to the identification of the substrate(s) regulated by VprBP in the cell.  That MCM 
proteins are still loaded onto chromatin in the absence of VprBP suggests that initial 
licensing of replication origins is intact in silenced cells.  The increased relative firing of 
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origins (Figure 3.5E) also supports this notion.  However, that the total level of BrDU 
incorporation is greatly reduced, and the cells are clearly not responsive to further 
inhibition by S-phase blocking agents, strongly indicates that VprBP is required for 
normal DNA replication.  The BrDU incorporation phenotype is similar to the silencing 
of two other genes: Chk1 (personal communication from Dr. Jean Cook) and Cdc7 
(Montagnoli et al. 2004).  Chk1 inhibition also causes an increase in the rate of 
replication origin firing, measured by increased Cdc45 loading onto chromatin (Syljuasen 
et al. 2005).  I have been unable to detect any changes in Chk1 protein level in VprBP-
silenced HeLa cells, nor activation of Chk1 by phosphorylated Ser-345 (data not shown), 
which may be consistent with an inhibition of Chk1 activity by VprBP.  However, what, 
if any, link there is between the two remains to be seen.  Cdc7, a kinase required for 
initiation of replication at each fork, when silenced produces similar phenotypes to 
VprBP inhibition: HeLa cells have decreased BrDU incorporation, S-phase arrest, and 
apoptosis; primary human fibroblasts deficient in Cdc7 activate p53 and p21, and arrest 
in G1 (Montagnoli et al. 2004).  The decreased BrDU incorporation in Cdc7-silenced 
cells is throughout S phase, and there is no report in the literature of increased firing of 
replication forks after Cdc7 silencing or loss, therefore it is somewhat questionable 
whether VprBP acts at the same level as Cdc7 in regulation of replication.  We are 
currently examining whether the Cdc7 activator Dbf4, a known target of the anaphase-
promoting complex E3 ligase (Ferreira et al. 2000), has altered protein levels and/or 
chromatin association in VprBP-silenced cells.  These two pathways, Chk1 and 
Cdc7/Dbf1, represent two possible avenues for VprBP regulation, but as we have yet to 
establish any mechanistic link, VprBP could be acting in an entirely novel manner.   
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My preliminary results indicate a clear biochemical relationship between 
CUL4A/DDB1 and VprBP, since VprBP is the major binding partner of CUL4A and 
DDB1 in the CUL4A immunocomplex (Figure 3.1A).  Furthermore, I can co-
immunoprecipitate VprBP and other DWD proteins (Figure 2.5C), which along with 
evidence for CUL4A oligomerization (Figure 2.5A and 2.5B), may present a mechanism 
by which VprBP can either target other proteins for degradation, or regulate the 
degradation of other DWD substrates in an oligomeric cullin complex.  I have also seen a 
correlation between VprBP silencing and reduction of the level of the CUL4A substrate 
CDT1 (Figure 3.11), but it is not at all clear whether that correlation is due to a regulation 
of ligase activity, or an indirect mechanism due to the perturbation of the cell cycle by 
silencing of VprBP.  However, that UV treatment does not increase VprBP chromatin 
association as it does DDB1 and CUL4A (Figure 3.7C) suggests that VprBP may not 
function in the active CUL4A/DDB1/DDB2 and CUL4A/DDB1/CSA complexes, 
although the similar chromatin association profiles throughout the cell cycle for VprBP 
and CUL4A (Figure 3.7A) are consistent with a CUL4A/DDB1/VprBP complex present 
on chromatin during S- and G2-phases of the normal cell cycle.  The substrates this 
complex regulates, as described earlier, are yet to be determined. 
 
These observations provide the first detailed characterization of a DWD protein, 
VprBP, which is essential for normal DNA replication and cellular proliferation.  Its 
abundant association with the CUL4A/DDB1 ligase, along with the well-characterized 
defects in DNA replication and repair associated with the loss of DDB1, suggests that 
VprBP may function to regulate the replication aspect of DDB1 function.  These 
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preliminary studies have generated many questions, first and foremost being how the 
replication phenotype seen in VprBP-silenced cells relates to dysfunction of the 
CUL4A/DDB1 ligase, if at all.  Identification of the DNA replication pathway modulated 
by VprBP will go a long way toward identifying the potential CUL4A/DDB1 substrates 
involved. 
 
   
 CHAPTER 4 
 
VprBP INTERACTS WITH HIV-1 Vpr AND LINKS THE Vpr 
UBIQUITINATION SUBSTRATE UNG2 TO THE CUL4A/DDB1 LIGASE
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Summary 
 
VprBP was originally discovered as a protein that interacts abundantly with the 
HIV-1 accessory protein Vpr.  In this chapter, I present preliminary data exploring how 
this interaction relates to the CUL4A/DDB1 E3 ubiquitin ligase.  I have further 
characterized the binding between Vpr and VprBP, showing that the association is 
through the WD40 domain of VprBP.  I then examined whether the cellular 
ubiquitination substrate of Vpr, UNG2, is able to interact with VprBP in the presence of 
Vpr.  It does so, and this interaction is stabilized by proteasome inhibition.  A Vpr mutant 
that does not interact with UNG2 still interacts with VprBP, so these two activities are 
separable.  I attempted to also examine the role VprBP might play in Vpr’s G2 cell cycle 
arrest phenotype, but the G1/S arrest produced byVprBP silencing alone precluded that 
possibility.  These data form the groundwork for future experimentation into the role 
VprBP may be playing in the degradation of UNG2, and possibly in the G2 arrest caused 
by Vpr. 
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Background 
 
The HIV-1 genome encodes for several accessory proteins in addition to the 
characteristic retroviral reverse transcriptase, protease, envelope, and capsid core 
proteins.  Vpr, a 96-amino-acid, 14 kDa HIV-1 accessory protein, is dispensible for in 
vitro viral growth and replication, yet is essential for HIV function in vivo.   It has been 
implicated in a number of different viral and cellular processes, from enhancing accuracy 
of reverse transcription to nuclear import of viral DNA, and from anti- and pro-apoptotic 
activities to transactivation of HIV LTR and host genes (Le Rouzic and Benichou 2005).  
Yet, its most well studied cellular phenotype, when expressed alone or in the context of 
whole viral infection, is arrest of the cell cycle in G2, followed subsequently by apoptosis 
(He et al. 1995; Re et al. 1995; Bartz et al. 1996; Stewart et al. 1997; Roshal et al. 2003; 
Andersen et al. 2005; Lai et al. 2005).   
 
 The G2 cell cycle arrest caused by Vpr expression is evidently the result of 
activation of a DNA damage response pathway, yet what is the initial insult or activation 
of the pathway remains a mystery. Vpr binds directly to chromatin (Lai et al. 2005), it 
induces H2AX phosphorylation and RPA foci, requires Rad17 and Hus1 (Zimmerman et 
al. 2004), and activates BRCA1 (Andersen et al. 2005), which is strongly suggestive of 
the actual damage of DNA.  Inhibition of either the ATR or Chk1 DNA damage 
checkpoint kinases inhibits this arrest (Roshal et al. 2003), as would be expected from 
other signs of DNA damage, and the G2 arrest does not require functional p53 or Rb 
pathways, as HeLa cells readily arrest. 
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However, the G2 arrest phenotype is not the only one relevant to our studies.  
Recently, Vpr was also found to target two cellular substrates, the uracil DNA 
glycosylases UNG2 and SMUG, for polyubiquitination and proteasome-dependent 
degradation (Schrofelbauer et al. 2005), and this interaction is physiologically significant, 
as Vpr’s interaction with UNG2 inhibits UNG2’s critical role in immunoglobulin class 
switch recombination, thereby impairing antibody production (Begum et al. 2006).  The 
authors of the UNG2 degradation manuscript also reported association of ectopically 
expressed CUL4A with Vpr, but did not pursue the significance of that association.  The 
same group very recently published a manuscript showing that CUL4A or DDB1 
silencing inhibits UNG2 and SMUG degradation, and Vpr physically interacts with 
DDB1 (Schrofelbauer et al. 2007).   They also found that Vpr disrupted DDB1-DDB2 
interaction and, consequently, global genomic repair of UV-damged DNA, and speculate 
that the G2 arrest caused by Vpr is due to the inability to repair this damage, since DDB1 
silencing also produces G2 accumulation.  However, they have not causally established 
such a link between Vpr’s cell cycle arrest and DDB1. 
 
As described in Chapter 3, I have focused my research on the characterization of 
VprBP (Vpr binding protein), which was, obviously by its name, originally discovered as 
a cellular protein that abundantly associated with Vpr (Zhao et al. 1994; Zhang et al. 
2001).  The combination of this physical link and the aforementioned evidence linking 
Vpr and the CUL4A/DDB1 ligase led me to examine the link between VprBP and Vpr 
function.  In this chapter, I present some preliminary data describing in greater detail the 
interaction between VprBP and Vpr, and the bridging of UNG2, Vpr’s ubiquitination 
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substrate, to VprBP.  These results would be greatly enhanced by evidence showing a 
requirement for VprBP in UNG2 degradation, experiments that are ongoing at the time of 
this writing.  I also present evidence that suggests a possible link between VprBP and the 
G2 arrest phenotype of Vpr expression, but is confounded by the cell cycle arrest 
produced by VprBP silencing alone. 
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Experimental Procedures 
 
Antibodies and immunopurification 
 
Antibodies to HA (12CA5, Boehringer-Mannheim), Myc (9E10, NeoMarkers), 
and UNG1/2 (Abcam) were purchased commercially. Rabbit polyclonal antibodies to 
CUL4A and DDB1 have been described (Hu et al. 2004). A rabbit polyclonal antibody 
against VprBP was produced by injection of a synthetic peptide antigen to residues 1493-
1507 of VprBP (DNSDLEDDIILSLNE).   
 
Plasmids, cell culture, and cell transfection 
 
A plasmid expressing UNG2 was produced by amplifying cDNA from a human 
HeLa cDNA library and subcloning into a pcDNA3-based mammalian expression vector.  
pFSZ2-VprBP-FLAG was the kind gift of Dr. L.J. Zhao (St. Louis University), and was 
used to subclone VprBP into a pcDNA3-based mammalian expression vector.  
pLHAVprSN was the kind gift of Dr. Wei Chun Goh (Tufts-New England Medical 
Center), and was used to subclone into a pcDNA3-based mammalian expression vector.  
Once in pcDNA3, HA-Vpr was subcloned into a pBABE-based retroviral expression 
vector for retrovirus production and transduction.   Mutations were introduced by site-
directed mutagenesis using the QuickChange Kit (Stratagene) and verified by DNA 
sequencing.  Cell lines were cultured as follows: U2OS cells in McCoy’s 5A medium 
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containing 15% FBS, and 293T cells in DMEM containing 10% newborn calf serum.  
Cell transfections were carried out using a calcium-phosphate buffer. 
 
RNA interference (RNAi) 
 
Two duplex oligonucleotides encoding human VprBP-specific shRNA (sh1:  5'-
CCGG GAA TAC TCT TCA AGA ATG ATG CCTCCTGTCA CAT CAT TCT TGA 
AGA GTA TTC TTTTTG-3' and sh2: 5’-CCGG GAA ATA CCT CGT CCT TCT ATG 
CTTCCTGTCA CAT AGA AGG ACG AGG TAT TTC TTTTTG), one duplex encoding 
human DDB1-specific shRNA  (5’-CCGG CAG CAT TGA CTT ACC AGG CAT 
CCTCCTGTCA ATG CCT GGT AAG TCA ATG CTG TTTTTG-3’) and one duplex 
oligonucleotide encoding firefly luciferase-specific shRNA (5’-CCGG GAGCT GTTTC 
TGAGG AGCC CCTCCTGTCA GGCT CCTCA GAAAC AGCTC CCGG TTTTTG-3’) 
were ligated into the PMKO.1 vector (Addgene plasmid 8452). Retrovirus production 
was carried out according to a standard protocol and then used to infect WI-38, U2OS, 
and HeLa cells. Twenty-four hours after infection, cell lines were selected by puromycin 
(2 µg/mL) for 2 d before cell cycle analysis, replating for cell proliferation assays, or 
analyzing protein expression and complex formation. 
 
Flow cytometry 
 
To analyse DNA content by propidium iodide staining, WI-38, U2OS, or HeLa 
cells were fixed in 75% ethanol overnight at 4ºC, then washed once in 1X PBS + 1% fetal 
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bovine serum, and permeabilized for 30-45 mins at 37ºC in 1X PBS + 0.1 mg/mL RNAse 
A + 0.1% Triton X-100.  The fixed and permeable cells were stained with 50 µg/mL 
propidium iodide for at least 90 mins at room temperature, shielded from light.  Stained 
cells were analyzed at the UNC School of Medicine Flow Cytometry Facility on either a 
FACScan (Becton Dickinson) or CyAN (Dako Cytomation) flow cytometer, and data 
analyzed using Summit 4.3 software (Dako Cytomation).  
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Results 
 
HIV-1 Vpr interacts in mammalian cells with VprBP. 
 
VprBP was originally named for its initial identification as an HIV-1 Vpr binding 
protein (Zhao et al. 1994; Zhang et al. 2001).  I further examined this interaction with the 
goal of ascertaining how Vpr’s interaction with VprBP might be potentiating its cellular 
effects.  The major phenotype of cells expressing Vpr is accumulation in the G2 phase of 
the cell cycle, in a manner requiring the ATR signaling pathway, followed subsequently 
by apoptosis.  However, because silencing of VprBP leads to cell cycle arrest without the 
presence of Vpr—in particular, I have observed a lack of response to the mitotic inhibitor 
nocodazole in every cell line I have tested (Figure 3.3D and data not shown)—it is 
impossible by this method to examine whether loss of VprBP inhibits this function of Vpr 
(Le Rouzic et al. 2007).   
 
However, Vpr has also been reported to target a specific cellular substrate, the 
uracil DNA glycosylase UNG2, for polyubiquitination and proteasome-dependent 
degradation, and Vpr co-purifies with overexpressed CUL4A (Schrofelbauer et al. 2005).  
These results led me to examine whether VprBP functioned to bridge Vpr and UNG2 to 
the CUL4A ubiquitin ligase machinery.  I first confirmed the Vpr-VprBP interaction, and 
that the WD-40 domain of VprBP is sufficient for this interaction, by overexpressing both 
proteins in mammalian cell culture (Figure 4.1).  These results are completely consistent 
with data published by another research group after I completed this series of  
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Figure 4.1 
 
 
 
Figure 4.1.  VprBP interacts with HIV-1 Vpr through its WD domain. 
 293T cells were transfected with plasmids expressing myc3-tagged VprBP (full-
length or WD domain only) and HA2-tagged Vpr.  24 hours after transfection, cells were 
lysed in 0.1% NP-40 lysis buffer, immunoprecipitated with an anti-HA antibody, and 
Western blotted as indicated. 
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experiments (Le Rouzic et al. 2007).  Further characterization within the WD domain of 
VprBP to determine the exact region of Vpr binding, as opposed to the DWD motif 
known to interact with DDB1, remains to be done. 
 
UNG2 interacts with VprBP when Vpr is co-expressed. 
 
I then examined UNG2’s interaction with Vpr and VprBP by ectopically 
expressing Vpr and UNG2 in 293T cells.  UNG2 only interacts with VprBP when Vpr is 
co-expressed, and this interaction is greatly stabilized by MG132 proteasome inhibition, 
as expected for a ubiquitin ligase substrate (Figure 4.2).  Vpr’s interaction with VprBP is 
not affected by co-expression of UNG2, suggesting that the complex is linked together by 
Vpr, but interestingly, in the presence of overexpressed UNG2, Vpr is significantly less 
stable, which may be due to its proteasomal degradation alongside its target (Figure 4.2).
  
Figure 4.2 
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Figure 4.2.  Vpr expression is required for UNG2-VprBP interaction, which is 
stabilized by proteasome inhibition. 
 
 293T cells were co-transfected with plasmids expressing HA2-tagged Vpr and/or 
myc3-tagged UNG2.  24 hours after transfection, cells were lysed with 0.1% NP-40 lysis 
buffer and immunoprecipitated with anti-HA or anti-myc antibodies.  After SDS-PAGE 
and transfer onto nitrocellulose membranes, the samples were Western blotted as 
indicated. 
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Endogenous UNG2 is not significantly stabilized by silencing of VprBP or DDB1. 
 
  To better understand the role that VprBP may play in UNG2 ubiquitination, I 
examined endogenous UNG2 stability in U2OS cells after silencing of VprBP and Vpr 
expression (Figure 4.3).  Although I was unable to detect expression of Vpr, a retrovirus 
expressing Vpr produced strong G2 arrest (Figure 4.4), indicating that the protein was 
expressed.  Vpr with arginine-90 mutated to lysine (R90K), which does not cause G2 
arrest (Selig et al. 1997), reduces UNG levels somewhat less efficiently than wildtype, 
but because of an inability to detect the Vpr protein, I cannot conclude anything from this 
result.  However, any stabilization of endogenous UNG2 after VprBP or DDB1 shRNA is 
minimal, which suggests two possibilities: either Vpr—not VprBP—is rate-limiting in 
this reaction, and whatever residual VprBP remaining after shRNA is sufficient to 
degrade UNG2; or, Vpr has additional transcriptional regulation activities that lower 
UNG2 expression.  My data cannot distinguish between these two, but after I performed 
these experiments, Schrofelbauer and colleagues clearly demonstrated that, using 
plasmid-based expression of UNG2, DDB1 and CUL4A siRNA inhibited its degradation 
(Schrofelbauer et al. 2007).  Their data are more consistent with additional regulation of 
endogenous UNG2, although this has yet to be demonstrated.  Vpr with tryptophan-54 
mutated to arginine (Vpr W54R) greatly reduces its interaction with UNG2 and does not 
promote its degradation (Schrofelbauer et al. 2005), but yet this mutant has complete 
interaction with VprBP, further suggesting that the interaction between Vpr and VprBP is 
not dependent upon association with their substrate UNG2 (Figure 4.5). 
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Figure 4.3 
 
 
Figure 4.3.  Vpr is capable of downregulating endogenous UNG after VprBP or 
DDB1 silencing. 
 
 U2OS cells were transduced with two retroviruses: one expressing shRNA to 
DDB1 or VprBP with puromycin resistance, and another expressing Vpr, either wildtype 
(WT) or R90K (RK).  24 hrs after transduction, the cells were selected with puromycin, 
and 48 hrs after selection, they were lysed in 0.1% NP-40 lysis buffer and Western 
blotted as indicated. 
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Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  A Vpr-expressing retrovirus leads to G2 arrest, which is inhibited by 
VprBP shRNA. 
 
U2OS cells were transduced with two retroviruses: one expressing shRNA to 
luciferase (as a negative control), DDB1, or VprBP with puromycin resistance, and 
another expressing Vpr, either wildtype (WT) or R90K (RK).  24 hrs after transduction, 
the cells were selected with puromycin, and 48 hrs after selection, they were trypsinized, 
fixed, and stained with propidium iodide.  A flow cytometer was used to analyze the 
DNA content based upon propidium iodide levels. 
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Figure 4.5 
 
 
 
Figure 4.5.  Vpr W54R interacts normally with VprBP but no longer binds UNG2. 
 293T cells were co-transfected with plasmids expressing HA2-tagged Vpr 
(wildtype or W54R mutant) and/or myc3-tagged UNG2.  24 hours after transfection, cells 
were lysed with 0.1% NP-40 lysis buffer and immunoprecipitated with anti-HA or anti-
myc antibodies.  After SDS-PAGE and transfer onto nitrocellulose membranes, the 
samples were Western blotted as indicated. 
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Discussion 
 
 The results presented in this chapter point toward future experiments to 
characterize how VprBP may mediate the cellular functions of HIV-1 Vpr.  I have shown 
conclusively that VprBP does interact in mammalian cells with Vpr, and this interaction 
is required for the binding of VprBP and Vpr’s cellular ubiquitination substrate, uracil 
DNA glycosylase.  However, I have been unable to better characterize the functional 
consequences of VprBP-Vpr interactions. 
 
 While I was conducting my studies, two manuscripts have been published that 
both shed further light on this subject, and make future prospects for understanding this 
system more confusing.  First, le Rouzic and colleagues examined the in vivo and in vitro 
interaction between Vpr and VprBP, and its consequences for the G2 cell cycle arrest that 
has been well-documented with Vpr expression (Le Rouzic et al. 2007).  The authors 
clearly define, in accordance with my data, that Vpr and VprBP interact, through 
VprBP’s WD-40 domain, and they also add yeast two-hybrid data to confirm the 
interaction.  However, they also claim that silencing of VprBP prevents Vpr-dependent 
G2 arrest.  As shown in this chapter, I generated very similar data, however, as described 
in Chapter 3, VprBP-silenced cells do not respond to G2 arrest by nocodazole, either.  
Therefore, the conclusions they reach based upon this data are not sound.  Moreover, they 
demonstrate that a Vpr mutant that does not bind to VprBP also does not cause a G2 cell 
cycle arrest.  However, as I demonstrate in this chapter, another Vpr mutant (R90K) that 
does not cause G2 cell cycle arrest readily interacts with VprBP.  Therefore, the link 
between Vpr-VprBP interaction and G2 arrest is tenuous at best. 
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 More importantly, Schrofelbauer and colleagues examined the link between Vpr 
and DDB1 (Schrofelbauer et al. 2007).  They clearly demonstrate that Vpr interacts with 
DDB1 and VprBP, though they do not explore the VprBP link further.  But, in a series of 
experiments, they showed clearly that Vpr disrupts DDB1-DDB2 interaction and DDB2-
dependent nucleotide excision repair.  Moreover, DDB1 and CUL4A are required for 
Vpr-dependent degradation of uracil DNA glycosylase UNG2.  This is somewhat at odds 
with my data, where DDB1 and VprBP shRNA do not appreciably affect endogenous 
UNG2 degradation by Vpr, but their data is exclusively with ectopically-expressed 
UNG2 and SMUG.  Perhaps there is another endogenous mechanism besides proteolytic 
degradation that downregulates UNG2 upon Vpr expression, which is eliminated by 
plasmid-based expression.  Another possibility is that, due to the inefficient silencing of 
my DDB1 shRNA construct, that I missed this effect in my experiments, and VprBP is 
not required for the Vpr-DDB1 association.  There is ample opportunity for future 
experiments along these lines.  Finally, the authors speculate that, due to the known 
phenotype of G2 accumulation after DDB1 silencing or knockout, that perhaps DDB1 
mediates Vpr’s G2 arrest, but they provide no experimental evidence to support this 
speculation.   
 
 Future directions for this research include establishing whether VprBP is required 
for UNG2 degradation, by using the same system as Schrofelbauer et al, overexpressing 
UNG2 to eliminate any transcriptional downregulation upon Vpr expression.  
Furthermore, by better characterizing Vpr mutants, or perhaps VprBP point mutants that 
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do not interact with Vpr, it should be possible to determine whether VprBP is required for 
the G2 arrest and/or apoptosis produced by Vpr.   
  
CHAPTER 5 
 
CONCLUSIONS AND PERSPECTIVES
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 Over the past four years, my studies have been focused on elucidating the 
substrate-targeting mechanism of CUL4A.  As shown in Chapter 2, I contributed to the 
discovery of a common motif found in many CUL4A/DDB1-interacting proteins, the 
“DWD box.”   With more than ninety proteins in the human genome containing this 
motif, there are many opportunities for future studies exploring the substrates targeted by 
any number of the heretofore-uncharacterized DWD proteins.  I then took the most 
abundant of these DWD proteins found in the CUL4A immunocomplex, VprBP, and 
carefully characterized its binding with CUL4A/DDB1 and have begun to explore its 
cellular functions, shown in Chapter 3.  VprBP also interacts with the HIV-1 accessory 
protein Vpr, hence its name, and I made preliminary investigations into the role that Vpr 
might play in recruiting a cellular substrate to CUL4A/DDB1, which I described in 
Chapter 4.  In each of these chapters, I have discussed the future prospects for each, but 
taking them as a whole, and using them as a lens to examine the entire cullin field, in this 
final chapter I will examine some of the future prospects for studying this intriguing 
family of ubiquitin ligases. 
 
VprBP as a substrate receptor for a protein (or proteins) involved in regulation of 
DNA replication 
 
 
 Because it contains a DWD box similar to that in other CUL4A/DDB1-interacting 
substrate receptors—DDB1, CSA, and Fbw5—the most obvious hypothesis for how 
VprBP functions in the CUL4A ligase is as another substrate receptor (Figure 5.1).   If 
not a receptor itself, in a dimeric cullin complex VprBP may serve as a regulator of other 
DWD protein function, but as of yet, I cannot distinguish between these two possibilities 
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(receptor or regulator of other receptors).  Examining the data I have accumulated over 
the past several years, what might be the targets of VprBP regulation?  The major 
phenotype of VprBP loss is inhibition of DNA replication, yet I did not identify any 
proteins known to be involved in DNA replication or metabolism in a large-scale 
immunocomplex purification (Figure 3.1A).   My laboratory will continue to explore this 
avenue to identify potential substrates, using advances in mass spectrometric technology 
since my initial screens.  But, at this point, the only way I can propose substrates is 
through the biological functions I have identified for VprBP.   
 
 Chromatin fractionation shows that VprBP is associated with chromatin in 
asynchronous cells actively replicating DNA, but not in cells arrested by nocodazole in 
mitosis (Figure 3.7A, 3.7C). VprBP and CUL4A follow an almost identical pattern of 
chromatin association along the cell cycle, lowest in M and G1, and increasing through S 
into G2, which is consistent with VprBP functioning alongside CUL4A in regulation of 
DNA replication.  However, VprBP silencing does not affect CUL4A or DDB1 
chromatin localization, and its chromatin association is not affected by UV damage 
unlike CUL4A or DDB1, therefore it is unlikely to function in the regulation of UV-
dependent CUL4A/DDB1 substrates (Figure 3.7C).  These fractionation data are most 
consistent with a heretofore undefined, VprBP-dependent, role for CUL4A/DDB1 in 
regulation of DNA replication.  This is also consonant with the inhibition of replication 
seen after VprBP silencing.   
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The chromatin fractionation data also help to narrow down where VprBP may be 
functioning in replication.  In VprBP-silenced cells, MCM2-7 loading onto chromatin is 
normal; therefore, whatever substrates might be targeted for ubiquitination must act after 
the assembly of the pre-replication complex in G1.  MCM2-7 loading requires the 
function of another CUL4A substrate, CDT1 (Nishitani et al. 2000), thus it is unlikely 
that VprBP acts on CDT1 as does another DWD protein, CDT2/L2DTL (Higa et al. 
2006a).  Thus, the decrease in CDT1 levels seen in two cell lines, both with and without 
functional p53 (Figure 3.11), is unlikely to be the cause of the VprBP S-phase arrest 
phenotype.  VprBP’s function occurs temporally after pre-replication complex formation 
(MCM2-7 loading), but it also must occur before actual elongation of replication forks.  
As shown in Table 3.1 and Figure 3.6, Dr. Paul Chastain has found no consistent change 
in the actual rate of fork progression in silenced cells.  Once a fork is fired, therefore, it is 
unlikely that the mechanics of replication are adversely affected. Hence, the most likely 
candidates for regulation by VprBP are proteins involved in the steps between the loading 
of the pre-replication complex on origins of replication and actual replication of DNA by 
polymerases. 
 
There are several potential CUL4A/DDB1/VprBP substrates that function in these 
initiatory steps in replication.  First, Mcm10, which is recruited to chromatin after DNA 
origin licensing and is required for the assembly of factors required for replication 
(Cdc45 and pol α), is diubiquitinated in G1 and throughout S phase in budding yeast 
(Das-Bradoo et al. 2006).  This diubiquitination is required for its binding to PCNA and 
functioning in DNA replication, yet it has not been studied in higher eukaryotes.   
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Figure 5.1 
 
 
 
 
Figure 5.1.  A model for VprBP function in the CUL4A/DDB1 ubiquitin ligase. 
 
 VprBP silencing results in decreased overall DNA synthesis in mid- and late S-
phase, as measured by BrdU incorporation (Figure 3.5B), but a two to threefold increase 
in firing of new origins of replication (Figure 3.5E).  One possible model is that VprBP 
acts to prevent improper origin firing in normal cells, either by targeting a heretofore 
unknown substrate for ubiquitination directly by the CUL4A/DDB1 ligase (left) or by 
regulating substrate ubiquitination in a targeted manner (right) in a dimeric cullin 
complex.   
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Perhaps VprBP is required for or modulates CUL4A-dependent ubiquitination of 
Mcm10?  As discussed earlier in Chapter 3, the Cdc7 kinase, also required for initiation 
of replication at individual forks, is another potential target of VprBP function.  The 
phenotype after Cdc7 silencing is similar to that of VprBP silencing in HeLa and in 
primary cells; however, that phenotype—a reduction in BrDU labeling and S-phase 
arrest—is not very specific and could just indicate a broad inhibition of DNA synthesis 
(Montagnoli et al. 2004).  Cdc7 is not known to be regulated by ubiquitination, but its co-
factor, Dbf4, is an APC substrate, therefore is a potential VprBP/CUL4A target (Ferreira 
et al. 2000).  If VprBP were a negative regulator of a CUL4A-dependent degradation of 
Dbf4, then loss of Dbf4 would be expected in VprBP-silenced cells.  This possibility 
remains to be tested.  Cdc45 loading onto chromatin, which is required for polymerase 
loading and initiation of replication at forks throughout S phase, may also be disrupted 
(Bell and Dutta 2002).  As antibodies are readily available for these potential substrates, 
they can be rapidly examined in the future. 
 
In addition to the possibility that VprBP is disrupting initiation of replication at 
licensed forks, careful examination of VprBP-silenced BrDU incorporation and combing 
data suggests other possibilities: that VprBP might be involved in the regulation of timing 
of origin firing, recovery from naturally stalled forks throughout S phase, or progression 
through regions of chromatin that replicate slowly.  I have consistently seen a decrease in 
overall BrDU incorporation per cell (Figure 3.5B, 3.5C), and the BrDU staining profile 
shows that cells with an early S-phase DNA content have almost normal incorporation, 
but BrdU staining per cell rapidly decreases with progression through DNA replication.  
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One explanation of this data is that VprBP is not required for initiation of replication at 
the beginning of S phase, but is required for ongoing maintenance of replication.  Two 
possibilities for this function are the firing of forks that are initiated in the middle of S 
phase, or resumption of fork progression after stalling, which occurs naturally in all cells 
even without additional DNA damage.   
 
Maintenance of normal S phase progression in eukaryotes requires the ATR/Chk1 
pathway.  In the same HeLa cell line as Dr. Chastain and I used to examine the S-phase 
phenotype of VprBP-silenced cells, Chk1 inhibition results in increased firing of new 
origins of replication, but decreased overall rate of fork progression (Petermann et al. 
2006; Maya-Mendoza et al. 2007).  Chk1 inhibition also results in the early firing of late 
origins of replication, indicating a loss of normal replication timing (Miao et al. 2003).  
Chk1-deficient cells also have decreased incorporation of BrDU per cell during S phase, 
similar to my findings (personal communication of Dr. Jean Cook).  However, VprBP 
deficiency is not entirely analogous to Chk1 deficiency, as VprBP loss does not 
appreciably affect fork progression.  A possible hypothesis is that VprBP is responsible 
for regulating, through targeting an unknown substrate for ubiquitination or regulating its 
CUL4A-dependent ubiquitination, the proper order of origin firing.  One can imagine 
that, if far too many origins fire, which we see in the combing experiments (Figure 3.5E), 
that replication might fail due to disruption of the stoichiometry of replication factors, or 
collision of forks firing too near to each other, or any number of other possibilities.  But, 
at this point, there is no obvious ubiquitination substrate to test; future experiments 
clarifying VprBP’s role in replication, along with continuing efforts to identify VprBP-
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associated proteins by immunopurification, will have to be done to further this line of 
research. 
 
Substrate recruiting by CUL4A/DDB1-DWD and other CUL4A/DDB1 complexes 
 
 In addition to the numerous experiments needed to ascertain the exact role of 
VprBP in the cell, there are still several avenues of research open in the general field of 
CUL4-DDB1 biology.  First and foremost, the DWD motif, which may not be all that is 
necessary for CUL4A/DDB1 binding, needs to be more carefully characterized, and a 
more systematic examination of the substrates targeted by these proteins might be 
possible (Angers et al. 2006; He et al. 2006; Higa et al. 2006b; Jin et al. 2006).   This 
would be a major undertaking, and perhaps the most efficient use of the DWD proteins 
identified by us and other groups would be simply their identification, for use by other 
laboratories whose focus is on particular candidate substrates.  As discussed in Chapter 2, 
another issue is the existence of DDB1-interacting substrate receptors, such as 
DET1/COP1 and the paramyxovirus SV5 V protein, which do not contain WD domains.   
The binding site of SV5 V, for example, compared with the DWD interacting surface, 
strongly suggests that multiple DDB1 binding pockets might be able to function in cullin 
substrate recruitment (Angers et al. 2006; Li et al. 2006).  The large size and multiple 
domains of DDB1 at the very least makes its potential functioning in a cullin complex 
significantly more complicated than that of the small proteins which function as linkers 
for the other cullins. 
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Regulation of COP9/signalosome association with CUL4A/DDB1 
 
Besides the problem of substrate recruitment and the identification of novel 
substrates, several lines of evidence suggest that CUL4A/DDB1 may be regulated at 
additional levels from the common regulatory machinery of all cullins.  The original 
description of the CUL4A/DDB1/DDB2 and CUL4A/DDB1/CSA complexes in 2003 
illustrated two unique features of these complexes: regulated association of the COP9 
signalosome and regulated binding with chromatin (Groisman et al. 2003).  The first 
observation, signalosome regulation, could potentially be a novel level of CUL4A/DDB1 
regulation.  In the case of DDB2, the authors showed that in the absence of UV treatment, 
there is a stable CUL4A/DDB1/DDB2/COP9 complex, and CUL4A is not Nedd8-
modified.  After UV treatment, this complex relocates to chromatin, the signalosome 
dissociates, and CUL4A becomes neddylated.  Within 2 hours of treatment, the 
signalosome reassociates with the DDB2 complex on chromatin, which correlates with 
loss of neddylation of CUL4A.  What contributes to this level of regulation—is it the 
association of DDB2 with its targets (histones H2B, H3, H4, and/or XPC) upon UV 
treatment, which leads to the dissociation of the signalosome, and then their subsequent 
ubiquitination and release, which allows its return?  The CSA complex has different 
properties of chromatin association and signalosome regulation upon UV damage, which 
may reflect the differences in the functions of its substrate, CSB, in transcription-coupled 
repair.  Future studies are necessary to examine what additional factors or post-
translational modifications might be required for this unique regulation, and furthermore, 
whether other CUL4A/DDB1 substrate receptors/substrates exhibit similar properties. 
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Functional consequences of CUL4A/DDB1-DWD dimerization 
 
As described earlier (Figure 2.5), I have accumulated some evidence showing that 
CUL4A forms dimeric complexes, both homodimers and heterodimers with CUL1.  In 
addition, both VprBP and DDB2, two DWD proteins, are capable of interacting with 
other DWD proteins.  These data, along with the large molecular weight size of 
CUL4A/DDB1 macromolecular complexes by gel filtration chromatography (Figure 
2.1A), imply that CUL4A/DDB1 does not function as a single unit.  But what role might 
this dimerization play in cullin function?  Are oligomeric complexes more active as 
ligases?  Evidence from E2 studies suggest that E2-E2 dimers are required for at least 
some instances of polyubiquitination (Li et al. 2007).   CUL4A/DDB1 oligomers would 
have two molecules of the RING domain protein ROC1, therefore could promote the 
interaction of two E2 molecules as well.  It should be possible to test this hypothesis 
experimentally: by mutational analysis, CUL4A and/or DDB1 mutants required for 
dimerization may be identified, and then examined to see what effect they have on in vivo 
or in vitro ubiquitination of substrates.  The potential of hetero-dimerization with CUL1 
adds another layer of complexity to CUL4A/DDB1 function, which could also be studied 
by mutagenesis, binding experiments, or the effects of CUL1 silencing on the 
ubiquitination and degradation of known CUL4A substrates.   
 
Moreover, we have yet to examine carefully what role CUL4B may play in 
CUL4/DDB1 biology.  As I discussed earlier, CUL4B loss, unlike that of CUL4A and 
DDB1, is not embryonic lethal but causes an X-linked mental retardation syndrome in 
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humans (Tarpey et al. 2007; Zou et al. 2007).  However, it may play a role in the 
degradation of CUL4A/DDB1 substrates, like CDT1 (Hu et al. 2004).  Since it clearly 
utilizes the same substrate-recruiting molecule, DDB1, several experiments might be 
designed to examine what role CUL4B is playing.  First, its tissue, developmental, cell 
cycle, and/or subcellular localization specificity should be examined, since this could 
easily explain its lack of redundancy on an organismal level.  Its binding properties also 
may be examined, particularly looking at the CUL4B immunocomplex to determine 
whether other factors interact with its unique 100 amino acid N-terminal extension.  From 
an evolutionary perspective, since CUL4A and CUL4B diverged in vertebrates, as 
opposed to a single CUL4 in Arabidopsis, Drosophila, C. elegans, and S. pombe, it is 
logical that CUL4B might play some higher developmental role, such as is apparent in 
the nervous system, as opposed to the pervasive and essential role of CUL4A in 
mammals and CUL4 in other organisms. 
 
Regulation of all cullins by CAND1 and ROC selectivity 
 
 In addition to the remaining questions about the regulation and function of 
CUL4A/B, not all is known about the general properties of the cullin ligases.  CAND1, 
the negative regulator of cullins identified in our lab and others, remains incompletely 
characterized (Liu et al. 2002; Zheng et al. 2002a; Oshikawa et al. 2003).  While we 
know that CAND1 must be dissociated from cullins in order for substrate receptors to 
bind, how this occurs is a mystery.  CAND1 binding to CUL1 obscures binding sites to 
both SKP1 and Ubc12, the Nedd8 E2, while Nedd8 modification of cullins inhibits 
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CAND1 binding (Liu et al. 2002; Goldenberg et al. 2004).  However, more recent studies 
have shown that, in an unknown manner, SKP1 complexed with an F-box protein, SKP2, 
is able to prompt the dissociation of CAND1 from CUL1, but SKP1 alone is unable to do 
so (Bornstein et al. 2006).  The physical mechanism by which this occurs—for example, 
whether the F-box protein increases SKP1 affinity for CUL1 to a sufficient extent to 
compete off CAND1—has yet to be determined.   
 
 Another aspect of the “cullin cycle”—the deneddylation of cullins after substrate 
recruitment and degradation, allowing the rebinding of CAND1 and resumption of an 
inhibited state, is also incompletely understood.  Deneddylation, catalyzed by the 
COP9/signalosome, must also be tightly regulated.  Recently, Bornstein et al found that 
in vitro, addition of the substrate p27Kip1 to a CUL1-SKP1-SKP2 complex prevented 
signalosome-dependent deneddylation under conditions where CUL1-SKP1-SKP2 was 
accessible for deneddylation (Bornstein et al. 2006).  They propose that substrate addition 
causes a conformational change in the cullin, leading to inhibition of signalosome 
association.  The actual location of COP9/signalosome binding to the cullins has never 
been conclusively ascertained, however.  Studies in budding yeast and in our lab have 
shown that mutation of two conserved residues, R473 and L474 in human CUL1, leads to 
hyperneddylation and inhibition of CAND1 association (Lammer et al. 1998; Patton et al. 
1998; Liu et al. 2002).  Unpublished data from Jidong Liu in our laboratory shows that 
these residues are required for signalosome association.  Whether this is because these 
residues are required for physical interaction, or whether their mutation leads to a change 
in CUL1 conformation, has not been established.  These unanswered questions make it 
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clear that the “cullin cycle,” while we understand it roughly, is much more complex than 
our initial characterization revealed. 
 
 A final poorly understood area of cullin biology is the presence of multiple 
ROC/Rbx RING finger proteins.  In studies in our laboratory of cullin function, we have 
treated them as essentially interchangeable, but recent reports have called that into 
question.  In Drosophila, there are three ROC proteins: Roc1a, Roc1b, and Roc2.  When 
mutated, these have differing effects on Drosophila development, and they have 
markedly different patters of cullin binding: CUL-1 and CUL-2 preferentially bound to 
Roc1a, CUL-3 to Roc1b, and CUL-5 to Roc2 (Donaldson et al. 2004).  What significance 
this has for cullin biology in higher eukaryotes has yet to be investigated.  Humans have 
two ROCs, ROC1 and ROC2, but evidence for their differing function is less clear.  
ROC2 was first identified as “SAG”—“sensitive to apoptosis gene,” and its silencing 
reduces the CUL1-dependent degradation of substrates pro-caspase-3 and c-Jun (Tan et 
al. 2006; Gu et al. 2007).  ROC2’s global effects on cullin function have yet to be 
examined—does it form a heterodimer with ROC1, promoting ubiquitination with certain 
cullin and at different catalytic rates than, for example, ROC1/ROC1 homodimers?  The 
Drosophila evidence strongly suggests that the ROCs are no more than partially 
redundant; therefore, this is another fertile area for future research. 
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Summary 
 
 In summary, while the general mechanism of ubiquitination and proteasomal 
degradation is fairly well understood, there are many avenues of investigation remaining.  
My research into the function of VprBP shows that the investigation of individual 
substrate receptors and/or regulators of cullin ligase activity will proceed as these 
receptors are identified and linked with particular cellular pathways.  We have only 
scratched the surface in the characterization of cullin ubiquitination substrates.  The 
number of DWD box, F-box, SOCS- and VHL-box, and BTB proteins in the human 
genome approaches a thousand in total, therefore we will likely continue to identify novel 
substrates for years to come.  Systematic approaches for identifying substrates have been 
singularly unproductive, but labs studying individual pathways will certainly discover 
links to proteins containing one of these motifs.  Improvements in mass spectrometric 
technology combined with a better understanding of methods of inhibiting ubiquitination 
and degradation may allow us to systematically identify substrates one day, but a 
candidate gene approach is currently the most efficient. 
 
 On the other end from substrate identification, I have discussed several areas of 
general cullin mechanism that, while broadly understood, are not well characterized on a 
mechanistic level.  How CAND1 and COP9/signalosome association are regulated, and 
how different RING finger proteins may play essential roles in cullin function, have not 
thoroughly been examined.  These mechanistic studies may not allow for major new 
insights into cullin function, but understanding cullin biology on a molecular level may 
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allow for better design of pharmacological inhibitors, which are of potentially great 
benefit to medicine. 
 
 In the end, the cullin family may become a very interesting target for molecular 
medicine.  We know that CUL4A is overexpressed in many breast, liver, and other 
cancers (Chen et al. 1998b; Yasui et al. 2002), but why increased ubiquitination of 
CUL4A substrates would promote carcinogenesis is unclear.  Perhaps disruption of DNA 
repair and metabolism would create increased genomic instability, which is a known 
hallmark of increasing malignancy in cancer.  Other cullins also have substrates that are 
of therapeutic potential: CUL1 degrades multiple cell cycle regulators; disrupting the cell 
cycle by its inhibition might be of general use as a cancer therapy; and, the CUL2 target 
HIF1α, which promotes response to hypoxia by driving vascular development and 
metabolic changes, is essential for tumor growth and blood supply.  As we better 
understand cullin biology, we will be in a better position to take this knowledge to the 
clinical bedside by developing therapeutics, which might be effective against cancer and 
other diseases. 
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APPENDIX 1: DWD-BOX PROTEINS IN DIFFERENT SPECIES
  
1.1. Homo sapiens DWD box proteins. 
 
Red = confirmed by immunoprecipitation with CUL4A/DDB1; Black = putative 
 
 
A16L1_HUMAN: (0399) LRHTLTGHSGKVLSAKFLLDNARIVSGSHDRTLKLWDLRSKVCI Autophagy-related protein 16-1 
DDB2_HUMAN: (0234) LWNLRMHKKKVTHVALNPCCDWFLATASVDQTVKIWDLRQVRGK DNA damage-binding protein 2 
ERCC8_HUMAN: (0178) SHILQGHRQEILAVSWSPRYDYILATASADSRVKLWDVRRASGC DNA excision repair protein ERCC-8 
FBXW8_HUMAN: (0464) GNIALSLSAHQLRVSAVQMDDWKIVSGGEEGLVSVWDYRMNQKL F-box/WD-repeat protein 8 
GBB2_HUMAN: (0174) QTVGFAGHSGDVMSLSLAPDGRTFVSGACDASIKLWDVRDSMCR Guanine nucleotide-binding protein beta subunit 2 
Q59ET5_HUMAN: (0325) RAHRAYTPNDECFFIFLDVSRDFVASGAEDRHGYIWDRHYNICL F-box and WD-40 domain protein 5 
Q5VYB6_HUMAN: (0270) ILSLTGDRVPLHCVDRHPNQQHVVATGGQDGMLSIWDVRQGTMP Nucleoporin 43kDa 
Q9NZJ0_HUMAN: (0207) GLAPSVDFQQSVTVVLFQDENTLVSAGAVDGIIKVWDLRKNYTA L2DTL protein 
RBBP4_HUMAN: (0264) SHSVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLK Histone-binding protein RBBP4 
RBBP7_HUMAN: (0264) SHLVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLK Histone-binding protein RBBP7 
WDR23_HUMAN: (0406) PVGALAGHQDGITFIDSKGDARYLISNSKDQTIKLWDIRRFSSRE WD-repeat protein 23 
WSB1_HUMAN: (0162) LLNLVDHTEVVRDLTFAPDGSLILVSASRDKTLRVWDLKDDGNM WD repeat and SOCS box-containing protein 1 
WSB2_HUMAN: (0189) QIQVLSGHLQWVYCCSISPDCSMLCSAAGEKSVFLWSMRSYTLI  WD repeat and Socs Box-containing protein 2 
GRWD1_HUMAN: (0253) QRPFVGHTRSVEDLQWSPTENTVFASCSADASIRIWDIRAAPSK Glutamate-rich WD repeat-containing protein 1 
KTNB1_HUMAN: (0096) ILRTLMGHKANICSLDFHPYGEFVASGSQDTNIKLWDIRRKGCV Katanin p80 WD40-containing subunit B1 
PWP1_HUMAN: (0292) AASLAVHTDKVQTLQFHPFEAQTLISGSYDKSVALYDCRSPDES Periodic tryptophan protein 1 homolog 
FBXW1_HUMAN: (0000) LQRIHCRSETSKGVYCLQYDDQKIVSGLRDNTIKIWD-KNTLEC F-box/WD-repeat protein 1A 
ARC1A_HUMAN: (0319) ETLHQNSITQVSIYEVDKQDCRKFCTTGIDGAMTIWDFKTLESS Actin-related protein 2/3 complex subunit 1A 
ARC1B_HUMAN: (0320) DSLHKNSVSQISVLSGGKAKCSQFCTTGMDGGMSIWDVKSLESA Actin-related protein 2/3 complex subunit 1B 
COPA_HUMAN: (0042) LIDKFDEHDGPVRGIDFHKQQPLFVSGGDDYKIKVWNYKLRRCL Coatomer subunit alpha 
DYI4_HUMAN: (0256) TIESSHRDPVYGTIWLQSKTGTECFSASTDGQVMWWDIRKMSEP Dynein intermediate chain 2, axonemal 
EMAL4_HUMAN: (0500) ISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWD-HDLNPER Echinoderm microtubule-associated protein-like 4 
FBXW7_HUMAN: (0613) LQTLQGPNKHQSAVTCLQFNKNFVITSSDDGTVKLWDLKTGEFI F-box/WD-repeat protein 7 
FBXW9_HUMAN: (0154) YFCLAEGHVASVDSVLLLQGGSLCLSGSRDRNVNLWDLRQLGTE F-box/WD-repeat protein 9 
GBB1_HUMAN: (0174) QTTTFTGHTGDVMSLSLAPDTRLFVSGACDASAKLWDVREGMCR Guanine nucleotide-binding protein beta subunit 1 
GBB3_HUMAN: (0175) QKTVFVGHTGDCMSLAVSPDFNLFISGACDASAKLWDVREGTCR Guanine nucleotide-binding protein beta subunit 3 
GBB4_HUMAN: (0174) QTTTFTGHSGDVMSLSLSPDMRTFVSGACDASSKLWDIRDGMCR Guanine nucleotide-binding protein beta subunit 4 
GBB5_HUMAN: (0230) QSFHGHGADVLCLDLAPSETGNTFVSGGCDKKAMVWDMRSGQCV Guanine nucleotide-binding protein beta subunit 5 
LIS1_HUMAN: (0370) CMKTLNAHEHFVTSLDFHKTAPYVVTGSVDQTVKVWECR----- Platelet-activating factor acetylhydrolase IB alpha subunit 
NLE1_HUMAN: (0404) YLASLRGHVAAVYQIAWSADSRLLVSGSSDSTLKVWDVKAQKLA Notchless homolog 1 
PK1IP_HUMAN: (0031) LVADFTHHAHTASLSAVAVNSRFVVTGSKDETIHIYDMKKKIEH p21-activated protein kinase-interacting protein 1 
PRP19_HUMAN: (0341) TKVTDETSGCSLTCAQFHPDGLIFGTGTMDSQIKIWDLKERTNV Pre-mRNA-splicing factor 19 
Q3MII9_HUMAN: (0489) KYIMCGSDEMNIRLWKANASEKLGVLTSREKAAKDYNQKLKEKF WD repeats and SOF1 domain containing 
Q4G115_HUMAN: (0113) TIESSHRDPVYGTIWLQSKTGTECFSASTDGQVMWWDIRKMSEP DNAI2 protein 
Q59GA8_HUMAN: (0189) HIQTLEGHHQEIWCLAVSPSGDYVVSSSHDKSLRLWE-RTREPLI WD repeat-containing protein 3 
Q59GD6_HUMAN: (0307) TQAQPPGPGRELTHCTLAHTAGVVLTATADHNLLLYEARSLRLQ Transducin beta-like 3 
Q5JTN6_HUMAN: (0012) RVKFFGQHGGEVNSSAFSPDGQMLLTGSEDGCVYGWETRSGQLL OTTHUMP00000022116 
Q5VTH9_HUMAN: (0738) PSLSFYPATSVVYDVAWSPKSSYIFAAANENRVEIWDLHISTLD Novel protein 
Q5VU06_HUMAN: (0126) IHMFGDHTNRVKRIATAPMWPNTFWSAAEDGLIRQYDLRENSKH Novel protein 
Q6FGN1_HUMAN: (0190) RIVIPAHQAEILSCDWCKYNENLLVTGAVDCSLRGWDLRNVRQP PEX7 protein 
Q6JZZ5_HUMAN: (0159) LSSYRAHAAQVTCVAASPHKDSVFLSCSEDNRILLWDTRCPKPA Androgen receptor cofactor p44 
128 
  
Q6NZ53_HUMAN: (0091) ENNYRGHGDSVDQLCWHPSNPDLFVTASGDKTIRIWDVRTTKCI THOC3 protein 
Q6PJI9_HUMAN: (0014) VEYLAAHLSKIHGLDWHPDSEHILATSSQDNSVKFWDYRQPRKY WDR59 protein 
Q6UXN9_HUMAN: (0098) YIRYFPGHSKRVVALSMSPVDDTFISGSLDKTIRLWDLRSPNCQ WD40 protein 
Q6ZQQ6_HUMAN: (0558) FIETLPLHLCAITSFDVCLSLSLFVTGSADGSVRIWDFHGRLIA CDNA FLJ46270 fis, clone TESTI4028042. 
Q86TI4_HUMAN: (0491) GELRRVFRGHTFIINCIQVHGQVLYTASHDGALRLWDVRGLRGA LOC349136 protein 
Q86XD6_HUMAN: (0087) VHSLIGHRRTPWCVTFHPTISGLIASGCLDGEVRIWDLHGGSES Hypothetical protein FLJ20294 
Q86YQ0_HUMAN: (0516) GHKEIINAIDGIGGLGIGEGAPEIVTGSRDGTVKVWDPRQKDDP HZGJ 
Q8IW98_HUMAN: (0186) RAELQGHLGPVTAVEFCPWRAGTLISASEDRGFKVWD-HCTGSLI MGC43690 protein 
Q8TBB7_HUMAN: (0134) TLDVFAHEDAVYGLSVSPVNDNIFASSSDDGRVLIWDIRESPHG WDR22 protein 
Q8TBY9_HUMAN: (0442) TEKTFNKLVGKFSQSIFHLNLTQILSATMEGKLVVWDIHRPPSS WD repeat domain 66 
Q8TCI4_HUMAN: (0058) LRHTLTGHSGKVLSAKFLLDNARIVSGSHDRTLKLWDLRSKVCI Hypothetical protein FLJ23854 
Q9BRX9_HUMAN: (0100) VVRKFRGHAGKVNTVQFNEEATVILSGSIDSSIRCWDCRSRRPE Mitogen-activated protein kinase organizer 1 
Q9BSW6_HUMAN: (0183) VEYLAAHLSKIHGLDWHPDSEHILATSSQDNSVKFWDYRQPRKY WDR59 protein 
Q9BTV9_HUMAN: (0159) FTRVLRGHTDYIHCLALRERSPEVLSGGEDGAVRLWDLRTAKEV THO complex subunit 6 homolog 
Q9BU59_HUMAN: (0340) TLKEFRGHSSFVNEATFTQDGHYIISASSDGTVKIWNMKTTECS Smu-1 suppressor of mec-8 and unc-52 homolog 
Q9BWV9_HUMAN: (0409) FIETLPLHLCAITSFDVCLSLSLFVTGSADGSVRIWDFHGRLIA NYD-SP11 
Q9C0C7_HUMAN: (0093) VHSLIGHRRTPWCVTFHPTISGLIASGCLDGEVRIWDLHGGSES KIAA1736 protein 
Q9NUL4_HUMAN: (0074) YEKTLYGHNLEISDVAWSSDSSRLVSASDDKTLKLWDVRSGKCL CDNA FLJ11287 fis, clone PLACE1009596 
Q9NXE7_HUMAN: (0087) VHSLIGHRRTPWCVTFHPTISGLIASGCLDGEVRIWDLHGGSES Hypothetical protein FLJ20294 
Q9UFJ8_HUMAN: (0178) CVHSYCEHGGFVTYVDFHPSGTCIAAAGMDNTVKVWDVRTHRLL WD-repeat protein 51A 
Q9UG25_HUMAN: (0162) LLNLVDHTGVVRDLTFAPDGSLILVSASRDKTLRVWDLRDDGNM Hypothetical protein DKFZp564A122 
RAE1L_HUMAN: (0264) TNTSAPQDIYAVNGIAFHPVHGTLATVGSDGRFSFWD-KDARTKL mRNA-associated protein mrnp 41 
RFWD2_HUMAN: (0547) SVASIEAKANVCCVKFSPSSRYHLAFGCADHCVHYYDLRNTKQP Ring finger and WD repeat domain protein 2 
RPTOR_HUMAN: (1157) VQDIPTGADSCVTSLSCDSHRSLIVAGLGDGSIRVYDRRMALSE Regulatory associated protein of mTOR 
SCAP_HUMAN: (1148) GSRVSHVFAHRGDVTSLTCTTSCVISSGLDDLISIWDRSTGIKF Sterol regulatory element-binding protein cleavage-activating 
protein 
SPG16_HUMAN: (0469) CRCTLYGHTDSVNSIEFFPFSNTLLTSSADKTLSIWDARTGICE Sperm-associated antigen 16 protein 
STB5L_HUMAN: (0102) DCYCQHESGAAVLQLQFLINEGALVSASSDDTLHLWNLRQKRPA Syntaxin-binding protein 5-like 
STRN4_HUMAN: (0392) GGGEVSLGDLADLTVTNDNDLSCDLSDSKDAFKKTWNPKFTLRS Striatin-4 
TAF5L_HUMAN: (0501) LYKELRGHTDNITSLTFSPDSGLIASASMDNSVRVWDIRNTYCS TAF5-like RNA polymerase II p300/CBP-associated factor 65 kDa 
subunit 5L 
TBL1R_HUMAN: (0257) LASTLGQHKGPIFALKWNKKGNFILSAGVDKTTIIWDAHTGEAK F-box-like/WD-repeat protein TBL1XR1 
TBL1X_HUMAN: (0269) LASTLGQHKGPIFALKWNRKGNYILSAGVDKTTIIWDAHTGEAK F-box-like/WD-repeat protein TBL1X 
TBL1Y_HUMAN: (0267) LASTLGQHKGPIFALKWNKKGNYVLSAGVDKTTIIWDAHTGEAK F-box-like/WD-repeat protein TBL1Y 
TBL3_HUMAN: (0169) TQAQPPGPGQELTHCTLAHTAGVVLTATADHNLLLYEARSLRLQ WD-repeat protein SAZD 
TEP1_HUMAN: (2052) CGTELRGHEGPVSCCSFSTDGGSLATGGRDRSLLCWDVRTPKTP Telomerase protein component 1 
TF3C2_HUMAN: (0605) FQCFLAHDQAVRTLQWCKANSHFLVSAGSDRKIKFWDLRRPYEP General transcription factor 3C polypeptide 2 
THOC3_HUMAN: (0091) ENNYRGHGDSVDQLCWHPSNPDLFVTASGDKTIRIWDVRTTKCI THO complex subunit 3 
TSSC1_HUMAN: (0176) ASLEGKGQLKFTSGRWSPHHNCTQVATANDTTLRGWDTRSMSQI Protein TSSC1 
WD51B_HUMAN: (0177) CVNNFSDSVGFANFVDFNPSGTCIASAGSDQTVKVWDVRVNKLL WD-repeat protein 51B 
WDR12_HUMAN: (0334) SLSLTSHTGWVTSVKWSPTHEQQLISGSLDNIVKLWDTRSCKAP WD-repeat protein 12 
WDR22_HUMAN: (0134) TLDVFAHEDAVYGLSVSPVNDNIFASSSDDGRVLIWDIRESPHG WD-repeat protein 22 
WDR31_HUMAN: (0052) AFQEYSPAHMDTVSVVAALNSDLCVSGGKDKTVVAYNWKTGNVV WD-repeat protein 31 
WDR37_HUMAN: (0314) LVHSLTGHDQELTHCCTHPTQRLVVTSSRDTTFRLWDFRDPSIH WD-repeat protein 37 
WDR3_HUMAN: (0666) HIQTLEGHHQEIWCLAVSPSGDYVVSSSHDKSLRLWE-RTREPLI WD-repeat protein 3 
WDR47_HUMAN: (0745) QGLHALSGHTGHILALYTWSGWMIASGSQDKTVRFWDLRVPSCV WD-repeat protein 47 
WDR48_HUMAN: (0066) YIASMEHHTDWVNDIVLCCNGKTLISASSDTTVKVWNAHKGFCM WD-repeat protein 48 
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WDR4_HUMAN: (0180) ESFCLGHTEFVSRISVVPTQPGLLLSSSGDGTLRLWEYRSGRQL WD-repeat protein 4 
WDR57_HUMAN: (0143) VKRLKGHTSFVNSCYPARRGPQLVCTGSDDGTVKLWDIRKKAAI WD-repeat protein 57 
WDR5_HUMAN: (0120) CLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCL WD-repeat protein 5
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1.2. Mus musculus DWD-box proteins. 
 
A16L1_MOUSE: (0399) LRHTLTGHSGKVLSAKFLLDNARIVSGSHDRTLKLWDLRSKVCI Autophagy-related protein 16-1 
APAF_MOUSE: (0873) KVADCRGHLSWVHGVMFSPDGSSFLTASDDQTIRVWETKKVCKN Apoptotic protease-activating factor 1 
ARC1A_MOUSE: (0319) ETLHQNSITQVSIYEVDKQDCRKFCTTGIDGAMTIWDFKTLESS Actin-related protein 2/3 complex subunit 1A 
ARC1B_MOUSE: (0320) DSLHKNSVSQISVLSGGKAKCSQFCTTGMDGGMSIWDVKSLESA Actin-related protein 2/3 complex subunit 1B 
DDB2_MOUSE: (0234) LWNLRMHKKKVAHVALNPCCDWLLATASIDQTVKIWDLRQIKGK DNA damage-binding protein 2 
ERCC8_MOUSE: (0178) SHILQGHRQEILAVSWSPRHDYILATASADSRVKLWDVRRASGC DNA excision repair protein ERCC-8 
FBXW5_MOUSE: (0463) RAHRAYTPNDECFFIFLDVSRDFVASGAEDRHGYIWDRHYNICL F-box/WD repeat protein 5 
FBXW7_MOUSE: (0535) LQTLQGPSKHQSAVTCLQFNKNFVITSSDDGTVKLWDLKTGEFI F-box/WD repeat protein 7 
FBXW8_MOUSE: (0464) DKIALSLSAHQLGVSAVQMDDWKVVSGGEEGLVSVWDYRMNQKL F-box/WD repeat protein 8 
GBB1_MOUSE: (0174) QTTTFTGHTGDVMSLSLAPDTRLFVSGACDASAKLWDVREGMCR Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1 
GBB2_MOUSE: (0174) QTVGFAGHSGDVMSLSLAPDGRTFVSGACDASIKLWDVRDSMCR Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 2 
GBB3_MOUSE: (0175) QKTVFVGHTGDCMSLAVSPDYKLFISGACDASAKLWDVREGTCR Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 3 
GBB4_MOUSE: (0174) QTTTFTGHSGDVMSLSLSPDLKTFVSGACDASSKLWDIRDGMCR Guanine nucleotide-binding protein subunit beta 4 
GBB5_MOUSE: (0230) QSFHGHGADVLCLDLAPSETGNTFVSGGCDKKAMVWDMRSGQCV Guanine nucleotide-binding protein subunit beta 5 
GRWD1_MOUSE: (0299) MLTTATAHDGDVNVISWSRREPFLLSGGDDGALKVWDLRQFKSG Glutamate-rich WD repeat-containing protein 1 
KTNB1_MOUSE: (0096) ILRTLMGHKANICSLDFHPYGEFVASGSQDTNIKLWDIRRKGCV Katanin p80 WD40-containing subunit B1 
LIS1_MOUSE: (0370) CMKTLNAHEHFVTSLDFHKTAPYVVTGSVDQTVKVWECR----- Platelet-activating factor acetylhydrolase IB subunit alpha 
MEP50_MOUSE: (0159) LNSYRAHAGQVTCVAASPHKDSVFLSCSEDSRILLWDTRCPKPA Methylosome protein 50 
NLE1_MOUSE: (0362) PLARMTGHQALINQVLFSPDSRIVASASFDKSIKLWDGRTGKYL Notchless homolog 1 
NUP43_MOUSE: (0209) ILSLTGDRVPLHCVDRHPDQQHVVATGGQDGMLSIWDVRQGTMP Nucleoporin Nup43 
PEX7_MOUSE: (0185) RIVIPAHQTEILSCDWCKYNENLVVTGAVDCSLRGWDLRNVRQP Peroxisomal targeting signal 2 receptor 
PK1IP_MOUSE: (0031) PVADFTHHSHTASLSVLASNSRYVVSGSKDETIHIYDMKRKVEH p21-activated protein kinase-interacting protein 1 
PLRG1_MOUSE: (0402) GFIQNLSGHNAIINTLAVNADGVLVSGADNGTMHLWDWRTGYNF Pleiotropic regulator 1 
PRP19_MOUSE: (0341) TKVTDETSGCSLTCAQFHPDGLIFGTGTMDSQIKIWDLKERTNV Pre-mRNA-splicing factor 19 
Q499G0_MOUSE: (0177) CVNNFSDSVGFANFVDFNPNGTCIASAGSDHAVKIWDIRMNKLL Hypothetical protein 
Q4ADG5_MOUSE: (0360) TKVTDETSGCSLTCAQFHPDGLIFGTGTMDSQIKIWDLKERTNV Prp19 beta protein 
Q54AE3_MOUSE: (0175) QKTVFVGHTGDCMSLAVSPDYKLFISGACDASAKLWDVREGTCR GTP-binding protein beta3 subunit 
Q5DU30_MOUSE: (0875) KVADCRGHLSWVHGVMFSPDGSSFLTASDDQTIRVWETKKVCKN MKIAA0413 protein 
Q5PPQ7_MOUSE: (0212) EKAHEGARPMRAIFLADGNVFTTGFSRMSERQLALWNPKNMQEP Coronin, actin binding protein 1C 
Q5QNT7_MOUSE: (0363) PLARMTGHQALINQVLFSPDSRIVASASFDKSIKLWDGRTGKYL Novel WD40 repeat containing protein 
Q5SW18_MOUSE: (0371) CMKTLNAHEHFVTSLDFHKTAPYVVTGSVDQTVKVWECR----- Platelet-activating factor acetylhydrolase, iso 1b, beta1 subunit 
Q5XKB2_MOUSE: (2060) CCAELRGHEGPVCCCSFSPDGGILATAGRDRNLLCWDMKIAQAP Telomerase associated protein 1 
Q69Z65_MOUSE: (0212) VEYLAAHLSKIHGLDWHPDSEHIFATSSQDNSVKFWDYRQPRKY MKIAA1923 protein 
Q6A0A6_MOUSE: (1147) GSRVSQTFAHRGDVTSLTCTASCVISSGLDDFISIWDRSTGIKL MKIAA0199 protein 
Q6GQT6_MOUSE: (1146) GSRVSQTFAHRGDVTSLTCTASCVISSGLDDFISIWDRSTGIKL SREBP cleavage activating protein 
Q6NZK7_MOUSE: (0183) VEYLAAHLSKIHGLDWHPDSEHIFATSSQDNSVKFWDYRQPRKY Wdr59 protein 
Q6PAN1_MOUSE: (0072) GLAPAVDSQQSVTVVLFQDENTLVSAGAVDGIIKVWDLRKNYTA 2810047L02Rik protein 
Q6ZPU3_MOUSE: (0195) VQDIPTGADSCVTSLSCDSHRSLIVAGLGDGSIRVYDRRMALSE MKIAA1303 protein 
Q7TQK6_MOUSE: (0087) VHSLIGHRRTPWCVTFHPTISGLIASGCLDGEVRIWDLHGGSES Hypothetical protein D030051N19Rik 
Q80UI6_MOUSE: (0416) GSRVSQTFAHRGDVTSLTCTASCVISSGLDDFISIWDRSTGIKL Scap protein 
Q80VY1_MOUSE: (0137) GHKEIINTIDGVGGLGIGEGAPEIVTGSRDGTVKVWDPRQKEDP HZGJ-like protein 
Q80WY1_MOUSE: (0089) CFKEWMAHWNAVFDLAWVPGELKLVTAAGDQTAKFWDVRAGELM Meth A retinoic-acid regulated nuclear matrix-associated protein 
Q80WY2_MOUSE: (0089) CFKEWMAHWNAVFDLAWVPGELKLVTAAGDQTAKFWDVRAGELM Retinoic-acid regulated nuclear matrix-associated protein 
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Q8CIE6_MOUSE: (0042) LIDKFDEHDGPVRGIDFHKQQPLFVSGGDDYKIKVWNYKLRRCL Coatomer protein complex subunit alpha 
Q8K265_MOUSE: (0161) TGKVFKGHRNQVTCLSVSTDGSVLLSGSHDESVRLWDVKSKQCL Wdr18 protein 
Q8K2G5_MOUSE: (0091) YIRYFPGHSKRVVALSMSPVDDTFISGSLDKTIRLWDLRSPNCQ Wdr82 protein 
Q8K335_MOUSE: (0195) MLTTATAHDGDVNVISWSRREPFLLSGGDDGALKVWDLRQFKSG Glutamate-rich WD repeat containing 1 
Q8K3A5_MOUSE: (0054) HIKTLSEAHEDCVNNIRFLDNRLFATSSDDTTIALWDLRKLNTK WD repeat domain 32 
Q8VEE8_MOUSE: (0036) YIRYFPGHSKRVVALSMSPVDDTFISGSLDKTIRLWDLRSPNCQ Wdr82 protein 
Q91Z25_MOUSE: (0325) DSLHKNSVSQISVLSGGKAKCSQFCTTGMDGGMSIWDVKSLESA Arpc1b protein 
RBBP4_MOUSE: (0264) SHSVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLK Histone-binding protein RBBP4 
RBBP7_MOUSE: (0264) SHLVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLK Histone-binding protein RBBP7 
SPG16_MOUSE: (0477) CRYTLYGHTDSVNSIEFFPFSNILLTASADKTLSVWDARTGKCE Sperm-associated antigen 16 protein 
STB5L_MOUSE: (0101) DCYCQHESGAAVLQLQFLINEGALVSASSDDTLHLWNLRQKRPA Syntaxin-binding protein 5-like 
TAF5L_MOUSE: (0501) LFKELRGHTDSITSLAFSPDSGLIASASMDNSVRVWDIRSTCCN TAF5-like RNA polymerase II p300/CBP-assoc fac 65 kDa subunit 5L 
TBL1R_MOUSE: (0257) LASTLGQHKGPIFALKWNKKGNFILSAGVDKTTIIWDAHTGEAK F-box-like/WD repeat protein TBL1XR1 
TBL2_MOUSE: (0175) PEDFPKKHKAPIINIGIADTGKFIMTASSDTTVLIWNLKGQVLS Transducin beta-like 2 protein 
TBLX_MOUSE: (0270) LASTLGQHKGPIFALKWNKKGNYILSAGVDKTTIIWDAHTGEAK F-box-like/WD repeat protein TBL1X 
TEP1_MOUSE: (2060) CCAELRGHEGPVCCCSFSPDGGILATAGRDRNLLCWDMKIAQAP Telomerase protein component 1 
TF3C2_MOUSE: (0601) FQCFLAHDQAVRTIQWCKANSHFLVSAGSDRKIKFWDLRRPYEP General transcription factor 3C polypeptide 2 
THOC3_MOUSE: (0091) ENNYRGHGDSVDQLCWHPSNPDLFVTASGDKTIRIWDVRTTKCI THO complex subunit 3 
WD51B_MOUSE: (0177) CVNNFSDSVGFANFVDFNPNGTCIASAGSDHAVKIWDIRMNKLL WD repeat protein 51B 
WDR12_MOUSE: (0334) SLSLTSHTGWVTSVKWSPTHEQQLISGSLDNIVKLWDTRSCKAP WD repeat protein 12 
WDR22_MOUSE: (0134) TLDVFAHEDAVYGLSVSPVNDNIFASSSDDGRVLIWDIRESPHG WD repeat protein 22 
WDR23_MOUSE: (0299) TLQIESHEDDVNAVAFADISSQILFSGGDDAICKVWDRRTMRED WD repeat protein 23 
WDR31_MOUSE: (0052) APQEYIPVHVDTVSVIATLNSDLCISGGKDKTAVAYNWKTGRMV WD repeat protein 31 
WDR37_MOUSE: (0316) LVHSLTGHDQELTHCCTHPTQRLVVTSSRDTTFRLWDFRDPSIH WD repeat protein 37 
WDR47_MOUSE: (0746) QGLHALSGHTGHILALYTWSGWMIASGSQDKTVRFWDLRVPSCV WD repeat protein 47 
WDR48_MOUSE: (0159) TTSSLSGNKDSIYSLAMNQLGTIIVSGSTEKVLRVWDPRTCAKL WD repeat protein 48 
WDR4_MOUSE: (0182) ESFCLGHTEFVSRILVVPSHPELLLSSSGDGTLRLWEYRSGRQL WD repeat protein 4 
WDR57_MOUSE: (0144) VKRLKGHTSFVNSCYPARRGPQLVCTGSDDGTVKLWDIRKKAAV WD repeat protein 57 
WDR5_MOUSE: (0120) CLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCL WD repeat protein 5 
WDTC1_MOUSE: (0571) LVRVLQGDESIVNCLQPHPSYCFLATSGIDPVVRLWNPRPESED WD and tetratricopeptide repeats protein 1 
WSB1_MOUSE: (0162) LLNLVDHIEMVRDLTFAPDGSLLLVSASRDKTLRVWDLKDDGNM WD repeat and SOCS box-containing protein 1 
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1.3. Drosophila melanogaster DWD-box proteins 
 
CAF1_DROME: (0269) SHTVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLK Probable histone-binding protein Caf1 
FBXW7_DROME: (1227) LQTLSGPNKHHSAVTCLQFNSRFVVTSSDDGTVKLWDVKTGDFI F-box/WD repeat protein 7 
GBB1_DROME: (0175) QVTSFLGHTGDVMALSLAPQCKTFVSGACDASAKLWDIREGVCK Guanine nucleotide-binding protein subunit beta 1 
L2DTL_DROME: (0137) LNSYVGHTRSVKSAAFKRTDPAVFATGGRDGAILIWDIRANLNM Protein lethal(2)denticleless 
LIS1_DROME: (0330) CLLTLSGHDNWVRGLAFHPGGKYLVSASDDKTIRVWDLRNKRCM Lissencephaly-1 homolog 
O18402_DROME: (0289) SERRLAGHRQEVCGLKWSPDNQYLASGGNDNRLYVWNQHSVNPV Fizzy-related protein 
O76523_DROME: (0126) KRCVGTFEQNNGKVYSMSVIDEKIVVATSDRKVLIWDLRKDGQL Mitotic checkpoint control protein Bub3 
O77285_DROME: (0042) LLEKFDEHDGPVRGVAFHQQMPLFVSGGDDYKIKVWNYKQRRCI Coatomer alpha subunit 
Q24055_DROME: (0014) LTKVIDTAEVGLTTAQFHPDGLIFGTGTVDSQVKIWDLKEQSNV Gbp protein 
Q4V4T3_DROME: (0226) LMSIEAHASEALCCDWSHFDRNVLVTGGSDGLIRGWDLRKMRTH IP11251p 
Q4V560_DROME: (0261) EREVCHRDPVNSVLWNNSKSGTEFFSGGSDGQVLWWDTRKLTEP IP13643p 
Q4V6K2_DROME: (0229) LMSIEAHASEALCCDWSHFDRNVLVTGGSDGLIRGWDLRKMRTH IP11351p 
Q4V6Q4_DROME: (00-1) -MSIEAHASEALCCDWSHFDRNVLVTGGSDGLIRGWDLRKMRTH IP11451p 
Q6NP36_DROME: (0220) TPFQAYSGHTGHILSLYSWNNAMFVSGSQDQTIRFWDLRVNVSV RE32047p 
Q7JVX4_DROME: (0257) TGTSGYQDIYAVNDIAFHPVHGTLVTVGSDGTFSFWD-KDARTKL LD40776p 
Q7KTE5_DROME: (0165) ALSLNAVCMSGATQVGFNRVSGNLLAAAHDGDLRIWDIRKGSCP CG4705-PB, isoform B 
Q86BR6_DROME: (0395) LRHTLTGHSGKVMAAKYVQEPIKVVTGSHDRTLKIWDLRSIACI CG31033-PC, isoform C 
Q8IGK7_DROME: (0157) TTSSLTGSKDSIYSLAMNPSGTVIVSGSTENILRIWDPRTCMRR RE72568p 
Q8MKW0_DROME: (0028) PPTDSPQSVSICGVRFLDEGPHNILVGTTDGYVRLYDLRLRGEQ CG12134-PB, isoform B 
Q8MKZ5_DROME: (0157) TTSSLTGSKDSIYSLAMNPSGTVIVSGSTENILRIWDPRTCMRR CG9062-PB 
Q8MSW6_DROME: (0126) KRCVGTFEQNNGKVYSMSVIDEKIVVATSDRKVLIWDLRKMDSY LD23540p 
Q8MTB1_DROME: (0266) PLEVSHRETTSALCWVHSKSNTEFYSGSLDGSIKYWDTRDLKMP AT07549p 
Q8SX92_DROME: (0454) YNDENERGRVRLFSIAHHPYAPEFCVSGSDDILRVYDKRNLAKA GH28796p 
Q8SXJ6_DROME: (0175) CLLTLSGHDNWVRGLAFHPGGKYLVSASDDKTIRVWDLRNKRCM RE19540p 
Q8SYL1_DROME: (0307) MLTCEDAHQSDVNVISWNRNEPFIASGGDDGYLHIWDLRQFQSK RE55020p 
Q8T3W2_DROME: (0100) VRVFGGHAKTINRLASQPGGENVFISAGRDDQVYMWDIRVKTHT AT28277p 
Q8T4D0_DROME: (0487) LVGVLKDHSGPITSLDINYLDTEVISACTDGSCVIWDIKRMTRK AT03371p 
Q95TJ1_DROME: (0210) LRHTLTGHSGKVMAAKYVQEPIKVVTGSHDRTLKIWDLRSIACI LP08352p 
Q960M2_DROME: (0081) EIFKVPDAHTDSVNCIKFFDERLFATGSDDFTVALWDLRNMKQK LD45447p 
Q9BII5_DROME: (0124) TLKVLRGHREDIYDLSWAPNSQFLVSGSVDNTAMLWDVHSGKSL Chromatin assembly factor-1 p105 subunit 
Q9V3B2_DROME: (0341) LTKVIDTAEVGLTTAQFHPDGLIFGTGTVDSQVKIWDLKEQSNV CG5519-PA 
Q9V5C7_DROME: (0552) SCIKRFDQECTILRAEFLDHGKFIISAASDGLLKLWNIKTNTCL CG1671-PA 
Q9V5E5_DROME: (0098) PPTDSPQSVSICGVRFLDEGPHNILVGTTDGYVRLYDLRLRGEQ CG12134-PA, isoform A 
Q9V5L7_DROME: (0124) TLKVLRGHREDIYDLSWAPNSQFLVSGSVDNTAMLWDVHSGKSL CG12892-PA 
Q9V5N6_DROME: (0753) LNKSQAHHLTVRRLQFRPGKQLQLASCGEDHLVRIYDIKLT--- CG11887-PA 
Q9V878_DROME: (0130) CVKVLEGHSRYSFSCCFNPQANLLASTSFDETVRLWDVRTGKTL CG10931-PA 
Q9V8W2_DROME: (0004) KILYKYEEPHGIGDVYFIWQKALLATTGTDGSVALYN-RQGQLVQ CG11237-PA 
Q9V951_DROME: (0259) RTHRMPGKDVNSVCFLHDKDPNVIIAGCDDGLLKVYDLRTTFRS CG9945-PA, isoform A 
Q9VAF9_DROME: (0236) LRHTLTGHSGKVMAAKYVQEPIKVVTGSHDRTLKIWDLRSIACI CG31033-PB, isoform B 
Q9VAJ2_DROME: (0126) KRCVGTFEQNNGKVYSMSVIDEKIVVATSDRKVLIWDLRKMDSY CG7581-PA 
Q9VAK0_DROME: (0227) ELQQLTHHGAEVIAARFNRDGQMLLTGSFDHSAAIWDVRSKSLG CG7568-PA 
Q9VAT2_DROME: (0081) EIFKVPDAHTDSVNCIKFFDERLFATGSDDFTVALWDLRNMKQK CG1523-PA 
Q9VCN9_DROME: (0656) QLAELKDHSASISSLSWSTHNRHLATACSDGTLRLWDIKKLSPM CG4448-PA 
Q9VD52_DROME: (0364) SRFTTRKMPFCVKFHPDNSKQHLFVAGTSDKKIICWDTRSGDIV CG6015-PA 
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Q9VE73_DROME: (0353) PAVSVFQGHTETVTSSVFARDDKVVSGSDDRTIKVWELRNMRSA CG12333-PA 
Q9VKK2_DROME: (0165) ALSLNAVCMSGATQVGFNRVSGNLLAAAHDGDLRIWDIRKGSCP CG4705-PA, isoform A 
Q9VKQ3_DROME: (0283) GIKTEISTNKSIFDASYSKLNRLILTASADKNLRLYDPRTNQGS CG6724-PA 
Q9VLN1_DROME: (0100) YLRYFPGHTKKVISLCISPVEDTFLSGSLDKTLRLWDLRSPNCQ CG17293-PA 
Q9VML2_DROME: (3275) GPKAEVQGERRKSSISGAKSLHEMKSATVEGQGSSYDPKSNEDE CG14001-PA 
Q9VPL0_DROME: (0173) HAAHTLESPFQVTAVCFGDTGEQVISGGIDNEVKIWDIRKQAVL CG3436-PA, isoform A 
Q9VQD1_DROME: (0100) VRVFGGHAKTINRLASQPGGENVFISAGRDDQVYMWDIRVKTHT CG3515-PA 
Q9VS00_DROME: (0487) LVGVLKDHSGPITSLDINYLDTEVISACTDGSCVIWDIKRMTRK CG10064-PA 
Q9VSN7_DROME: (0204) LMSIEAHASEALCCDWSHFDRNVLVTGGSDGLIRGWDLRKMRTH CG6486-PA 
Q9VTM3_DROME: (0252) EREVCHRDPVNSVLWNNSKSGTEFFSGGSDGQVLWWDTRKLTEP CG6053-PA 
Q9VTY5_DROME: (0219) WSINDAHGQMVRDLDCNPNKQCHLVTGGDDGYLRIWDCRMPKAP CG10646-PA 
Q9VU65_DROME: (0051) RCIRFASHSAPVNGVAWSPKGNLVASAGHDRTVKIWEPKLRGVS CG10191-PA 
Q9VUN7_DROME: (0266) DTRKLQTPLKVHFDHVSAVTDVDYSPTGKEFVSASYD-KTIRIYN CG7275-PA 
Q9VVI0_DROME: (0386) EVLHQEGHAKPVHCLSYHSDGSVLVTGGLDAFGRVWDLRTGRCI CG6322-PA 
Q9VVM7_DROME: (0105) AHNGIINTIDAIGGTQIDCGAPEIVTGSRDGAVKVWDIRQGQAP CG14353-PA 
Q9VYQ9_DROME: (0247) VIRHYHGHLSAVYSLALHPTIDVLATSGRDSTARIWDMRTKANV CG1796-PA 
Q9W091_DROME: (0459) YNDENERGRVRLFSIAHHPYAPEFCVSGSDDILRVYDKRNLAKA CG8001-PA 
Q9W097_DROME: (0282) SPTSQRDTNQVCFYSPLGKIYRTLKVPGTDITSLSWEGKSLRIA CG2069-PA 
Q9W0B8_DROME: (0042) LLEKFDEHDGPVRGVAFHQQMPLFVSGGDDYKIKVWNYKQRRCI CG7961-PA, isoform A 
Q9W1G4_DROME: (0170) TPFQAYSGHTGHILSLYSWNNAMFVSGSQDQTIRFWDLRVNVSV CG2812-PA 
Q9W1J3_DROME: (0323) KTRAQGGLRTNAASCNFNRDATLIAAGCVDGSIQTWDTRKMFVN CG5543-PA 
Q9W1N4_DROME: (0137) QPEEYAGHTGAIKRALFCRGDKCIISAAEDKTVRLWD-RMTGIEV CG3957-PA 
Q9W2E7_DROME: (0243) TGTSGYQDIYAVNDIAFHPVHGTLVTVGSDGTFSFWD-KDARTKL CG9862-PA 
Q9W351_DROME: (0264) MMQPLKRLGPPGSLLKWSPDNDWLFAATVDRVFRVWNCHQQWTT CG16892-PA 
Q9W3J1_DROME: (0193) QSFHGHSGDVMAIDLAPNETGNTFVSGSCDRMAFIWDMRSGHVV CG10763-PA 
Q9W3K3_DROME: (0328) PLAKLLCHSTAMSALAVEPKGQYLVTAGLDRAVKVWDIRMLVHD CG2260-PA 
Q9W3L0_DROME: (0266) PLEVSHRETTSALCWVHSKSNTEFYSGSLDGSIKYWDTRDLKMP CG1571-PA 
Q9W4H9_DROME: (0289) SERRLAGHRQEVCGLKWSPDNQYLASGGNDNRLYVWNQHSVNPV CG3000-PA, isoform A 
Q9XYF7_DROME: (0126) KRCLGTFEQNNGKVYSMSVIDEKIVVATSDRKVLIWDLRKMDSY WD-40 repeat protein 
TAF5_DROME: (0609) LVTTLLRHTSTVTTITFSRDGTVLAAAGLDNNLTLWDFHKVTED Transcription initiation factor TFIID subunit 5 
WDS_DROME: (0147) SLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVRTGKCL Protein will die slowly 
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1.4. Caenorhabditis elegans DWD-box proteins 
 
FZY1_CAEEL: (0306) SWGGDNGHCRDVTALEWSADENMCVSGSSDRTAKIWDGRHVRGS WD repeat-containing protein fzy-1 
GBB1_CAEEL: (0175) QCTAFTGHTGDVMSLSLSPDFRTFISGACDASAKLWDIRDGMCK Guanine nucleotide-binding protein subunit beta 1 
GBB2_CAEEL: (0191) QNFHGHTGDVFAIDVPKCDTGNTFISAGADKHSLVWDIRSGQCV Guanine nucleotide-binding protein subunit beta 2 
LIN23_CAEEL: (0374) LEFVRTLAGHRRGIACLQYRGRLVVSGSSDNTIRLWDIHSGVCL F-box/WD repeat protein lin-23 
LIN53_CAEEL: (0257) GHCIDAHSAEVNCLAFNPYSEFILATGSADKTVALWDLRNLRMK Probable histone-binding protein lin-53 
LIS1_CAEEL: (0365) CMKAIEAHEHFVSTVAFHQTSPFVITGSVDMSCKVWECR----- Lissencephaly-1 homolog 
NPP17_CAEEL: (0123) AVVGTHDGPVKTCHWINGNNYQCLMTGSFDKTLRFWDMKNLPNQ Nucleoporin-17 
O45401_CAEEL: (0048) QMQTLKGHKDLVYTVAWSHNGELFASGGADKLVILWNEKHEGTL Hypothetical protein 
O45604_CAEEL: (0248) VKEYRHHNMGITSVDWNKADDRLVISSGCDGQVVIWNHETSEVL Hypothetical protein 
P90814_CAEEL: (0183) NLEFERVHQVDIQNIGIAGNAKYLMSAALDNKICLYDLRGQLLQ Hypothetical protein 
P91867_CAEEL: (0039) SWVGSSHSSSVEQVACSEKQPNLFASASADRNICVWDIRQSKPT Hypothetical protein 
PRP19_CAEEL: (0329) KVSVEPGSQIAVHSIEFHPDGLIFGTGAADAVVKIWDLKNQTVA PRP19/PSO4 homolog 
PWP2_CAEEL: (0351) YVMKQQAHSLRITTAEYSPDGSLMATGAEDGKVKIWNSRSSFCT Periodic tryptophan protein 2 homolog 
Q09649_CAEEL: (0513) MGRKLTNHRQEVCGLKWSPDKQLLASGGNDNQLLVWNLRRNEPI Hypothetical protein fzr-1 
Q19211_CAEEL: (0156) EPVKTYTNRYQQTAVTFNDSSDQVISGGIDNVLKVWDMRRDEIT Hypothetical protein 
Q19433_CAEEL: (0662) MVQVLDRHTLDIRCLAQFTNGSVMFSASHDKSIRCWEKTDEILI Hypothetical protein F13H8.2 
Q19873_CAEEL: (0323) PLVKILTHLSAVKGIAVDDQGNYMATTGLDRKCRIWDVRMFRQL Hypothetical protein 
Q22059_CAEEL: (0131) SQVFFGHEGSVRSICFAPDDPNVFVTGGRDFQVKIWDMRVSTVK Hypothetical protein 
Q8IA70_CAEEL: (0499) IQSMKGHTAPILGLYTWSQAGNQFVSCSQDKTIRFWDLRQQTAV Hypothetical protein 
Q93339_CAEEL: (0371) CIMFLDGHTKEIHSVEWMPNGYEMITGSSDNSMKVWDLRMRRNT Hypothetical protein 
Q93759_CAEEL: (0394) VARLRNHEATINGLSWAPHSGSHICTAGDDYQALIWDVHEMPKP Hypothetical protein swan-2 
Q95X41_CAEEL: (0353) QSVAVFQGHQDSVTSVSFNTDYRIVSSSDDATVKIWDLRNMRTP Hypothetical protein 
Q95X42_CAEEL: (0355) QSVAVFQGHQDSVTSVSFNTDYRIVSSSDDATVKIWDLRNMRTP Hypothetical protein 
Q95X65_CAEEL: (0765) IQSMKGHTAPILGLYTWSQAGNQFVSCSQDKTIRFWDLRQQTAV Hypothetical protein 
Q95X66_CAEEL: (0765) IQSMKGHTAPILGLYTWSQAGNQFVSCSQDKTIRFWDLRQQTAV Hypothetical protein 
Q9N4H7_CAEEL: (0044) LLEKFDEHDGPVRGICFHHDQPIFVSGGDDYKIKVWNYKQKRCI Hypothetical protein 
Q9N533_CAEEL: (0136) KSVFKSHERSATCLDWHATTPYILVSGSRDCTVKSYDMRVKDNH Hypothetical protein 
Q9NAN8_CAEEL: (0294) CLATLQEHKSSVMAVEFNKNGNWLLTGGRDHLVKMYDIRMMKEM Hypothetical protein 
Q9TYV3_CAEEL: (0308) VEECQKVAQTRYEAALEIAGGERLVSGSDDFTLFMWNPKETKQS Hypothetical protein W07E6.2 
Q9U1Q0_CAEEL: (0200) LKIRDAHIHRTISMDFNPNLQHVIATCGDDGYVRIWDTRSTSSA Hypothetical protein 
RBA1_CAEEL: (0256) QLTAVGHTAEVNCITFNPFSEYILATGSVDKTVALWDMRNMRKK Probable histone-binding protein rba-1 
YDEM_CAEEL: (0411) SRSLFPASKVLDVATNMGASPSLFASGHFDKKLRFYDGRSTDPV Hypothetical WD repeat protein F02E8.5 
YH92_CAEEL: (0288) CLRTMRGHTNYVFCCSFNPQSSLIASAGFDETVRVWDFKTGLCV Hypothetical WD repeat protein ZC302.2 
YKY4_CAEEL: (0162) MTKTLKGHNNYVFCCNFNPQSSLVVSGSFDESVRIWDVKTGMCI Hypothetical WD repeat protein C14B1.4 
YRG5_CAEEL: (0295) LKSYLVGSTVFDIVAKCGVSQSSFISSHFDKKVRFWDARSSDAT Hypothetical WD repeat protein K06A1.5 
YRIQ_CAEEL: (0303) RTIVNAHEDDVNSVCFADLGSNLIYSAGDDGLVKVWDKRAWSDG Hypothetical WD repeat protein D2030.9 
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1.5. Arabidopsis thaliana DWD-box proteins 
 
GBB_ARATH: (0196) GEFQSGHTADVLSVSISGSNPNWFISGSCDSTARLWDTRAASRA Guanine nucleotide-binding protein beta subunit 
IF32_ARATH: (0184) QSDEEVGHKKDITSLCKAADDSHFLTGSLDKTAKLWDMRTLTLL Eukaryotic translation initiation factor 3 subunit 2 
KTNB1_ARATH: (0092) IVRTLTGHRSNCISVDFHPFGEFFASGSLDTNLKIWDIRKKGCI Katanin p80 WD40-containing subunit B1 homolog 1 
MSI2_ARATH: (0209) MFVYEGHESAIADVSWHMKNENLFGSAGEDGRLVIWDTRTNQMQ WD-40 repeat protein MSI2 
MSI3_ARATH: (0210) MHVYEGHQSIIEDVAWHMKNENIFGSAGDDCQLVIWDLRTNQMQ WD-40 repeat protein MSI3 
MSI4_ARATH: (0284) RGVYHGHEDTVEDVAFSPTSAQEFCSVGDDSCLILWDARTGTNP WD-40 repeat protein MSI4 
O22725_ARATH: (0101) MVRAFTGHRSNCSAVEFHPFGEFLASGSSDANLKIWDIRKKGCI F11P17.7 protein 
O22785_ARATH: (0360) ANVAKFDGHTGEVTAISFSENGYFLATAAEDGVRLWDLRKLRNF Putative PRP19-like spliceosomal protein 
O22826_ARATH: (0130) IKKMAEHSSFVNSCCPTRRGPPLIISGSDDGTAKLWDMRQRGAI Putative splicing factor 
O82341_ARATH: (0184) QSDEEVGHKEAITSLCKAADDSHFLTGSHDKTAKLWDMRTLTLI Eukaryotic translation initiation factor 3 delta subunit 
O82506_ARATH: (0334) TPWCILSGHNKAVSYAKFLDNETLVTASTDNTLKLWDLKKTTHG F2P3.13 protein 
PRL1_ARATH: (0293) QIFALSGHDNTVCSVFTRPTDPQVVTGSHDTTIKFWDLRYGKTM PP1/PP2A phosphatases pleiotropic regulator PRL1 
PRL2_ARATH: (0286) MQIFVLPHDSDVFSVLARPTDPQVITGSHDSTIKFWDLRYGKSM PP1/PP2A phosphatases pleiotropic regulator PRL2 
Q2V435_ARATH: (0385) ANVAKFDGHTGEVTAISFSENGYFLATAAEDGVRLWDLRKLRNF Protein At2g33340 
Q2V4K8_ARATH: (0182) SHTLSGHRDGVMSVEWSTSSEWVLYTGGCDGAIRFWDIRRAGCF Protein At1g27840 
Q3E7F3_ARATH: (0227) IIGTYVGHTEEVCGLKWSESGKKLASGGNDNVVHIWDRSLASSN Protein At5g27945 
Q3E906_ARATH: (0209) IVETYLGHTEEVCGLKWSESGKKLASGGNDNVVHIWDHRSVASS Protein At5g27570 
Q3E9H4_ARATH: (0304) DSLNLFCGKALNTVDVGGESSALIAAGGSDPILRVWDPRKPGTS Protein At5g15550 
Q3E9R4_ARATH: (0196) GEFQSGHTADVLSVSISGSNPNWFISGSCDSTARLWDTRAASRA Protein At4g34460 
Q3E9R5_ARATH: (0134) GEFQSGHTADVLSVSISGSNPNWFISGSCDSTARLWDTRAASRA Protein At4g34460 
Q3EBF5_ARATH: (0184) QSDEEVGHKKDITSLCKAADDSHFLTGSLDKTAKLWDMRTLTLL Protein At2g46280 
Q3EBP5_ARATH: (0385) ANVAKFDGHTGEVTAISFSENGYFLATAAEDGVRLWDLRKLRNF Protein At2g33340 
Q3ECF4_ARATH: (0085) TVDTIGRHDDISTSIVYSYEKGEVISTGFDEKIKFWDTRQRESL Protein At1g69400 
Q3EDB9_ARATH: (0382) CFITFTEHTNAVTALHFMADNHSLLSASLDGTVRAWDFKRYKNY Protein At1g15440 
Q42175_ARATH: (0044) RLGTYRGHNGAVWCCDVSRDSSRLITGSADQTAKLWDVKSGKEL G-protein 
Q42339_ARATH: (0001) CLAIMEKHFSAVTSIALSEDGLTLFSAGRDKVVNLWDLHDYSCK Transducin homologue 
Q4PSE4_ARATH: (0243) IVETYLGHTEEVCGLKWSESGNKQASGGNDNVVHIWDRSLASSK WD-40 repeat family protein 
Q5HZ33_ARATH: (0210) MHVYEGHQSIIEDVAWHMKNENIFGSAGDDCQLVIWDLRTNQMQ At4g35050 
Q5PNR9_ARATH: (0286) MQIFVLPHDSDVFSVLARPTDPQVITGSHDSTIKFWDLRYGKSM At3g16650 
Q5PNT1_ARATH: (0196) GEFQSGHTADVLSVSISGSNPNWFISGSCDSTARLWDTRAASRA At4g34460 
Q5XEV4_ARATH: (0255) ARIKGIVVLTRNDSDGSLEDPYLIGSASSDGIIRVWDVRMAAKE At1g65030 
Q680F0_ARATH: (0125) SHTLSGHRDGVMSVEWSTSSEWVLYTGGCDGAIRFWDIRRAGCF MRNA, , clone: RAFL22-57-P16 
Q6NLV4_ARATH: (0282) ELCSLHGHKNIVLSVKWNQNGNWLLTASKDQIIKLYDIRTMKEL At5g13480 
Q7DLS8_ARATH: (0251) VIRSYHGHLSGVYCLALHPTLDVLLTGGRDSVCRVWDIRTKMQI PRL1 protein 
Q84WM8_ARATH: (0293) QIFALSGHDNTVCSVFTRPTDPQVVTGSHDTTIKFWDLRYGKTM Putative PRL1 protein 
Q84WQ9_ARATH: (0210) MHVYEGHQSIIEDVAWHMKNENIFGSAGDDCQLVIWDLRTNQMQ Putative WD-40 repeat protein 
Q8GWC2_ARATH: (0211) QSDEEVGHKEAITSLCKAADDSHFLTGSHDKTAKLWDMRTLTLI Putative eukaryotic translation initiation factor 3 delta subunit 
Q8GYY7_ARATH: (0575) QVFANMHQEHINVVKFSNHSPFLFATSSFDKDVKLWDLRQEPSR Hypothetical protein At4g34280/F10M10_50 
Q8H177_ARATH: (0255) ARIKGIVVFTRNDSDGSLEDPYLIGSASSDGIIRVWDVRMAAKE Hypothetical protein At1g65030 
Q8L4M1_ARATH: (0192) IKMTFKGHSDYLHTVVSRSSASQILTGSEDGTARIWDCKTGKCV Putative WD-40 repeat protein 
Q8L7M8_ARATH: (0314) VLRGHTGAVTAIAFSPRQASVYQLLSSSDDGTCRIWDARYSQWL Putative WD-40 repeat protein 
Q8L830_ARATH: (0183) CLAIMEKHFSAVTSIALSEDGLTLFSAGRDKVVNLWDLHDYSCK WD40-repeat protein 
Q8LA29_ARATH: (0085) TFDTIGRHDDIATSIVYSYEKGEVISTGFDEKIKFWDTRQRESL Mitotic checkpoint protein, putative 
Q8LA40_ARATH: (0209) MFVYEGHESAIADVSWHMKNENLFGSAGEDGRLVIWDTRTNQMQ Putative WD-40 repeat protein, MSI2 
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Q8LAL9_ARATH: (0365) ELIGTLKMNGSVRSLAFSEDGKHLLSSGGDGQVYVWDLRTMKCL Hypothetical protein 
Q8LBC4_ARATH: (0254) VLGSVSEKGKAITCLAYCADGNLLISGSEDGVVCVWDPKSLRHV Hypothetical protein 
Q8LBH5_ARATH: (0159) ERDEHGGRRIWSVDYTLYNGSLLGASGSDDGTVQMWDPRNGGTL Contains similarity to photomorphogenesis repressor protein 
Q8LEL2_ARATH: (0263) VISSLRGHKDYSFASAWHPNGLILATGNQDTTCRLWDIRNPSES Hypothetical protein 
Q8LF96_ARATH: (0293) QIFALSGHDNTVCSVFTRPTDPQVVTGSHDTTIKFWDLRYGKTM PRL1 protein 
Q8LFX4_ARATH: (0111) YLRYFKGHHDRVVSLSLCSGGECFISGSLDRTVLLWDQRVEKCQ WD repeat protein-like 
Q8LG28_ARATH: (0310) TIGTLKGHLDYSFASAWHPNGVTFATGSQDKTCRIWDTRKLSES WD-repeat protein-like 
Q8LPI5_ARATH: (0263) SLRTVAHTSDVNTVCFADESGNLILSGSDDNLCKVWDRRCFIGR Putative WD-repeat protein 
Q8RXA7_ARATH: (0929) QLLEELKGHDSQVSCVKMLSGERVLTAAHDGTVKMWDVRTDMCV Stomatal cytokinesis defective 
Q8RXD8_ARATH: (0111) YLRYFKGHHDRVVSLSLCSGGECFISGSLDRTVLLWDQRVEKCQ WD repeat protein-like 
Q8RYE4_ARATH: (0307) PDGMPISVLRGHTGAVTAIAFSPRQASSDDGTCRIWDARYSQWL Hypothetical protein At2g47410 
Q8VYZ5_ARATH: (0422) CFITFTEHTNAVTALHFMADNHSLLSASLDGTVRAWDFKRYKNY Hypothetical protein At1g15440 
Q8VZH9_ARATH: (0444) GFISSWRAHDGYVTKLVAPESHLLVSSSLDKTLRIWDLRKSWTP AT5g18530/T28N17_10 
Q8VZS9_ARATH: (0283) HVSKLKGHKSEICGLKWSSDNRELASGGNDNKLFVWNQHSTQPV Putative Srw1 protein 
Q8W117_ARATH: (0338) LLKEFRGHTSYVNHAIFTSDGSRIITASSDCTVKVWDSKTTDCL At1g73720/F25P22_14 
Q93VK1_ARATH: (0195) VQSFQWGTDSVISVRFNPGEPNLLATSASDRSITIYDLRLSSAA AT4g28450/F20O9_130 
Q93ZG3_ARATH: (0182) SHTLSGHRDGVMSVEWSTSSEWVLYTGGCDGAIRFWDIRRAGCF At1g27840/F28L5_15 
Q93ZS6_ARATH: (0204) TPTIAKGHKESVYALAMNDTGTMLVSGGTEKVLRVWDPRTGSKS Hypothetical protein At3g05090 
Q93ZT0_ARATH: (00-4) ----MEKHFSAVTSIALSEDGLTLFSAGRDKVVNLWDLHDYSCK Putative WD40-repeat protein 
Q94AH2_ARATH: (0093) VIRKFRGHDGEVNAVKFNDSSSVVVSAGFDRSLRVWDCRSHSVE Hypothetical protein At5g64730 
Q94BQ3_ARATH: (0207) LADPPKQTLSLKSCDISATRPHLLLVGGSDAFARLYDRRMLPPL Hypothetical protein At5g10940 
Q94C55_ARATH: (0162) TGVLIGHTGTVKSMCSHPTNSDLLVSGSRDGCFALWDLRCKSSS Hypothetical protein At3g27640 
Q94C94_ARATH: (0137) LKILTGHRRTPWVVRFHPRHSEIVASGSLDHEVRLWNAKTGECI Hypothetical protein At1g04140 
Q94JT6_ARATH: (0312) VIHGLEGHLDYSFSSAWHPNGQILATGNQDTTCRLWDVRNLSQS At1g78070/F28K19_28 
Q9C6N4_ARATH: (0182) SHTLSGHRDGVMSVEWSTSSEWVLYTGGCDGAIRFWDIRRAGCF Hypothetical protein F28L5.15 
Q9C795_ARATH: (0085) TVDTIGRHDDISTSIVYSYEKGEVISTGFDEKIKFWDTRQRESL Mitotic checkpoint protein, putative 
Q9C8W2_ARATH: (0276) VISSLRGHKDYSFASAWHPNGLILATGNQDTACRLWDIRNPSES Hypothetical protein T22A15.1 
Q9C9T9_ARATH: (0349) LLKEFRGHTSYVNHAIFTSDGSRIITASSDCTVKVWDSKTTDCL Hypothetical protein F25P22.14 
Q9CAF0_ARATH: (0284) PLVQMQCHPGPVSSVAFHPNGHLMATSGKERKIKIWDLRKFEEV Hypothetical protein F13M14.19 
Q9FFY8_ARATH: (0289) FVSKLVGHKSEVCGLKWSHDDRELASGGNDNQLLVWNNHSQQPI Cell cycle switch protein 
Q9FGG0_ARATH: (0093) VIRKFRGHDGEVNAVKFNDSSSVVVSAGFDRSLRVWDCRSHSVE Similarity to unknown protein 
Q9FH64_ARATH: (0108) YLRYFKGHHDRVVSLSLCSGGECFISGSLDRTVLLWDQRVEKCQ WD repeat protein-like 
Q9FKT5_ARATH: (0058) DLELKGHTDSVDQLCWDPKHSDLVATASGDKSVRLWDARSGKCT Gb|AAF54217.1 
Q9FLX9_ARATH: (0393) FVTVFRGHVGPVYQVSWSADSRLLLSGSKDSTLKIWEIRTKKLK Notchless protein homolog 
Q9FN19_ARATH: (0356) LISTLSKHKGPIFSLKWNKKGDYLLTGSVDRTAVVWDVKAEEWK Arabidopsis thaliana genomic DNA, chromosome 5, TAC clone:K8K14 
Q9FND4_ARATH: (0434) KFSGHRQSKYVIRSCFGGLDSSFIASGSEDSQVYIWNLKNTKPL WD-repeat protein-like 
Q9FT96_ARATH: (0185) VVRTLTGHRSNCVSVNFHPFGEFFASGSLDTNLKIWDIRKKGCI Katanin p80 subunit-like protein 
Q9FXH4_ARATH: (0182) SHTLSGHRDGVMSVEWSTSSEWVLYTGGCDGAIRFWDIRRAGCF F6F9.19 protein 
Q9FY53_ARATH: (0231) VMPCNAGHGWDVKSVDWHPTKSLLVSGGKDQLVKLWDTRSGREL Hypothetical protein T6I14_10 
Q9FYL1_ARATH: (0271) LVATLEKHKSAVNALALNDDGSVLFSGSCDRSILVWEREDTSNY F21J9.19 
Q9LEU6_ARATH: (0207) LADPPKQTLSLKSCDISATRPHLLLVGGSDAFARLYDRRMLPPL Hypothetical protein T30N20_210 
Q9LF27_ARATH: (0304) DSLNLFCGKALNTVDVGGESSALIAAGGSDPILRVWDPRKPGTS Hypothetical protein T20K14_160 
Q9LFE2_ARATH: (0183) CLAIMEKHFSAVTSIALSEDGLTLFSAGRDKVVNLWDLHDYSCK WD40-repeat protein 
Q9LP54_ARATH: (0184) TMIIPAHDFEILSCDWNKYDDCILATSSVDKTVKVWDVRSYRVP Peroxisomal targeting signal type 2 receptor, Pex7p 
Q9LPP3_ARATH: (0272) PLVQMQCHPGPVSSVAFHPNGHLMATSGKERKIKIWDLRKFEEV F18K10.11 protein 
Q9LRZ0_ARATH: (0864) MTTFMPPPPASTFLAFHPQDNNIIAIGMEDSSIHIYNVRVDEVK Arabidopsis thaliana genomic DNA, chromosome 3, TAC clone:K20I9 
Q9LTJ6_ARATH: (0159) ERDEHGGRRIWSVDYTLYNGSLIGASGSDDGTVQMWDPRNGGTL Similarity to photomorphogenesis repressor COP1 
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Q9LVF2_ARATH: (0657) HLLTLEGHHAEIWCLAISNRGDFLVTGSHDRSMRRWDRSEEPFF Arabidopsis thaliana genomic DNA, chromosome 3, P1 clone: MIL23 
Q9LVX5_ARATH: (0193) TGVLIGHTGTVKSMCSHPTNSDLLVSGSRDGCFALWDLRCKSSS Similarity to unknown protein 
Q9LXN4_ARATH: (0109) AVMTLRGHTADVVDLNWSPDDSMLASGSLDNTVHIWNMRTGMCT WD repeat domain protein 
Q9LYK6_ARATH: (0105) ILRYFKGHKDRVVSLCMSPINDSFMSGSLDRSVRLWDLRVNACQ Hypothetical protein T15N1_20 
Q9M0E5_ARATH: (1072) LVAHLQEHRSAVNDIATSSDHSFFVSASDDSTVKVWDSRKLEKD Hypothetical protein AT4g29380 
Q9M1E5_ARATH: (0192) RRHHSSSRIRLNSIAIDPRNSYYLAVGGSDEYARVYDTRRVQLA Hypothetical protein F9K21.200 
Q9M3B4_ARATH: (0254) VLGSVSEKGKAITCLAYCADGNLLISGSEDGVVCVWDPKSLRHV Hypothetical protein F2K15.40 
Q9M9A6_ARATH: (0025) CVATVGRCSSAILSLEYDDSTGILAAAGRDTVANIWDIRSGKQM F27J15.17 
Q9MAB0_ARATH: (0206) TPTIAKGHKESVYALAMNDTGTMLVSGGTEKVLRVWDPRTGSKS T12H1.5 protein 
Q9SAI7_ARATH: (0340) VFHWELHERRINSIDFNPQNPHVMATSSTDGTACLWDLRSMGAK F23A5.6 protein 
Q9SGZ4_ARATH: (0386) VIHGLEGHLDYSFSSAWHPNGQILATGNQDTTCRLWDVRNLSQS F28K19.28 
Q9SIB8_ARATH: (0121) LATASTDRTEKIWKTDGTLLQTFKASSGFDSLARVWDLRTARNI Putative U4/U6 small nuclear ribonucleoprotein 
Q9SJT9_ARATH: (0042) LIDRFDEHEGPVRGVHFHNSQPLFVSGGDDYKIKVWNYKTHRCL Coatomer alpha subunit 
Q9SKW4_ARATH: (0390) VISSLRGHKDYSFASAWHPNGLILATGNQDTACRLWDIRNPSES F5J5.6 
Q9SLN3_ARATH: (0187) PDGMPISVLRGHTGAVTAIAFSPRQASSDDGTCRIWDARYSQWL Putative WD-40 repeat protein 
Q9SS57_ARATH: (0275) ARIKGIVVLTRNDSDGSLEDPYLIGSASSDGIIRVWDVRMAAKE F16G16.2 protein 
Q9SXA3_ARATH: (0091) MVRAFTGHRSNCSAVEFHPFGEFLASGSSDTNLRVWDTRKKGCI T28P6.17 protein 
Q9SY00_ARATH: (0161) CVRMIKAHSMPISSVHFNRDGSLIVSASHDGSCKIWDAKEGTCL Putative WD-repeat protein 
Q9SZ03_ARATH: (0315) LAQVLLKQENAVTALAVKSQSSIVYCGSSDGLVNYWERSKRSFT Hypothetical protein AT4g34380 
Q9SZA4_ARATH: (0257) IVETYRGHTQEVCGLKWSGSGQQLASGGNDNVVHIWDRSVASSN WD-repeat protein-like protein 
Q9SZQ5_ARATH: (0234) LLGSMSGHTSWVLSVDASPDGGAIATGSSDRTVRLWDLKMRAAI Hypothetical protein F27B13.70 
Q9T014_ARATH: (0895) TPWCILSGHNKAVSYAKFLDNETLVTASTDNTLKLWDLKKTTHG COP1 like protein 
Q9T060_ARATH: (0297) HVSKLKGHKSEICGLKWSSDNRELASGGNDNKLFVWNQHSTQPV Srw1-like protein 
Q9XF57_ARATH: (0141) VRTFKEHAYCVYQAVWNPKHGDVFASASGDCTLRIWDVREPGST Peroxisomal targeting signal type 2 receptor 
Q9XI24_ARATH: (0422) CFITFTEHTNAVTALHFMADNHSLLSASLDGTVRAWDFKRYKNY F9L1.40 protein 
Q9XIB2_ARATH: (0325) LVQVLMKQENAVTALAVNLTDAVVYCGSSDGTVNFWERQKYLTH F13F21.11 protein 
Q9ZPY3_ARATH: (2366) LWYIPKAHLGSVTKIATIPRTSLFLTGSKDGEVKLWDAKAAKLI Hypothetical protein At2g46560 
Q9ZT99_ARATH: (0325) SLRTVAHTSDVNTVCFADESGNLILSGSDDNLCKVWDRRCFIGR Putative WD-repeat protein 
RAE1L_ARATH: (0237) KCHRDGNDIYSVNSLNFHPVHGTFATAGSDGAFNFWDKDSKQRL Rae1-like protein At1g80670 
WDR50_ARATH: (0365) ELIGTLKMNGSVRSLAFSEDGKHLLSSGGDGQVYVWDLRTMKCL WD-repeat protein At5g14050 
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1.6. Schizosaccharomyces pombe DWD-box proteins 
 
CORO_SCHPO: (0167) VAHVSLKMDVMCQSMSFNADGTRLVTTSRDKKVRVWDPRTDKPV Coronin-like protein crn1 
GBB_SCHPO: (0139) ISVLKGHEMDIVSLDFLPSNPNLFVTGGCDKLAKLWDLRAAYCC Guanine nucleotide-binding protein beta subunit 
IF32_SCHPO: (0043) RLGTYEGHTGAIWTCDINKSSTLMVSGAADNTMRLWDVKTGKQL Eukaryotic translation initiation factor 3 39 kDa subunit 
MIP1_SCHPO: (1170) TDVWKEHSSEIVNVEMQSSGMRELISASSDGEVKLWDIRMNHSL WD-repeat protein mip1 
O60097_SCHPO: (0343) TESTTNNDNIKAPSESSSEESNIFLTTSIDGVMNVWDHRMVDSV SPBC14C8.17c protein 
O74340_SCHPO: (0179) VTKFEWGADTLPVVKFNYTETSVLASAGMDRSIVIYDLRTSSPL SPBC1A4.07c protein 
O74855_SCHPO: (0422) FLATLRGHVAAVYQCAWSTDSRLLVSSSQDTTLKVWDVRSKKMK SPCC18.05c protein 
O94244_SCHPO: (0273) PKVIQAHSKAINAVAINPFNDYLLATASADKTVALWDLRNPYQR Histone acetyltransferase type B subunit 2 
O94527_SCHPO: (0662) SYYGHCNVESIKNVNFYGQNDEYVMSGSDDGRFFIWD-KLNASIL SPBC609.03 protein 
POF1_SCHPO: (0302) FQQVALLEGHSSGVTCLQFDQCKLISGSMDKTIRIWNYRTSECI F-box/WD-repeat protein pof1 
POP1_SCHPO: (0435) GVLIRSLEEHEGDVWTFEYVGDTLVTGSTDRTVRVWDLRTGECK WD-repeat protein pop1 
PRP46_SCHPO: (0238) VIRHYHGHLSGVYALKLHPTLDVLVTAGRDAVARVWDMRTRQNV Pre-mRNA-splicing factor prp46 
Q96WV5_SCHPO: (0044) LLDRFDGHDGPVRGIAFHPTQPLFVSGGDDYKVNVWNYKSRKLL SPBPJ4664.04 protein 
Q9C1X0_SCHPO: (0131) FSPIQVLADAKDSVSSIDIAEHLIVTGSTDGTLRTYDIRKGTLS SPBC713.05 protein 
Q9P4X3_SCHPO: (0256) PLVKMLTHRGPVRDLAVNRDGRYMVTAGADSLLKVWDLRTYKEL SPAC959.03c protein 
Q9USN3_SCHPO: (0180) SMAVFEGHSSVIRGLTFEPTGSFLLSGSRDKTVQVWNIKKRSAV Probable U3 small nucleolar RNA-associated protein 13 
Q9USR0_SCHPO: (0181) THSLSGHTGNVLAVDWCPKNEFVLASGSADGTCRLWDIRKVSSS SPBC577.09 protein 
Q9USZ0_SCHPO: (0272) TYTYTGHRGKHIWSLVVSSANPIIYTGGNDGSVRSWDYKTRIQE SPBC1306.02 protein 
Q9UT39_SCHPO: (0247) FQELPFSNNFHGGSTTFVPQGNFVIGSADDRTLNVWNLRHTFHH SPAC824.04 protein 
Q9UTC7_SCHPO: (0298) ELLMQEGHSEGIFSIACQPDGSLVSSGGNDAIGRIWDLRSGKSI SPAC227.12 protein 
Q9Y7K5_SCHPO: (0291) SVSAKLPHSDSVLTGSWHPNGNILATGGQDTTAKVWDIRALGKS SPBC2A9.03 protein 
SKB15_SCHPO: (0228) GKILHEFTAHKKRVKSVYPVDDYLITASSDGSVCIWD-KDWNLVI Shk1 kinase-binding protein 15 
SLP1_SCHPO: (0295) QIGTLQGHSSEVCGLAWRSDGLQLASGGNDNVVQIWDARSSIPK WD-repeat-containing protein slp1 
SRW1_SCHPO: (0365) YFRVLTAHRQEVCGLEWNSNENLLASGGNDNALMVWD-KFEEKPL WD-repeat-containing protein srw1 
SWD1_SCHPO: (0057) VSRVLTGHTRAIQSVCWSSCDRFLLTASRDWKCILWDLRDGSIV Set1 complex component swd1 
SWD2_SCHPO: (0103) YLRYFPGHKQTVTSIDVSPADETFLSASLDNTIRLWDLRSPNCQ Set1 complex component swd2 
TAF5_SCHPO: (0454) PLRVFAGHLSDVDCVTFHPNSAYVLTGSSDKTCRLWDVHRGHSV Transcription initiation factor TFIID subunit 5 
YAGE_SCHPO: (0155) NVKIVQAHEMEVRDVAFSPNDSKFVTASDDGSLKVWNFHMSTEE Hypothetical WD-repeat protein C12G12.14c in chromosome I 
YCSB_SCHPO: (0479) VCLNFTTTQKDINHATISNSGILVTSSGTDNQTFVWDSRKPDKP Hypothetical WD-repeat protein C613.12c in chromosome III 
YCSB_SCHPO: (0537) DGANEEEVDAGINMAQWQPKGNLFVTGGSDGIVKVWDLRLNNPF Hypothetical WD-repeat protein C613.12c in chromosome III 
YDSB_SCHPO: (0126) LYDFNEHSRAVHKLDISSFHPSYVLTASQDGLIKLWDYKESSST Hypothetical WD-repeat protein C4F8.11 in chromosome I 
YTM1_SCHPO: (0347) SHTLSGHKNLVSGLSASPENPYMFASVSHDNTCRVWDVRATSGS Microtubule-associated protein ytm1 
CDT2_SCHPO: (0281) HENSGRDCSITSATWLPQSTSQVISSCSANSALKLWDLRTVHTV CDT2 
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1.7. Saccharomyces cerevisiae DWD-box proteins 
 
 
CDC20_YEAST: (0376) IVSTWAEHTGEVCGLSYKSDGLQLASGGNDNTVMIWDTRTSLPQ APC/C activator protein CDC20 
CDC4_YEAST: (0412) KFLLQLSGHDGGVWALKYAHGGILVSGSTDRTVRVWDIKKGCCT Cell division control protein 4 
DIP2_YEAST: (0153) VGLYKLRSHKDSITGFWCQGEDWLISTSKDGMIKLWDLKTHQCI DOM34-interacting protein 2 
GID7_YEAST: (0664) QKYFGQKQQHFIIRSCFAYGNKLVMSGSEDGKIYIWDRIRGNLV Glucose-induced degradation protein 7 
GLE2_YEAST: (0260) PGSNGQSLVYPVNSIAFHPLYGTFVTAGGDGTFNFWDKNQRHRL Nucleoporin GLE2 
HAT2_YEAST: (0287) LHHMSGHEDAVNNLEFSTHVDGVVVSSGSDNRLMMWDLKQIGAE Histone acetyltransferase type B subunit 2 
MSI1_YEAST: (0288) QSNREKHDGGVNSCRFNYKNSLILASADSNGRLNLWDIRNMNKS Chromatin assembly factor 1 subunit p50 
PEX7_YEAST: (0212) NNFLVHSGLEALTCDFNKYRPYVVATGGVDNAIRIWDIRMLNKN Peroxisomal targeting signal 2 receptor 
PFS2_YEAST: (0210) QERVLSGHHWDVKSCDWHPEMGLIASASKDNLVKLWDPRSGNCI Polyadenylation factor subunit 2 
PRP46_YEAST: (0215) IIRDYYGHLSGVRTVSIHPTLDLIATAGRDSVIKLWDMRTRIPV Pre-mRNA-splicing factor PRP46 
PRP4_YEAST: (0298) ELLLQEGHDKGVFSLSFQCDGSLVCSGGMDSLSMLWDIRSGSKV U4/U6 small nuclear ribonucleoprotein PRP4 
RRB1_YEAST: (0313) QPFTVSNNKSIEDIQWSRTESTVFATAGCDGYIRIWDTRSKKHK Ribosome assembly protein RRB1 
TUP1_YEAST: (0476) IVMILQGHEQDIYSLDYFPSGDKLVSGSGDRTVRIWDLRTGQCS Glucose repression regulatory protein TUP1 
WTM1_YEAST: (0213) ILRTVHVPGTTVTHTVRFFDNHIFASCSDDNILRFWDTRTSDKP Transcriptional modulator WTM1 
YCW2_YEAST: (0393) PIARMTGHQKLVNHVAFSPDGRYIVSASFDNSIKLWDGRDGKFI Hypothetical WD-repeat protein YCR072C 
YHY6_YEAST: (1378) RAGNDKQGVWINNVHLQRGGYRELVSGATNGVVELWDIRSEDPV Hypothetical 175.8 kDa wd protein in GND1-IKI1 intergenic region 
YJL2_YEAST: (0555) KSTLLTQRNERPSIGALQSFDAALATGTKDGVVRLWDLRSGKVI Hypothetical 80.0 kDa wd protein in ASF1-CCT7 intergenic region 
YK16_YEAST: (0534) GKPVRLLEGHTDGITSLKFDSEKLVTGSMDNSVRIWDLRTSSIL Hypothetical 74.7 kDa wd protein in DAL80-GAP1 intergenic region 
YNA6_YEAST: (0066) PVASFEGHRGNVTSVSFQQDNRWMVTSSEDGTIKVWDVRSPSIP Hypothetical 34.0 kDa wd protein in SIS1-MRPL2 intergenic region 
YTM1_YEAST: (0367) QQQLIGHKNFVSSLDTCPENEYILCSGSHDGTVKVWDVRSTSPM Microtubule-associated protein YTM1 
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